<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Cancer immunotherapy - Wikipedia</title>
<script>document.documentElement.className = document.documentElement.className.replace( /(^|\s)client-nojs(\s|$)/, "$1client-js$2" );</script>
<script>(window.RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Cancer_immunotherapy","wgTitle":"Cancer immunotherapy","wgCurRevisionId":878193815,"wgRevisionId":878193815,"wgArticleId":1661124,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["CS1: long volume value","Wikipedia articles needing page number citations from February 2018","Use dmy dates from December 2018","Articles with short description","Wikipedia articles needing clarification from April 2016","All articles with unsourced statements","Articles with unsourced statements from February 2018","Monoclonal antibodies for tumors","Branches of immunology"],"wgBreakFrames":false,"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgMonthNamesShort":["","Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"wgRelevantPageName":"Cancer_immunotherapy","wgRelevantArticleId":1661124,"wgRequestId":"XE4SzwpAADgAADAsqBQAAABB","wgCSPNonce":false,"wgIsProbablyEditable":true,"wgRelevantPageIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgFlaggedRevsParams":{"tags":{}},"wgStableRevisionId":null,"wgCategoryTreePageCategoryOptions":"{\"mode\":0,\"hideprefix\":20,\"showcount\":true,\"namespaces\":false}","wgWikiEditorEnabledModules":[],"wgBetaFeaturesFeatures":[],"wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wgPopupsShouldSendModuleToUser":true,"wgPopupsConflictsWithNavPopupGadget":false,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en","usePageImages":true,"usePageDescriptions":true},"wgMFExpandAllSectionsUserOption":true,"wgMFEnableFontChanger":true,"wgMFDisplayWikibaseDescriptions":{"search":true,"nearby":true,"watchlist":true,"tagline":false},"wgRelatedArticles":null,"wgRelatedArticlesUseCirrusSearch":true,"wgRelatedArticlesOnlyUseCirrusSearch":false,"wgWMESchemaEditAttemptStepOversample":false,"wgPoweredByHHVM":true,"wgULSCurrentAutonym":"English","wgNoticeProject":"wikipedia","wgCentralNoticeCookiesToDelete":[],"wgCentralNoticeCategoriesUsingLegacy":["Fundraising","fundraising"],"wgWikibaseItemId":"Q2012719","wgScoreNoteLanguages":{"arabic":"العربية","catalan":"català","deutsch":"Deutsch","english":"English","espanol":"español","italiano":"italiano","nederlands":"Nederlands","norsk":"norsk","portugues":"português","suomi":"suomi","svenska":"svenska","vlaams":"West-Vlams"},"wgScoreDefaultNoteLanguage":"nederlands","wgCentralAuthMobileDomain":false,"wgCodeMirrorEnabled":true,"wgVisualEditorToolbarScrollOffset":0,"wgVisualEditorUnsupportedEditParams":["undo","undoafter","veswitched"],"wgEditSubmitButtonLabelPublish":true,"oresWikiId":"enwiki","oresBaseUrl":"http://ores.discovery.wmnet:8081/","oresApiVersion":3});mw.loader.state({"ext.gadget.charinsert-styles":"ready","ext.globalCssJs.user.styles":"ready","ext.globalCssJs.site.styles":"ready","site.styles":"ready","noscript":"ready","user.styles":"ready","ext.globalCssJs.user":"ready","ext.globalCssJs.site":"ready","user":"ready","user.options":"ready","user.tokens":"loading","ext.cite.styles":"ready","mediawiki.legacy.shared":"ready","mediawiki.legacy.commonPrint":"ready","mediawiki.toc.styles":"ready","wikibase.client.init":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.uls.interlanguage":"ready","ext.wikimediaBadges":"ready","ext.3d.styles":"ready","mediawiki.skinning.interface":"ready","skins.vector.styles":"ready"});mw.loader.implement("user.tokens@0tffind",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"editToken":"+\\","patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});RLPAGEMODULES=["ext.cite.ux-enhancements","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","mediawiki.searchSuggest","ext.gadget.teahouse","ext.gadget.ReferenceTooltips","ext.gadget.watchlist-notice","ext.gadget.DRN-wizard","ext.gadget.charinsert","ext.gadget.refToolbar","ext.gadget.extra-toolbar-buttons","ext.gadget.switcher","ext.centralauth.centralautologin","mmv.head","mmv.bootstrap.autostart","ext.popups","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eventLogging","ext.wikimediaEvents","ext.navigationTiming","ext.uls.eventlogger","ext.uls.init","ext.uls.compactlinks","ext.uls.interface","ext.quicksurveys.init","ext.centralNotice.geoIP","ext.centralNotice.startUp","skins.vector.js"];mw.loader.load(RLPAGEMODULES);});</script>
<link rel="stylesheet" href="/w/load.php?debug=false&amp;lang=en&amp;modules=ext.3d.styles%7Cext.cite.styles%7Cext.uls.interlanguage%7Cext.visualEditor.desktopArticleTarget.noscript%7Cext.wikimediaBadges%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.skinning.interface%7Cmediawiki.toc.styles%7Cskins.vector.styles%7Cwikibase.client.init&amp;only=styles&amp;skin=vector"/>
<script async="" src="/w/load.php?debug=false&amp;lang=en&amp;modules=startup&amp;only=scripts&amp;skin=vector"></script>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?debug=false&amp;lang=en&amp;modules=ext.gadget.charinsert-styles&amp;only=styles&amp;skin=vector"/>
<link rel="stylesheet" href="/w/load.php?debug=false&amp;lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=vector"/>
<meta name="generator" content="MediaWiki 1.33.0-wmf.14"/>
<meta name="referrer" content="origin"/>
<meta name="referrer" content="origin-when-crossorigin"/>
<meta name="referrer" content="origin-when-cross-origin"/>
<meta property="og:image" content="https://upload.wikimedia.org/wikipedia/commons/thumb/f/f5/Peptide_bound_to_Rituximab_FAB.png/1200px-Peptide_bound_to_Rituximab_FAB.png"/>
<link rel="alternate" href="android-app://org.wikipedia/http/en.m.wikipedia.org/wiki/Cancer_immunotherapy"/>
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit"/>
<link rel="edit" title="Edit this page" href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit"/>
<link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png"/>
<link rel="shortcut icon" href="/static/favicon/wikipedia.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd"/>
<link rel="license" href="//creativecommons.org/licenses/by-sa/3.0/"/>
<link rel="canonical" href="https://en.wikipedia.org/wiki/Cancer_immunotherapy"/>
<link rel="dns-prefetch" href="//login.wikimedia.org"/>
<link rel="dns-prefetch" href="//meta.wikimedia.org" />
<!--[if lt IE 9]><script src="/w/load.php?debug=false&amp;lang=en&amp;modules=html5shiv&amp;only=scripts&amp;skin=vector&amp;sync=1"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject mw-editable page-Cancer_immunotherapy rootpage-Cancer_immunotherapy skin-vector action-view">		<div id="mw-page-base" class="noprint"></div>
		<div id="mw-head-base" class="noprint"></div>
		<div id="content" class="mw-body" role="main">
			<a id="top"></a>
			<div id="siteNotice" class="mw-body-content"><!-- CentralNotice --></div><div class="mw-indicators mw-body-content">
</div>
<h1 id="firstHeading" class="firstHeading" lang="en">Cancer immunotherapy</h1>			<div id="bodyContent" class="mw-body-content">
				<div id="siteSub" class="noprint">From Wikipedia, the free encyclopedia</div>				<div id="contentSub"></div>
				<div id="jump-to-nav"></div>				<a class="mw-jump-link" href="#mw-head">Jump to navigation</a>
				<a class="mw-jump-link" href="#p-search">Jump to search</a>
				<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><p class="mw-empty-elt">
</p>
<div class="shortdescription nomobile noexcerpt noprint searchaux" style="display:none">The artificial stimulation of the immune system to treat cancer, improving on the system's natural ability to fight cancer</div>
<table class="infobox" style="width:22em"><tbody><tr><th colspan="2" style="text-align:center;font-size:125%;font-weight:bold;background-color: lightblue">Cancer immunotherapy</th></tr><tr><td colspan="2" style="text-align:center"><a href="/wiki/File:Peptide_bound_to_Rituximab_FAB.png" class="image"><img alt="Peptide bound to Rituximab FAB.png" src="//upload.wikimedia.org/wikipedia/commons/thumb/f/f5/Peptide_bound_to_Rituximab_FAB.png/280px-Peptide_bound_to_Rituximab_FAB.png" decoding="async" width="280" height="190" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/f/f5/Peptide_bound_to_Rituximab_FAB.png/420px-Peptide_bound_to_Rituximab_FAB.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/f/f5/Peptide_bound_to_Rituximab_FAB.png/560px-Peptide_bound_to_Rituximab_FAB.png 2x" data-file-width="2000" data-file-height="1356" /></a><div><a href="/wiki/Peptide" title="Peptide">Peptide</a> <a href="/wiki/Epitope" title="Epitope">epitope</a> of <a href="/wiki/CD20" title="CD20">CD20</a> bound to <a href="/wiki/Rituximab" title="Rituximab">rituximab</a>'s <a href="/wiki/Fragment_antigen-binding" title="Fragment antigen-binding">FAB</a></div></td></tr><tr class="noprint"><td colspan="2" style="text-align:center"><div style="text-align: right;">&#91;<a href="https://www.wikidata.org/wiki/Q2012719" class="extiw" title="d:Q2012719">edit on Wikidata</a>]</div></td></tr></tbody></table>
<p><b>Cancer immunotherapy</b> (sometimes called <b>immuno-oncology</b>) is the artificial stimulation of the <a href="/wiki/Immune_system" title="Immune system">immune system</a> to treat cancer, improving on the system's natural ability to fight cancer. It is an application of the <a href="/wiki/Basic_research" title="Basic research">fundamental research</a> of <a href="/wiki/Cancer_immunology" title="Cancer immunology">cancer immunology</a> and a growing subspecialty of <a href="/wiki/Oncology" title="Oncology">oncology</a>. It exploits the fact that <a href="/wiki/Cancer_cells" class="mw-redirect" title="Cancer cells">cancer cells</a> often have <a href="/wiki/Tumor_antigen" title="Tumor antigen">tumor antigens</a>, molecules on their surface that can be detected by the <a href="/wiki/Antibody" title="Antibody">antibody</a> proteins of the immune system, binding to them. The tumor <a href="/wiki/Antigens" class="mw-redirect" title="Antigens">antigens</a> are often <a href="/wiki/Protein" title="Protein">proteins</a> or other macromolecules (e.g. <a href="/wiki/Carbohydrate" title="Carbohydrate">carbohydrates</a>). Normal antibodies bind to external pathogens, but the modified immunotherapy antibodies bind to the tumor antigens marking and identifying the cancer cells for the immune system to inhibit or kill.  
</p>
<h2><span class="mw-headline" id="Immunotherapy_categories">Immunotherapy categories</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=1" title="Edit section: Immunotherapy categories">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p><a href="/wiki/Immunotherapy" title="Immunotherapy">Immunotherapies</a> can be categorized as active, passive or hybrid (active and passive). Active immunotherapy directs the immune system to attack <a href="/wiki/Tumor" class="mw-redirect" title="Tumor">tumor</a> cells by targeting tumor antigens. Passive immunotherapies enhance existing anti-tumor responses and include <a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">the use of monoclonal antibodies</a>, <a href="/wiki/Lymphocyte" title="Lymphocyte">lymphocytes</a> and <a href="/wiki/Cytokine" title="Cytokine">cytokines</a>.
</p><p>A wide range of cancers can be treated by various immunotherapy medicines that have been approved in many jurisdictions around the world.<sup id="cite_ref-1" class="reference"><a href="#cite_note-1">&#91;1&#93;</a></sup> 
</p><p>Passive antibody therapies commonly involve the targeting of <a href="/wiki/Cell_surface_receptor" title="Cell surface receptor">Cell surface receptors</a> and include <a href="/wiki/CD20" title="CD20">CD20</a>, <a href="/wiki/CD274" class="mw-redirect" title="CD274">CD274</a> and <a href="/wiki/CD279" class="mw-redirect" title="CD279">CD279</a> antibodies. Once bound to a cancer antigen, the modified antibodies can induce <a href="/wiki/Antibody-dependent_cell-mediated_cytotoxicity" class="mw-redirect" title="Antibody-dependent cell-mediated cytotoxicity">antibody-dependent cell-mediated cytotoxicity</a>, activate the <a href="/wiki/Complement_system" title="Complement system">complement system</a>, or prevent a receptor from interacting with its <a href="/wiki/Ligand_(biochemistry)" title="Ligand (biochemistry)">ligand</a>, all of which can lead to cell death. 
</p><p>Approved immunotherapy antibodies include <a href="/wiki/Alemtuzumab" title="Alemtuzumab">alemtuzumab</a>, <a href="/wiki/Ipilimumab" title="Ipilimumab">ipilimumab</a>, <a href="/wiki/Nivolumab" title="Nivolumab">nivolumab</a>, <a href="/wiki/Ofatumumab" title="Ofatumumab">ofatumumab</a> and <a href="/wiki/Rituximab" title="Rituximab">rituximab</a>.
</p><p>Active cellular therapies usually involve the removal of immune cells from the blood or from a tumor. Those specific for the tumor are grown in culture and returned to the patient where they attack the tumor; alternatively, immune cells can be <a href="/wiki/Genetically_engineer" class="mw-redirect" title="Genetically engineer">genetically engineered</a> to express a tumor-specific <a href="/wiki/Receptor_(biochemistry)" title="Receptor (biochemistry)">receptor</a>, cultured and returned to the patient. Cell types that can be used in this way are <a href="/wiki/Natural_killer_cell" title="Natural killer cell">natural killer (NK) cells</a>, <a href="/wiki/Lymphokine-activated_killer_cell" title="Lymphokine-activated killer cell">lymphokine-activated killer cells</a>, <a href="/wiki/Cytotoxic_T_cell" title="Cytotoxic T cell">cytotoxic T cells</a> and <a href="/wiki/Dendritic_cell" title="Dendritic cell">dendritic cells</a>. 
</p>
<style data-mw-deduplicate="TemplateStyles:r872693506">.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}</style><div class="toclimit-3"><div id="toc" class="toc"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2>Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Immunotherapy_categories"><span class="tocnumber">1</span> <span class="toctext">Immunotherapy categories</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Cellular_immunotherapy"><span class="tocnumber">2</span> <span class="toctext">Cellular immunotherapy</span></a>
<ul>
<li class="toclevel-2 tocsection-3"><a href="#Dendritic_cell_therapy"><span class="tocnumber">2.1</span> <span class="toctext">Dendritic cell therapy</span></a>
<ul>
<li class="toclevel-3 tocsection-4"><a href="#Approved_drugs"><span class="tocnumber">2.1.1</span> <span class="toctext">Approved drugs</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-5"><a href="#CAR-T_cell_therapy"><span class="tocnumber">2.2</span> <span class="toctext">CAR-T cell therapy</span></a>
<ul>
<li class="toclevel-3 tocsection-6"><a href="#Approved_drugs_2"><span class="tocnumber">2.2.1</span> <span class="toctext">Approved drugs</span></a></li>
</ul>
</li>
</ul>
</li>
<li class="toclevel-1 tocsection-7"><a href="#Antibody_therapy"><span class="tocnumber">3</span> <span class="toctext">Antibody therapy</span></a>
<ul>
<li class="toclevel-2 tocsection-8"><a href="#Antibody_types"><span class="tocnumber">3.1</span> <span class="toctext">Antibody types</span></a>
<ul>
<li class="toclevel-3 tocsection-9"><a href="#Conjugation"><span class="tocnumber">3.1.1</span> <span class="toctext">Conjugation</span></a></li>
<li class="toclevel-3 tocsection-10"><a href="#Fc_regions"><span class="tocnumber">3.1.2</span> <span class="toctext">Fc regions</span></a></li>
<li class="toclevel-3 tocsection-11"><a href="#Human/non-human_balance"><span class="tocnumber">3.1.3</span> <span class="toctext">Human/non-human balance</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-12"><a href="#Cell_death_mechanisms"><span class="tocnumber">3.2</span> <span class="toctext">Cell death mechanisms</span></a>
<ul>
<li class="toclevel-3 tocsection-13"><a href="#Antibody-dependent_cell-mediated_cytotoxicity_(ADCC)"><span class="tocnumber">3.2.1</span> <span class="toctext">Antibody-dependent cell-mediated cytotoxicity (ADCC)</span></a></li>
<li class="toclevel-3 tocsection-14"><a href="#Complement"><span class="tocnumber">3.2.2</span> <span class="toctext">Complement</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-15"><a href="#FDA-approved_antibodies"><span class="tocnumber">3.3</span> <span class="toctext">FDA-approved antibodies</span></a>
<ul>
<li class="toclevel-3 tocsection-16"><a href="#Alemtuzumab"><span class="tocnumber">3.3.1</span> <span class="toctext">Alemtuzumab</span></a></li>
<li class="toclevel-3 tocsection-17"><a href="#Atezolizumab"><span class="tocnumber">3.3.2</span> <span class="toctext">Atezolizumab</span></a></li>
<li class="toclevel-3 tocsection-18"><a href="#Ipilimumab"><span class="tocnumber">3.3.3</span> <span class="toctext">Ipilimumab</span></a></li>
<li class="toclevel-3 tocsection-19"><a href="#Nivolumab"><span class="tocnumber">3.3.4</span> <span class="toctext">Nivolumab</span></a></li>
<li class="toclevel-3 tocsection-20"><a href="#Ofatumumab"><span class="tocnumber">3.3.5</span> <span class="toctext">Ofatumumab</span></a></li>
<li class="toclevel-3 tocsection-21"><a href="#Pembrolizumab"><span class="tocnumber">3.3.6</span> <span class="toctext">Pembrolizumab</span></a></li>
<li class="toclevel-3 tocsection-22"><a href="#Rituximab"><span class="tocnumber">3.3.7</span> <span class="toctext">Rituximab</span></a></li>
</ul>
</li>
</ul>
</li>
<li class="toclevel-1 tocsection-23"><a href="#Cytokine_therapy"><span class="tocnumber">4</span> <span class="toctext">Cytokine therapy</span></a>
<ul>
<li class="toclevel-2 tocsection-24"><a href="#Interferon"><span class="tocnumber">4.1</span> <span class="toctext">Interferon</span></a></li>
<li class="toclevel-2 tocsection-25"><a href="#Interleukin"><span class="tocnumber">4.2</span> <span class="toctext">Interleukin</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-26"><a href="#Combination_immunotherapy"><span class="tocnumber">5</span> <span class="toctext">Combination immunotherapy</span></a></li>
<li class="toclevel-1 tocsection-27"><a href="#Polysaccharide-K"><span class="tocnumber">6</span> <span class="toctext">Polysaccharide-K</span></a></li>
<li class="toclevel-1 tocsection-28"><a href="#Genetic_pre-testing_for_therapeutic_significance"><span class="tocnumber">7</span> <span class="toctext">Genetic pre-testing for therapeutic significance</span></a></li>
<li class="toclevel-1 tocsection-29"><a href="#Research"><span class="tocnumber">8</span> <span class="toctext">Research</span></a>
<ul>
<li class="toclevel-2 tocsection-30"><a href="#Adoptive_T-cell_therapy"><span class="tocnumber">8.1</span> <span class="toctext">Adoptive T-cell therapy</span></a></li>
<li class="toclevel-2 tocsection-31"><a href="#Anti-CD47_therapy"><span class="tocnumber">8.2</span> <span class="toctext">Anti-CD47 therapy</span></a></li>
<li class="toclevel-2 tocsection-32"><a href="#Anti-GD2_antibodies"><span class="tocnumber">8.3</span> <span class="toctext">Anti-GD2 antibodies</span></a></li>
<li class="toclevel-2 tocsection-33"><a href="#Immune_checkpoints"><span class="tocnumber">8.4</span> <span class="toctext">Immune checkpoints</span></a>
<ul>
<li class="toclevel-3 tocsection-34"><a href="#CTLA-4_blockade"><span class="tocnumber">8.4.1</span> <span class="toctext">CTLA-4 blockade</span></a></li>
<li class="toclevel-3 tocsection-35"><a href="#PD-1_inhibitors"><span class="tocnumber">8.4.2</span> <span class="toctext">PD-1 inhibitors</span></a></li>
<li class="toclevel-3 tocsection-36"><a href="#PD-L1_inhibitors"><span class="tocnumber">8.4.3</span> <span class="toctext">PD-L1 inhibitors</span></a></li>
<li class="toclevel-3 tocsection-37"><a href="#Other"><span class="tocnumber">8.4.4</span> <span class="toctext">Other</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-38"><a href="#Oncolytic_virus"><span class="tocnumber">8.5</span> <span class="toctext">Oncolytic virus</span></a></li>
<li class="toclevel-2 tocsection-39"><a href="#Polysaccharides"><span class="tocnumber">8.6</span> <span class="toctext">Polysaccharides</span></a></li>
<li class="toclevel-2 tocsection-40"><a href="#Neoantigens"><span class="tocnumber">8.7</span> <span class="toctext">Neoantigens</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-41"><a href="#See_also"><span class="tocnumber">9</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1 tocsection-42"><a href="#References"><span class="tocnumber">10</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-43"><a href="#External_links"><span class="tocnumber">11</span> <span class="toctext">External links</span></a></li>
</ul>
</div>
</div>
<h2><span class="mw-headline" id="Cellular_immunotherapy">Cellular immunotherapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=2" title="Edit section: Cellular immunotherapy">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Dendritic_cell_therapy">Dendritic cell therapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=3" title="Edit section: Dendritic cell therapy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="thumb tright"><div class="thumbinner" style="width:292px;"><a href="/wiki/File:Dendritic_cell_therapy.png" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/2/21/Dendritic_cell_therapy.png/290px-Dendritic_cell_therapy.png" decoding="async" width="290" height="218" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/2/21/Dendritic_cell_therapy.png/435px-Dendritic_cell_therapy.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/2/21/Dendritic_cell_therapy.png/580px-Dendritic_cell_therapy.png 2x" data-file-width="960" data-file-height="720" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/wiki/File:Dendritic_cell_therapy.png" class="internal" title="Enlarge"></a></div>Blood cells are removed from the body, incubated with tumour antigen(s) and activated.  Mature dendritic cells are then returned to the original cancer-bearing donor to induce an immune response.</div></div></div>
<p>Dendritic cell therapy provokes anti-tumor responses by causing dendritic cells to present tumor antigens to lymphocytes, which activates them, priming them to kill other cells that present the antigen. Dendritic cells are antigen presenting cells (APCs) in the mammalian immune system.<sup id="cite_ref-pmid11481463_2-0" class="reference"><a href="#cite_note-pmid11481463-2">&#91;2&#93;</a></sup> In cancer treatment they aid cancer antigen targeting.<sup id="cite_ref-pmid23890062_3-0" class="reference"><a href="#cite_note-pmid23890062-3">&#91;3&#93;</a></sup> The only approved cellular cancer therapy based on dendritic cells is <a href="/wiki/Sipuleucel-T" title="Sipuleucel-T">sipuleucel-T</a>.
</p><p>One method of inducing dendritic cells to present tumor antigens is by vaccination with autologous tumor lysates<sup id="cite_ref-pmid27235694_4-0" class="reference"><a href="#cite_note-pmid27235694-4">&#91;4&#93;</a></sup> or short peptides (small parts of protein that correspond to the protein antigens on cancer cells). These peptides are often given in combination with <a href="/wiki/Adjuvants" class="mw-redirect" title="Adjuvants">adjuvants</a> (highly <a href="/wiki/Immunogenic" class="mw-redirect" title="Immunogenic">immunogenic</a> substances) to increase the immune and anti-tumor responses. Other adjuvants include proteins or other chemicals that attract and/or activate dendritic cells, such as <a href="/wiki/Granulocyte_macrophage_colony-stimulating_factor" class="mw-redirect" title="Granulocyte macrophage colony-stimulating factor">granulocyte macrophage colony-stimulating factor</a> (GM-CSF). The most common source of antigens used for dendritic cell vaccine in Glioblastoma (GBM) as an aggressive brain tumor were whole tumor lysate, CMV antigen RNA and tumor associated peptides like EGFRvIII.<sup id="cite_ref-5" class="reference"><a href="#cite_note-5">&#91;5&#93;</a></sup>
</p><p>Dendritic cells can also be activated <i><a href="/wiki/In_vivo" title="In vivo">in vivo</a></i> by making tumor cells express GM-CSF. This can be achieved by either genetically engineering tumor cells to produce GM-CSF or by infecting tumor cells with an <a href="/wiki/Oncolytic_virus" title="Oncolytic virus">oncolytic virus</a> that expresses GM-CSF.
</p><p>Another strategy is to remove dendritic cells from the blood of a patient and activate them outside the body. The dendritic cells are activated in the presence of tumor antigens, which may be a single tumor-specific peptide/protein or a tumor <a href="/wiki/Cell_lysate" class="mw-redirect" title="Cell lysate">cell lysate</a> (a solution of broken down tumor cells). These cells (with optional adjuvants) are infused and provoke an immune response.
</p><p>Dendritic cell therapies include the use of antibodies that bind to receptors on the surface of dendritic cells. Antigens can be added to the antibody and can induce the dendritic cells to mature and provide immunity to the tumor. Dendritic cell receptors such as <a href="/wiki/TLR3" title="TLR3">TLR3</a>, <a href="/wiki/TLR7" title="TLR7">TLR7</a>, <a href="/wiki/TLR8" title="TLR8">TLR8</a> or <a href="/wiki/CD40" class="mw-redirect" title="CD40">CD40</a> have been used as antibody targets.<sup id="cite_ref-pmid23890062_3-1" class="reference"><a href="#cite_note-pmid23890062-3">&#91;3&#93;</a></sup> Dendritic cell-NK cell interface also has an important role in immunotherapy. The design of new dendritic cell-based vaccination strategies should also encompass NK cell-stimulating potency. It is critical to systematically incorporate NK cells monitoring as an outcome in antitumor DC-based clinical trials.<sup id="cite_ref-6" class="reference"><a href="#cite_note-6">&#91;6&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Approved_drugs">Approved drugs</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=4" title="Edit section: Approved drugs">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Sipuleucel-T (Provenge) was approved for treatment of asymptomatic or minimally symptomatic metastatic castration-resistant <a href="/wiki/Prostate_cancer" title="Prostate cancer">prostate cancer</a> in 2010. The treatment consists of removal of <a href="/wiki/Antigen_presenting_cell" class="mw-redirect" title="Antigen presenting cell">antigen presenting cells</a> from blood by <a href="/wiki/Leukapheresis" title="Leukapheresis">leukapheresis</a> and growing them with the <a href="/wiki/Fusion_protein" title="Fusion protein">fusion protein</a> PA2024 made from GM-CSF and prostate-specific <a href="/wiki/Prostatic_acid_phosphatase" title="Prostatic acid phosphatase">prostatic acid phosphatase</a> (PAP) and reinfused. This process is repeated three times.<sup id="cite_ref-7" class="reference"><a href="#cite_note-7">&#91;7&#93;</a></sup><sup id="cite_ref-8" class="reference"><a href="#cite_note-8">&#91;8&#93;</a></sup><sup id="cite_ref-9" class="reference"><a href="#cite_note-9">&#91;9&#93;</a></sup><sup id="cite_ref-10" class="reference"><a href="#cite_note-10">&#91;10&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="CAR-T_cell_therapy">CAR-T cell therapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=5" title="Edit section: CAR-T cell therapy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/Chimeric_antigen_receptor" title="Chimeric antigen receptor">Chimeric antigen receptor</a></div>
<p>The premise of CAR-T immunotherapy is to modify T cells to recognize cancer cells in order to more effectively target and destroy them. Scientists harvest T cells from people, genetically alter them to add a chimeric antigen receptor (CAR) that specifically recognizes cancer cells, then infuse the resulting CAR-T cells into patients to attack their tumors.
</p>
<h4><span class="mw-headline" id="Approved_drugs_2">Approved drugs</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=6" title="Edit section: Approved drugs">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p><a href="/wiki/Tisagenlecleucel" title="Tisagenlecleucel">Tisagenlecleucel</a> (Kymriah), a <a href="/wiki/Chimeric_antigen_receptor" title="Chimeric antigen receptor">chimeric antigen receptor</a> (CAR-T) therapy, was approved by FDA in 2017 to treat <a href="/wiki/Acute_lymphoblastic_leukemia" title="Acute lymphoblastic leukemia">acute lymphoblastic leukemia</a> (ALL).<sup id="cite_ref-11" class="reference"><a href="#cite_note-11">&#91;11&#93;</a></sup> This treatment removes <a href="/wiki/CD19" title="CD19">CD19</a> positive cells (B-cells) from the body (including the diseased cells, but also normal antibody producing cells).
</p><p><a href="/wiki/Axicabtagene_ciloleucel" title="Axicabtagene ciloleucel">Axicabtagene ciloleucel</a> (Yescarta) is another CAR-T therapeutic, approved in 2017 for treatment of <a href="/wiki/Diffuse_large_B-cell_lymphoma" title="Diffuse large B-cell lymphoma">diffuse large B-cell lymphoma</a> (DLBCL).<sup id="cite_ref-fda.gov_12-0" class="reference"><a href="#cite_note-fda.gov-12">&#91;12&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Antibody_therapy">Antibody therapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=7" title="Edit section: Antibody therapy">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright"><div class="thumbinner" style="width:292px;"><a href="/wiki/File:Engineered_monoclonal_antibodies.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/2/2e/Engineered_monoclonal_antibodies.svg/290px-Engineered_monoclonal_antibodies.svg.png" decoding="async" width="290" height="134" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/2/2e/Engineered_monoclonal_antibodies.svg/435px-Engineered_monoclonal_antibodies.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/2/2e/Engineered_monoclonal_antibodies.svg/580px-Engineered_monoclonal_antibodies.svg.png 2x" data-file-width="520" data-file-height="240" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/wiki/File:Engineered_monoclonal_antibodies.svg" class="internal" title="Enlarge"></a></div>Many forms of antibodies can be engineered.</div></div></div>
<div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/Monoclonal_antibody_therapy" title="Monoclonal antibody therapy">Monoclonal antibody therapy</a></div>
<p><a href="/wiki/Antibody" title="Antibody">Antibodies</a> are a key component of the <a href="/wiki/Adaptive_immune_system" title="Adaptive immune system">adaptive immune response</a>, playing a central role in both recognizing foreign antigens and stimulating an immune response. Antibodies are Y-shaped proteins produced by some <a href="/wiki/B_cells" class="mw-redirect" title="B cells">B cells</a> and are composed of two regions: an <a href="/wiki/Fragment_antigen-binding" title="Fragment antigen-binding">antigen-binding fragment (Fab)</a>, which binds to antigens, and a <a href="/wiki/Fragment_crystallizable_region" title="Fragment crystallizable region">Fragment crystallizable (Fc)</a> region, which interacts with so-called <a href="/wiki/Fc_receptors" class="mw-redirect" title="Fc receptors">Fc receptors</a> that are expressed on the surface of different immune cell types including <a href="/wiki/Macrophages" class="mw-redirect" title="Macrophages">macrophages</a>, <a href="/wiki/Neutrophils" class="mw-redirect" title="Neutrophils">neutrophils</a> and NK cells. Many immunotherapeutic regimens involve antibodies. <a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">Monoclonal antibody</a> technology engineers and generates antibodies against specific antigens, such as those present on tumor surfaces. These antibodies that are specific to the antigens of the tumor, can then be injected into a tumor
</p>
<h3><span class="mw-headline" id="Antibody_types">Antibody types</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=8" title="Edit section: Antibody types">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<h4><span class="mw-headline" id="Conjugation">Conjugation</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=9" title="Edit section: Conjugation">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Two types are used in cancer treatments:<sup id="cite_ref-pmid22437872_13-0" class="reference"><a href="#cite_note-pmid22437872-13">&#91;13&#93;</a></sup>
</p>
<ul><li>Naked monoclonal antibodies are antibodies without added elements. Most antibody therapies use this antibody type.</li>
<li>Conjugated monoclonal antibodies are joined to another molecule, which is either cytotoxic or <a href="/wiki/Radioactive" class="mw-redirect" title="Radioactive">radioactive</a>. The toxic chemicals are those typically used as <a href="/wiki/Chemotherapy" title="Chemotherapy">chemotherapy</a> drugs, but other toxins can be used. The antibody binds to specific antigens on cancer cell surfaces, directing the therapy to the tumor. Radioactive compound-linked antibodies are referred to as radiolabelled. Chemolabelled or immunotoxins antibodies are tagged with chemotherapeutic molecules or toxins, respectively.<sup id="cite_ref-:0_14-0" class="reference"><a href="#cite_note-:0-14">&#91;14&#93;</a></sup></li></ul>
<h4><span class="mw-headline" id="Fc_regions">Fc regions</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=10" title="Edit section: Fc regions">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Fc's ability to bind <a href="/wiki/Fc_receptors" class="mw-redirect" title="Fc receptors">Fc receptors</a> is important because it allows antibodies to activate the immune system. Fc regions are varied: they exist in numerous subtypes and can be further modified, for example with the addition of sugars in a process called <a href="/wiki/Glycosylation" title="Glycosylation">glycosylation</a>. Changes in the <a href="/wiki/Fc_region" class="mw-redirect" title="Fc region">Fc region</a> can alter an antibody's ability to engage Fc receptors and, by extension, will determine the type of immune response that the antibody triggers.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15">&#91;15&#93;</a></sup> Many cancer immunotherapy drugs, including <a href="/wiki/PD-1_and_PD-L1_inhibitors" title="PD-1 and PD-L1 inhibitors">PD-1 and PD-L1 inhibitors</a>, are antibodies. For example, <a href="/wiki/Immune_checkpoint" title="Immune checkpoint">immune checkpoint</a> blockers targeting PD-1 are antibodies designed to bind PD-1 expressed by T cells and reactivate these cells to eliminate <a href="/wiki/Tumors" class="mw-redirect" title="Tumors">tumors</a>.<sup id="cite_ref-16" class="reference"><a href="#cite_note-16">&#91;16&#93;</a></sup> <a href="/wiki/Programmed_cell_death_protein_1" title="Programmed cell death protein 1">Anti-PD-1 drugs</a> contain not only an Fab region that binds PD-1 but also an Fc region. Experimental work indicates that the Fc portion of cancer immunotherapy drugs can affect the outcome of treatment. For example, anti-PD-1 drugs with Fc regions that bind inhibitory Fc receptors can have decreased therapeutic efficacy.<sup id="cite_ref-17" class="reference"><a href="#cite_note-17">&#91;17&#93;</a></sup> Imaging studies have further shown that the Fc region of anti-PD-1 drugs can bind Fc receptors expressed by tumor-associated macrophages. This process removes the drugs from their intended targets (i.e. PD-1 molecules expressed on the surface of T cells) and limits therapeutic efficacy.<sup id="cite_ref-18" class="reference"><a href="#cite_note-18">&#91;18&#93;</a></sup> Furthermore, antibodies targeting the co-stimulatory protein <a href="/wiki/CD40" class="mw-redirect" title="CD40">CD40</a> require engagement with selective Fc receptors for optimal therapeutic efficacy.<sup id="cite_ref-19" class="reference"><a href="#cite_note-19">&#91;19&#93;</a></sup> Together, these studies underscore the importance of Fc status in antibody-based <a href="/wiki/Immune_checkpoint" title="Immune checkpoint">immune checkpoint</a> targeting strategies.
</p>
<h4><span id="Human.2Fnon-human_balance"></span><span class="mw-headline" id="Human/non-human_balance">Human/non-human balance</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=11" title="Edit section: Human/non-human balance">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Antibodies are also referred to as murine, chimeric, humanized and human. Murine antibodies are from a different species and carry a risk of immune reaction. Chimeric antibodies attempt to reduce murine antibodies' <a href="/wiki/Immunogenicity" title="Immunogenicity">immunogenicity</a> by replacing part of the antibody with the corresponding human counterpart, known as the constant region. Humanized antibodies are almost completely human; only the <a href="/wiki/Complementarity_determining_regions" class="mw-redirect" title="Complementarity determining regions">complementarity determining regions</a> of the <a href="/wiki/Variable_region" class="mw-redirect" title="Variable region">variable regions</a> are derived from murine sources. Human antibodies have been produced using unmodified human DNA.<sup id="cite_ref-:0_14-1" class="reference"><a href="#cite_note-:0-14">&#91;14&#93;</a></sup>
</p>
<div class="thumb tleft"><div class="thumbinner" style="width:222px;"><a href="/wiki/File:Antibody-dependent_cell-mediated_cytotoxicity.png" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/0/09/Antibody-dependent_cell-mediated_cytotoxicity.png/220px-Antibody-dependent_cell-mediated_cytotoxicity.png" decoding="async" width="220" height="165" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/0/09/Antibody-dependent_cell-mediated_cytotoxicity.png/330px-Antibody-dependent_cell-mediated_cytotoxicity.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/0/09/Antibody-dependent_cell-mediated_cytotoxicity.png/440px-Antibody-dependent_cell-mediated_cytotoxicity.png 2x" data-file-width="960" data-file-height="720" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/wiki/File:Antibody-dependent_cell-mediated_cytotoxicity.png" class="internal" title="Enlarge"></a></div>Antibody-dependent cell-mediated cytotoxicity. When the Fc receptors on natural killer (NK) cells interact with Fc regions of antibodies bound to cancer cells, the NK cell releases perforin and granzyme, leading to cancer cell apoptosis.</div></div></div>
<h3><span class="mw-headline" id="Cell_death_mechanisms">Cell death mechanisms</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=12" title="Edit section: Cell death mechanisms">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<h4><span id="Antibody-dependent_cell-mediated_cytotoxicity_.28ADCC.29"></span><span class="mw-headline" id="Antibody-dependent_cell-mediated_cytotoxicity_(ADCC)">Antibody-dependent cell-mediated cytotoxicity (ADCC)</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=13" title="Edit section: Antibody-dependent cell-mediated cytotoxicity (ADCC)">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p><a href="/wiki/Antibody-dependent_cell-mediated_cytotoxicity" class="mw-redirect" title="Antibody-dependent cell-mediated cytotoxicity">Antibody-dependent cell-mediated cytotoxicity</a> (ADCC) requires antibodies to bind to target cell surfaces. Antibodies are formed of a binding region (Fab) and the Fc region that can be detected by immune system cells via their <a href="/wiki/Fc_receptor" title="Fc receptor">Fc surface receptors</a>. Fc receptors are found on many immune system cells, including NK cells. When NK cells encounter antibody-coated cells, the latter's Fc regions interact with their Fc receptors, releasing <a href="/wiki/Perforin" title="Perforin">perforin</a> and <a href="/wiki/Granzyme_B" title="Granzyme B">granzyme B</a> to kill the tumor cell. Examples include <a href="/wiki/Rituximab" title="Rituximab">Rituximab</a>, <a href="/wiki/Ofatumumab" title="Ofatumumab">Ofatumumab</a> and Alemtuzumab. Antibodies under development have altered Fc regions that have higher affinity for a specific type of Fc receptor, FcγRIIIA, which can dramatically increase effectiveness.<sup id="cite_ref-20" class="reference"><a href="#cite_note-20">&#91;20&#93;</a></sup><sup id="cite_ref-21" class="reference"><a href="#cite_note-21">&#91;21&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Complement">Complement</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=14" title="Edit section: Complement">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>The <a href="/wiki/Complement_system" title="Complement system">complement system</a> includes blood proteins that can cause cell death after an antibody binds to the cell surface (the <a href="/wiki/Classical_complement_pathway" title="Classical complement pathway">classical complement pathway</a>, among the ways of complement activation). Generally the system deals with foreign pathogens, but can be activated with therapeutic antibodies in cancer. The system can be triggered if the antibody is chimeric, humanized or human; as long as it contains the <a href="/wiki/IgG1" class="mw-redirect" title="IgG1">IgG1</a> <a href="/wiki/Fc_region" class="mw-redirect" title="Fc region">Fc region</a>. Complement can lead to cell death by activation of the <a href="/wiki/Membrane_attack_complex" class="mw-redirect" title="Membrane attack complex">membrane attack complex</a>, known as complement-dependent <a href="/wiki/Cytotoxicity" title="Cytotoxicity">cytotoxicity</a>; enhancement of <a href="/wiki/Antibody-dependent_cell-mediated_cytotoxicity" class="mw-redirect" title="Antibody-dependent cell-mediated cytotoxicity">antibody-dependent cell-mediated cytotoxicity</a>; and CR3-dependent cellular cytotoxicity. Complement-dependent cytotoxicity occurs when antibodies bind to the cancer cell surface, the C1 complex binds to these antibodies and subsequently protein pores are formed in the cancer <a href="/wiki/Cell_membrane" title="Cell membrane">cell membrane</a>.<sup id="cite_ref-22" class="reference"><a href="#cite_note-22">&#91;22&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="FDA-approved_antibodies">FDA-approved antibodies</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=15" title="Edit section: FDA-approved antibodies">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<table class="wikitable" style="margin: 1em auto 1em auto" width="600px" align="right">
<caption><b>Cancer immunotherapy:Monoclonal antibodies</b><sup id="cite_ref-pmid22437872_13-1" class="reference"><a href="#cite_note-pmid22437872-13">&#91;13&#93;</a></sup><sup id="cite_ref-Waldmann_23-0" class="reference"><a href="#cite_note-Waldmann-23">&#91;23&#93;</a></sup>
</caption>
<tbody><tr>
<th>Antibody
</th>
<th>Brand name
</th>
<th>Type
</th>
<th>Target
</th>
<th>Approval date
</th>
<th>Approved treatment(s)
</th></tr>
<tr>
<td><a href="/wiki/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a>
</td>
<td>Campath
</td>
<td>humanized
</td>
<td><a href="/wiki/CD52" title="CD52">CD52</a></td>
<td>2001</td>
<td><a href="/wiki/B-cell" class="mw-redirect" title="B-cell">B-cell</a> <a href="/wiki/Chronic_lymphocytic_leukemia" title="Chronic lymphocytic leukemia">chronic lymphocytic leukemia</a> (CLL)<sup id="cite_ref-24" class="reference"><a href="#cite_note-24">&#91;24&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Atezolizumab" title="Atezolizumab">Atezolizumab</a>
</td>
<td>Tecentriq
</td>
<td>humanized
</td>
<td><a href="/wiki/PD-L1" title="PD-L1">PD-L1</a>
</td>
<td>2016
</td>
<td><a href="/wiki/Bladder_cancer" title="Bladder cancer">bladder cancer</a><sup id="cite_ref-FDA-BC-2016_25-0" class="reference"><a href="#cite_note-FDA-BC-2016-25">&#91;25&#93;</a></sup>
</td></tr>
<tr>
<td>Avelumab
</td>
<td>Bavencio
</td>
<td>human
</td>
<td><a href="/wiki/PD-L1" title="PD-L1">PD-L1</a>
</td>
<td>2017
</td>
<td>metastatic Merkel cell carcinoma<sup id="cite_ref-26" class="reference"><a href="#cite_note-26">&#91;26&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Ipilimumab" title="Ipilimumab">Ipilimumab</a>
</td>
<td>Yervoy
</td>
<td>human
</td>
<td><a href="/wiki/CTLA4" class="mw-redirect" title="CTLA4">CTLA4</a>
</td>
<td>2011
</td>
<td>metastatic <a href="/wiki/Melanoma" title="Melanoma">melanoma</a><sup id="cite_ref-27" class="reference"><a href="#cite_note-27">&#91;27&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Ofatumumab" title="Ofatumumab">Ofatumumab</a>
</td>
<td>Arzerra
</td>
<td>human
</td>
<td><a href="/wiki/CD20" title="CD20">CD20</a>
</td>
<td>2009
</td>
<td>refractory <a href="/wiki/Chronic_myelomonocytic_leukaemia" class="mw-redirect" title="Chronic myelomonocytic leukaemia">CLL</a><sup id="cite_ref-28" class="reference"><a href="#cite_note-28">&#91;28&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Nivolumab" title="Nivolumab">Nivolumab</a>
</td>
<td>Opdivo
</td>
<td>human
</td>
<td><a href="/wiki/PD-1" class="mw-redirect" title="PD-1">PD-1</a>
</td>
<td>2014
</td>
<td><a href="/wiki/Surgery#Types_of_surgery" title="Surgery">unresectable</a> or <a href="/wiki/Metastatic_melanoma" class="mw-redirect" title="Metastatic melanoma">metastatic melanoma</a>, <a href="/wiki/Non-small_cell_lung_cancer" class="mw-redirect" title="Non-small cell lung cancer">squamous non-small cell lung cancer</a>, Renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, classical hodgkin lymphoma<sup id="cite_ref-sa15_29-0" class="reference"><a href="#cite_note-sa15-29">&#91;29&#93;</a></sup><sup id="cite_ref-30" class="reference"><a href="#cite_note-30">&#91;30&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Pembrolizumab" title="Pembrolizumab">Pembrolizumab</a>
</td>
<td>Keytruda
</td>
<td>humanized
</td>
<td><a href="/wiki/PD-1" class="mw-redirect" title="PD-1">PD-1</a>
</td>
<td>2014
</td>
<td>metastatic melanoma<sup id="cite_ref-sa15_29-1" class="reference"><a href="#cite_note-sa15-29">&#91;29&#93;</a></sup>
</td></tr>
<tr>
<td><a href="/wiki/Rituximab" title="Rituximab">Rituximab</a>
</td>
<td>Rituxan, Mabthera
</td>
<td>chimeric
</td>
<td><a href="/wiki/CD20" title="CD20">CD20</a>
</td>
<td>1997
</td>
<td><a href="/wiki/Non-Hodgkin_lymphoma" title="Non-Hodgkin lymphoma">non-Hodgkin lymphoma</a><sup id="cite_ref-31" class="reference"><a href="#cite_note-31">&#91;31&#93;</a></sup>
</td></tr>
<tr>
<td>Durvalumab
</td>
<td>Imfinzi
</td>
<td>human
</td>
<td>PD-L1
</td>
<td>2017
</td>
<td>bladder cancer<sup id="cite_ref-32" class="reference"><a href="#cite_note-32">&#91;32&#93;</a></sup> non-small cell lung cancer<sup id="cite_ref-33" class="reference"><a href="#cite_note-33">&#91;33&#93;</a></sup>
</td></tr>
</tbody></table>
<h4><span class="mw-headline" id="Alemtuzumab">Alemtuzumab</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=16" title="Edit section: Alemtuzumab">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p><a href="/wiki/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a> (Campath-1H) is an anti-<a href="/wiki/CD52" title="CD52">CD52</a> humanized IgG1 monoclonal antibody indicated for the treatment of <a href="/wiki/Fludarabine" title="Fludarabine">fludarabine</a>-refractory <a href="/wiki/Chronic_lymphocytic_leukemia" title="Chronic lymphocytic leukemia">chronic lymphocytic leukemia</a> (CLL), <a href="/wiki/Cutaneous_T-cell_lymphoma" class="mw-redirect" title="Cutaneous T-cell lymphoma">cutaneous T-cell lymphoma</a>, <a href="/wiki/Peripheral_T-cell_lymphoma" title="Peripheral T-cell lymphoma">peripheral T-cell lymphoma</a> and <a href="/wiki/T-cell_prolymphocytic_leukemia" title="T-cell prolymphocytic leukemia">T-cell prolymphocytic leukemia</a>. CD52 is found on &gt;95% of peripheral blood <a href="/wiki/Lymphocyte" title="Lymphocyte">lymphocytes</a> (both T-cells and B-cells) and <a href="/wiki/Monocyte" title="Monocyte">monocytes</a>, but its function in lymphocytes is unknown. It binds to CD52 and initiates its cytotoxic effect by complement fixation and ADCC mechanisms. Due to the antibody target (cells of the immune system) common complications of alemtuzumab therapy are infection, toxicity and <a href="/wiki/Myelosuppression" class="mw-redirect" title="Myelosuppression">myelosuppression</a>.<sup id="cite_ref-34" class="reference"><a href="#cite_note-34">&#91;34&#93;</a></sup><sup id="cite_ref-35" class="reference"><a href="#cite_note-35">&#91;35&#93;</a></sup><sup id="cite_ref-36" class="reference"><a href="#cite_note-36">&#91;36&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Atezolizumab">Atezolizumab</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=17" title="Edit section: Atezolizumab">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/Atezolizumab" title="Atezolizumab">Atezolizumab</a></div>
<p><a href="/wiki/Durvalumab" title="Durvalumab">Durvalumab</a> (Imfinzi) is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules. Durvalumab is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
</p>
<ul><li>have disease progression during or following platinum-containing chemotherapy.</li>
<li>have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.</li></ul>
<h4><span class="mw-headline" id="Ipilimumab">Ipilimumab</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=18" title="Edit section: Ipilimumab">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p><a href="/wiki/Ipilimumab" title="Ipilimumab">Ipilimumab</a> (Yervoy) is a human <a href="/wiki/IgG1" class="mw-redirect" title="IgG1">IgG1</a> antibody that binds the surface protein <a href="/wiki/CTLA4" class="mw-redirect" title="CTLA4">CTLA4</a>. In normal physiology T-cells are activated by two signals: the <a href="/wiki/T-cell_receptor" title="T-cell receptor">T-cell receptor</a> binding to an <a href="/wiki/Antigen" title="Antigen">antigen</a>-<a href="/wiki/Major_histocompatibility_complex" title="Major histocompatibility complex">MHC complex</a> and T-cell surface receptor CD28 binding to <a href="/wiki/CD80" title="CD80">CD80</a> or <a href="/wiki/CD86" title="CD86">CD86</a> proteins. CTLA4 binds to CD80 or CD86, preventing the binding of CD28 to these surface proteins and therefore negatively regulates the activation of T-cells.<sup id="cite_ref-pmid21629286_37-0" class="reference"><a href="#cite_note-pmid21629286-37">&#91;37&#93;</a></sup><sup id="cite_ref-pmid21900389_38-0" class="reference"><a href="#cite_note-pmid21900389-38">&#91;38&#93;</a></sup><sup id="cite_ref-pmid21294471_39-0" class="reference"><a href="#cite_note-pmid21294471-39">&#91;39&#93;</a></sup><sup id="cite_ref-pmid11244047_40-0" class="reference"><a href="#cite_note-pmid11244047-40">&#91;40&#93;</a></sup>
</p><p>Active <a href="/wiki/Cytotoxic_T-cell" class="mw-redirect" title="Cytotoxic T-cell">cytotoxic T-cells</a> are required for the immune system to attack melanoma cells. Normally inhibited active melanoma-specific cytotoxic T-cells can produce an effective anti-tumor response. Ipilumumab can cause a shift in the ratio of <a href="/wiki/Regulatory_T_cell" title="Regulatory T cell">regulatory T-cells</a> to cytotoxic T-cells to increase the anti-tumor response. Regulatory T-cells inhibit other T-cells, which may benefit the tumor.<sup id="cite_ref-pmid21629286_37-1" class="reference"><a href="#cite_note-pmid21629286-37">&#91;37&#93;</a></sup><sup id="cite_ref-pmid21900389_38-1" class="reference"><a href="#cite_note-pmid21900389-38">&#91;38&#93;</a></sup><sup id="cite_ref-pmid21294471_39-1" class="reference"><a href="#cite_note-pmid21294471-39">&#91;39&#93;</a></sup><sup id="cite_ref-pmid11244047_40-1" class="reference"><a href="#cite_note-pmid11244047-40">&#91;40&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Nivolumab">Nivolumab</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=19" title="Edit section: Nivolumab">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/Nivolumab" title="Nivolumab">Nivolumab</a></div>
<h4><span class="mw-headline" id="Ofatumumab">Ofatumumab</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=20" title="Edit section: Ofatumumab">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p><a href="/wiki/Ofatumumab" title="Ofatumumab">Ofatumumab</a> is a second generation human <a href="/wiki/IgG1" class="mw-redirect" title="IgG1">IgG1</a> antibody that binds to <a href="/wiki/CD20" title="CD20">CD20</a>. It is used in the treatment of <a href="/wiki/Chronic_lymphocytic_leukemia" title="Chronic lymphocytic leukemia">chronic lymphocytic leukemia</a> (CLL) because the cancerous cells of CLL are usually CD20-expressing B-cells. Unlike <a href="/wiki/Rituximab" title="Rituximab">rituximab</a>, which binds to a large loop of the CD20 protein, ofatumumab binds to a separate, small loop. This may explain their different characteristics. Compared to rituximab, ofatumumab induces complement-dependent cytotoxicity at a lower dose with less <a href="/wiki/Immunogenicity" title="Immunogenicity">immunogenicity</a>.<sup id="cite_ref-41" class="reference"><a href="#cite_note-41">&#91;41&#93;</a></sup><sup id="cite_ref-42" class="reference"><a href="#cite_note-42">&#91;42&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Pembrolizumab">Pembrolizumab</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=21" title="Edit section: Pembrolizumab">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>As of 2017, <a href="/wiki/Pembrolizumab" title="Pembrolizumab">pembrolizumab</a>, which blocks <a href="/wiki/PD-1" class="mw-redirect" title="PD-1">PD-1</a>, programmed cell death protein 1, has been used via intravenous infusion to treat inoperable or metastatic <a href="/wiki/Melanoma" title="Melanoma">melanoma</a>, metastatic <a href="/wiki/Non-small_cell_lung_cancer" class="mw-redirect" title="Non-small cell lung cancer">non-small cell lung cancer</a> (NSCLC) in certain situations, as a second-line treatment for <a href="/wiki/Head_and_neck_squamous_cell_carcinoma" class="mw-redirect" title="Head and neck squamous cell carcinoma">head and neck squamous cell carcinoma</a> (HNSCC), after <a href="/wiki/Platinum-based_antineoplastic" title="Platinum-based antineoplastic">platinum-based chemotherapy</a>, and for the treatment of adult and pediatric patients with refractory classic <a href="/wiki/Hodgkin%27s_lymphoma" title="Hodgkin&#39;s lymphoma">Hodgkin's lymphoma</a> (cHL).<sup id="cite_ref-USlabel2016_43-0" class="reference"><a href="#cite_note-USlabel2016-43">&#91;43&#93;</a></sup><sup id="cite_ref-UKlabel2016_44-0" class="reference"><a href="#cite_note-UKlabel2016-44">&#91;44&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Rituximab">Rituximab</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=22" title="Edit section: Rituximab">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p><a href="/wiki/Rituximab" title="Rituximab">Rituximab</a> is a chimeric monoclonal IgG1 antibody specific for CD20, developed from its parent antibody <a href="/wiki/Ibritumomab" class="mw-redirect" title="Ibritumomab">Ibritumomab</a>. As with ibritumomab, rituximab targets CD20, making it effective in treating certain B-cell malignancies. These include aggressive and indolent lymphomas such as <a href="/wiki/Diffuse_large_B-cell_lymphoma" title="Diffuse large B-cell lymphoma">diffuse large B-cell lymphoma</a> and follicular lymphoma and <a href="/wiki/Leukemia" title="Leukemia">leukemias</a> such as B-cell <a href="/wiki/Chronic_lymphocytic_leukemia" title="Chronic lymphocytic leukemia">chronic lymphocytic leukemia</a>. Although the function of CD20 is relatively unknown, CD20 may be a <a href="/wiki/Calcium_channel" title="Calcium channel">calcium channel</a> involved in B-cell activation. The antibody's mode of action is primarily through the induction of ADCC and <a href="/wiki/Complement_system" title="Complement system">complement-mediated cytotoxicity.</a> Other mechanisms include apoptosis<sup class="noprint Inline-Template" style="margin-left:0.1em; white-space:nowrap;">&#91;<i><a href="/wiki/Wikipedia:Please_clarify" title="Wikipedia:Please clarify"><span title="Vague (April 2016)">clarification needed</span></a></i>&#93;</sup> and cellular growth arrest. Rituximab also increases the sensitivity of cancerous B-cells to chemotherapy.<sup id="cite_ref-45" class="reference"><a href="#cite_note-45">&#91;45&#93;</a></sup><sup id="cite_ref-Plosker_2003_803–43_46-0" class="reference"><a href="#cite_note-Plosker_2003_803–43-46">&#91;46&#93;</a></sup><sup id="cite_ref-Plosker_2003_803–43_46-1" class="reference"><a href="#cite_note-Plosker_2003_803–43-46">&#91;46&#93;</a></sup><sup id="cite_ref-47" class="reference"><a href="#cite_note-47">&#91;47&#93;</a></sup><sup id="cite_ref-Janeway_48-0" class="reference"><a href="#cite_note-Janeway-48">&#91;48&#93;</a></sup><sup id="cite_ref-49" class="reference"><a href="#cite_note-49">&#91;49&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Cytokine_therapy">Cytokine therapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=23" title="Edit section: Cytokine therapy">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p><a href="/wiki/Cytokine" title="Cytokine">Cytokines</a> are proteins produced by many types of cells present within a tumor. They can modulate immune responses. The tumor often employs them to allow it to grow and reduce the immune response. These immune-modulating effects allow them to be used as drugs to provoke an immune response. Two commonly used cytokines are interferons and interleukins.<sup id="cite_ref-pmid14708024_50-0" class="reference"><a href="#cite_note-pmid14708024-50">&#91;50&#93;</a></sup>
</p><p><a href="/wiki/Interleukin-2" class="mw-redirect" title="Interleukin-2">Interleukin-2</a> and <a href="/wiki/Interferon" title="Interferon">interferon</a>-α are cytokines, proteins that regulate and coordinate the behavior of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as passive cancer treatments. Interferon-α is used in the treatment of <a href="/wiki/Hairy-cell_leukaemia" class="mw-redirect" title="Hairy-cell leukaemia">hairy-cell leukaemia</a>, AIDS-related <a href="/wiki/Kaposi%27s_sarcoma" title="Kaposi&#39;s sarcoma">Kaposi's sarcoma</a>, <a href="/wiki/Follicular_lymphoma" title="Follicular lymphoma">follicular lymphoma</a>, <a href="/wiki/Chronic_myeloid_leukaemia" class="mw-redirect" title="Chronic myeloid leukaemia">chronic myeloid leukaemia</a> and <a href="/wiki/Malignant_melanoma" class="mw-redirect" title="Malignant melanoma">malignant melanoma</a>. Interleukin-2 is used in the treatment of <a href="/wiki/Malignant_melanoma" class="mw-redirect" title="Malignant melanoma">malignant melanoma</a> and <a href="/wiki/Renal_cell_carcinoma" title="Renal cell carcinoma">renal cell carcinoma</a>.
</p>
<h3><span class="mw-headline" id="Interferon">Interferon</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=24" title="Edit section: Interferon">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Interferon" title="Interferon">Interferons</a> are produced by the immune system. They are usually involved in anti-viral response, but also have use for cancer. They fall in three groups: <a href="/wiki/Interferon_type_I" title="Interferon type I">type I</a> (IFNα and IFNβ), <a href="/wiki/Interferon_type_II" title="Interferon type II">type II</a> (IFNγ) and <a href="/wiki/Type_III_interferon" class="mw-redirect" title="Type III interferon">type III</a> (IFNλ). IFNα has been approved for use in <a href="/wiki/Hairy-cell_leukaemia" class="mw-redirect" title="Hairy-cell leukaemia">hairy-cell leukaemia</a>, AIDS-related Kaposi's sarcoma, follicular lymphoma, <a href="/wiki/Chronic_myeloid_leukaemia" class="mw-redirect" title="Chronic myeloid leukaemia">chronic myeloid leukaemia</a> and melanoma. Type I and II IFNs have been researched extensively and although both types promote anti-tumor immune system effects, only type I IFNs have been shown to be clinically effective. IFNλ shows promise for its anti-tumor effects in <a href="/wiki/Animal_model" class="mw-redirect" title="Animal model">animal models</a>.<sup id="cite_ref-51" class="reference"><a href="#cite_note-51">&#91;51&#93;</a></sup><sup id="cite_ref-52" class="reference"><a href="#cite_note-52">&#91;52&#93;</a></sup>
</p><p>Unlike type I IFNs, <a href="/wiki/Interferon_gamma" title="Interferon gamma">Interferon gamma</a> is not approved yet for the treatment of any cancer.However, improved survival was observed when <a href="/wiki/Interferon_gamma" title="Interferon gamma">Interferon gamma</a> was administrated to patients with <a href="/wiki/Bladder_carcinoma" class="mw-redirect" title="Bladder carcinoma">bladder carcinoma</a> and <a href="/wiki/Melanoma" title="Melanoma">melanoma</a> cancers. The most promising result was achieved in patients with stage 2 and 3 of <a href="/wiki/Ovarian_carcinoma" class="mw-redirect" title="Ovarian carcinoma">ovarian carcinoma</a>.The <i><a href="/wiki/In_vitro" title="In vitro">in vitro</a></i> study of IFN-gamma in cancer cells is more extensive and results indicate anti-proliferative activity of IFN-gamma leading to the growth inhibition or cell death, generally induced by <a href="/wiki/Apoptosis" title="Apoptosis">apoptosis</a> but sometimes by <a href="/wiki/Autophagy" title="Autophagy">autophagy</a>.<sup id="cite_ref-53" class="reference"><a href="#cite_note-53">&#91;53&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Interleukin">Interleukin</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=25" title="Edit section: Interleukin">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Interleukin" title="Interleukin">Interleukins</a> have an array of immune system effects. <a href="/wiki/Interleukin-2" class="mw-redirect" title="Interleukin-2">Interleukin-2</a> is used in the treatment of <a href="/wiki/Malignant_melanoma" class="mw-redirect" title="Malignant melanoma">malignant melanoma</a> and <a href="/wiki/Renal_cell_carcinoma" title="Renal cell carcinoma">renal cell carcinoma</a>. In normal physiology it promotes both effector T cells and T-regulatory cells, but its exact mechanism of action is unknown.<sup id="cite_ref-pmid14708024_50-1" class="reference"><a href="#cite_note-pmid14708024-50">&#91;50&#93;</a></sup><sup id="cite_ref-54" class="reference"><a href="#cite_note-54">&#91;54&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Combination_immunotherapy">Combination immunotherapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=26" title="Edit section: Combination immunotherapy">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Combining various immunotherapies such as PD1 and CTLA4 inhibitors can enhance anti-tumor response leading to durable responses.<sup id="cite_ref-55" class="reference"><a href="#cite_note-55">&#91;55&#93;</a></sup><sup id="cite_ref-56" class="reference"><a href="#cite_note-56">&#91;56&#93;</a></sup>
</p><p><a href="/wiki/Combinatorial_ablation_and_immunotherapy" title="Combinatorial ablation and immunotherapy">Combining ablation therapy of tumors with immunotherapy</a> enhances the immunostimulating response and has synergistic effects for curative metastatic cancer treatment.<sup id="cite_ref-hindawi9251375_57-0" class="reference"><a href="#cite_note-hindawi9251375-57">&#91;57&#93;</a></sup>
</p><p>Combining checkpoint immunotherapies with pharmaceutical agents has the potential to improve response, and such combination therapies are a highly investigated area of clinical investigation.<sup id="cite_ref-58" class="reference"><a href="#cite_note-58">&#91;58&#93;</a></sup> Immunostimulatory drugs such as <a href="/wiki/Colony_stimulating_factor_1_receptor" title="Colony stimulating factor 1 receptor">CSF-1R</a> inhibitors and <a href="/wiki/Toll-like_receptor" title="Toll-like receptor">TLR</a> agonists have been particularly effective in this setting.<sup id="cite_ref-59" class="reference"><a href="#cite_note-59">&#91;59&#93;</a></sup><sup id="cite_ref-60" class="reference"><a href="#cite_note-60">&#91;60&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Polysaccharide-K">Polysaccharide-K</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=27" title="Edit section: Polysaccharide-K">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Japan's <a href="/wiki/Ministry_of_Health,_Labour_and_Welfare_(Japan)" class="mw-redirect" title="Ministry of Health, Labour and Welfare (Japan)">Ministry of Health, Labour and Welfare</a> approved the use of <a href="/wiki/Polysaccharide-K" title="Polysaccharide-K">polysaccharide-K</a> extracted from the mushroom, <i><a href="/wiki/Coriolus_versicolor" class="mw-redirect" title="Coriolus versicolor">Coriolus versicolor</a></i>, in the 1980s, to stimulate the immune systems of patients undergoing chemotherapy.  It is a <a href="/wiki/Dietary_supplement" title="Dietary supplement">dietary supplement</a> in the US and other jurisdictions.<sup id="cite_ref-CoriolusVersicolor_61-0" class="reference"><a href="#cite_note-CoriolusVersicolor-61">&#91;61&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Genetic_pre-testing_for_therapeutic_significance">Genetic pre-testing for therapeutic significance</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=28" title="Edit section: Genetic pre-testing for therapeutic significance">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Because of the high cost of many of the immunotherapy medications and the reluctance of medical insurance companies to prepay for their prescriptions various test methods have been proposed, to attempt to forecast the effectiveness of these medications. The detection of <a href="/wiki/PD-L1" title="PD-L1">PD-L1</a> protein seemed to be an indication of cancer susceptible to several immunotherapy medications, but research found that both the lack of this protein or its inclusion in the cancerous tissue was inconclusive, due to the little-understood varying quantities of the protein during different times and locations within the infected cells and tissue.<sup id="cite_ref-62" class="reference"><a href="#cite_note-62">&#91;62&#93;</a></sup><sup id="cite_ref-63" class="reference"><a href="#cite_note-63">&#91;63&#93;</a></sup><sup id="cite_ref-64" class="reference"><a href="#cite_note-64">&#91;64&#93;</a></sup>
</p><p>In 2018 some genetic indications such as <a href="/w/index.php?title=Tumor_Mutational_Burden&amp;action=edit&amp;redlink=1" class="new" title="Tumor Mutational Burden (page does not exist)">Tumor Mutational Burden</a> (TMB, the number of mutations within a targeted genetic region in the cancerous cell's DNA), and <a href="/wiki/Microsatellite_instability" title="Microsatellite instability">Microsatellite instability</a> (MSI, the quantity of impaired DNA mismatch leading to probable mutations), have been approved by the FDA as good indicators for the probability of effective treatment of immunotherapy medication for certain cancers, but research is still in progress.<sup id="cite_ref-65" class="reference"><a href="#cite_note-65">&#91;65&#93;</a></sup><sup id="cite_ref-66" class="reference"><a href="#cite_note-66">&#91;66&#93;</a></sup><sup id="cite_ref-67" class="reference"><a href="#cite_note-67">&#91;67&#93;</a></sup> 
</p><p>In some cases the FDA has approved genetic tests for medication that is specific to certain genetic markers. For example, the FDA approved <a href="/wiki/BRAF_(gene)" title="BRAF (gene)">BRAF</a> associated medication for metastatic melanoma, to be administered to patients after testing for the BRAF genetic mutation.<sup id="cite_ref-68" class="reference"><a href="#cite_note-68">&#91;68&#93;</a></sup>
</p><p>Tests of this sort are being widely advertised for general cancer treatment and are expensive. In the past, some genetic testing for cancer treatment has been involved in scams such as the Duke University Cancer Fraud scandal, or claimed to be hoaxes.<sup id="cite_ref-69" class="reference"><a href="#cite_note-69">&#91;69&#93;</a></sup><sup id="cite_ref-70" class="reference"><a href="#cite_note-70">&#91;70&#93;</a></sup><sup id="cite_ref-71" class="reference"><a href="#cite_note-71">&#91;71&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Research">Research</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=29" title="Edit section: Research">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Adoptive_T-cell_therapy">Adoptive T-cell therapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=30" title="Edit section: Adoptive T-cell therapy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="thumb tright"><div class="thumbinner" style="width:222px;"><a href="/wiki/File:Adoptive_T-cell_therapy.png" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/9/9e/Adoptive_T-cell_therapy.png/220px-Adoptive_T-cell_therapy.png" decoding="async" width="220" height="165" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/9/9e/Adoptive_T-cell_therapy.png/330px-Adoptive_T-cell_therapy.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/9/9e/Adoptive_T-cell_therapy.png/440px-Adoptive_T-cell_therapy.png 2x" data-file-width="960" data-file-height="720" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/wiki/File:Adoptive_T-cell_therapy.png" class="internal" title="Enlarge"></a></div>Cancer specific T-cells can be obtained by fragmentation and isolation of tumour infiltrating lymphocytes, or by genetically engineering cells from peripheral blood. The cells are activated and grown prior to transfusion into the recipient (tumor bearer).</div></div></div>
<p>Adoptive T cell therapy is a form of <a href="/wiki/Passive_immunization" class="mw-redirect" title="Passive immunization">passive immunization</a> by the transfusion of T-cells (<a href="/wiki/Adoptive_cell_transfer" title="Adoptive cell transfer">adoptive cell transfer</a>). They are found in blood and tissue and usually activate when they find foreign <a href="/wiki/Pathogen" title="Pathogen">pathogens</a>. Specifically they activate when the T-cell's surface receptors encounter cells that display parts of foreign proteins on their surface antigens. These can be either infected cells, or <a href="/wiki/Antigen_presenting_cell" class="mw-redirect" title="Antigen presenting cell">antigen presenting cells</a> (APCs). They are found in normal tissue and in tumor tissue, where they are known as <a href="/wiki/Tumor_infiltrating_lymphocyte" class="mw-redirect" title="Tumor infiltrating lymphocyte">tumor infiltrating lymphocytes</a> (TILs). They are activated by the presence of APCs such as dendritic cells that present <a href="/wiki/Tumor_antigen" title="Tumor antigen">tumor antigens</a>. Although these cells can attack the tumor, the environment within the tumor is highly immunosuppressive, preventing immune-mediated tumour death.<sup id="cite_ref-NatureRev2012_72-0" class="reference"><a href="#cite_note-NatureRev2012-72">&#91;72&#93;</a></sup>
</p><p>Multiple ways of producing and obtaining tumour targeted T-cells have been developed. T-cells specific to a tumor antigen can be removed from a tumor sample (TILs) or filtered from blood. Subsequent activation and culturing is performed <i>ex vivo,</i> with the results reinfused. Activation can take place through gene therapy, or by exposing the T cells to tumor antigens.
</p><p>As of 2014, multiple ACT clinical trials were underway.<sup id="cite_ref-73" class="reference"><a href="#cite_note-73">&#91;73&#93;</a></sup><sup id="cite_ref-74" class="reference"><a href="#cite_note-74">&#91;74&#93;</a></sup><sup id="cite_ref-75" class="reference"><a href="#cite_note-75">&#91;75&#93;</a></sup><sup id="cite_ref-76" class="reference"><a href="#cite_note-76">&#91;76&#93;</a></sup><sup id="cite_ref-77" class="reference"><a href="#cite_note-77">&#91;77&#93;</a></sup> Importantly, one study from 2018 showed that clinical responses can be obtained in patients with metastatic melanoma resistant to multiple previous immunotherapies.<sup id="cite_ref-pmid29688262_78-0" class="reference"><a href="#cite_note-pmid29688262-78">&#91;78&#93;</a></sup>
</p><p>The first 2 adoptive T-cell therapies, <a href="/wiki/Tisagenlecleucel" title="Tisagenlecleucel">tisagenlecleucel</a> and <a href="/wiki/Axicabtagene_ciloleucel" title="Axicabtagene ciloleucel">axicabtagene ciloleucel</a>, were approved by the FDA in 2017.<sup id="cite_ref-79" class="reference"><a href="#cite_note-79">&#91;79&#93;</a></sup><sup id="cite_ref-fda.gov_12-1" class="reference"><a href="#cite_note-fda.gov-12">&#91;12&#93;</a></sup>
</p><p>Another approach is adoptive transfer of haploidentical <a href="/wiki/%CE%93%CE%B4_T_cells" class="mw-redirect" title="Γδ T cells">γδ T cells</a> or <a href="/wiki/NK_cells" class="mw-redirect" title="NK cells">NK cells</a> from a healthy donor. The major advantage of this approach is that these cells do not cause <a href="/wiki/GVHD" class="mw-redirect" title="GVHD">GVHD</a>. The disadvantage is frequently impaired function of the transferred cells.<sup id="cite_ref-pmid_=_24528541_80-0" class="reference"><a href="#cite_note-pmid_=_24528541-80">&#91;80&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Anti-CD47_therapy">Anti-CD47 therapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=31" title="Edit section: Anti-CD47 therapy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Many tumor cells overexpress <a href="/wiki/CD47" title="CD47">CD47</a> to escape <a href="/wiki/Immunosurveillance" class="mw-redirect" title="Immunosurveillance">immunosurveilance</a> of host immune system. CD47 binds to its receptor <a href="/wiki/Signal-regulatory_protein_alpha" title="Signal-regulatory protein alpha">signal regulatory protein alpha (SIRPα)</a> and downregulate <a href="/wiki/Phagocytosis" title="Phagocytosis">phagocytosis</a> of tumor cell.<sup id="cite_ref-81" class="reference"><a href="#cite_note-81">&#91;81&#93;</a></sup> Therefore, anti-CD47 therapy aims to restore clearance of tumor cells. Additionally, growing evidence supports the employment of tumor antigen-specific <a href="/wiki/Cell-mediated_immunity" title="Cell-mediated immunity">T cell response</a> in response to anti-CD47 therapy.<sup id="cite_ref-:1_82-0" class="reference"><a href="#cite_note-:1-82">&#91;82&#93;</a></sup><sup id="cite_ref-83" class="reference"><a href="#cite_note-83">&#91;83&#93;</a></sup> A number of therapeutics is being developed, including anti-CD47 <a href="/wiki/Antibodies" class="mw-redirect" title="Antibodies">antibodies</a>, engineered <a href="/wiki/Decoy_receptors" title="Decoy receptors">decoy receptors</a>, anti-SIRPα <a href="/wiki/Antibody" title="Antibody">antibodies</a> and bispecific agents.<sup id="cite_ref-:1_82-1" class="reference"><a href="#cite_note-:1-82">&#91;82&#93;</a></sup> As of 2017, wide range of solid and hematologic malignancies were being clinically tested.<sup id="cite_ref-:1_82-2" class="reference"><a href="#cite_note-:1-82">&#91;82&#93;</a></sup><sup id="cite_ref-84" class="reference"><a href="#cite_note-84">&#91;84&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Anti-GD2_antibodies">Anti-GD2 antibodies</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=32" title="Edit section: Anti-GD2 antibodies">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="thumb tright"><div class="thumbinner" style="width:222px;"><a href="/wiki/File:GD2_ganglioside.png" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/eb/GD2_ganglioside.png/220px-GD2_ganglioside.png" decoding="async" width="220" height="79" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/eb/GD2_ganglioside.png/330px-GD2_ganglioside.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/eb/GD2_ganglioside.png/440px-GD2_ganglioside.png 2x" data-file-width="3921" data-file-height="1410" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/wiki/File:GD2_ganglioside.png" class="internal" title="Enlarge"></a></div>The GD2 ganglioside</div></div></div>
<p><a href="/wiki/Carbohydrate" title="Carbohydrate">Carbohydrate</a> <a href="/wiki/Antigen" title="Antigen">antigens</a> on the surface of cells can be used as targets for immunotherapy. <a href="/wiki/GD2" title="GD2">GD2</a> is a <a href="/wiki/Ganglioside" title="Ganglioside">ganglioside</a> found on the surface of many types of cancer cell including <a href="/wiki/Neuroblastoma" title="Neuroblastoma">neuroblastoma</a>, <a href="/wiki/Retinoblastoma" title="Retinoblastoma">retinoblastoma</a>, <a href="/wiki/Melanoma" title="Melanoma">melanoma</a>, <a href="/wiki/Small_cell_lung_cancer" class="mw-redirect" title="Small cell lung cancer">small cell lung cancer</a>, <a href="/wiki/Brain_tumor" title="Brain tumor">brain tumors</a>, <a href="/wiki/Osteosarcoma" title="Osteosarcoma">osteosarcoma</a>, <a href="/wiki/Rhabdomyosarcoma" title="Rhabdomyosarcoma">rhabdomyosarcoma</a>, <a href="/wiki/Ewing%27s_sarcoma" title="Ewing&#39;s sarcoma">Ewing's sarcoma</a>, <a href="/wiki/Liposarcoma" title="Liposarcoma">liposarcoma</a>, <a href="/wiki/Fibrosarcoma" title="Fibrosarcoma">fibrosarcoma</a>, <a href="/wiki/Leiomyosarcoma" title="Leiomyosarcoma">leiomyosarcoma</a> and other <a href="/wiki/Soft_tissue_sarcoma" class="mw-redirect" title="Soft tissue sarcoma">soft tissue sarcomas</a>. It is not usually expressed on the surface of normal tissues, making it a good target for immunotherapy. As of 2014, clinical trials were underway.<sup id="cite_ref-85" class="reference"><a href="#cite_note-85">&#91;85&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Immune_checkpoints"><span id="Immune_checkpoint_blockade"></span> Immune checkpoints</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=33" title="Edit section: Immune checkpoints">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div role="note" class="hatnote navigation-not-searchable">Main articles: <a href="/wiki/Immune_checkpoint" title="Immune checkpoint">Immune checkpoint</a> and <a href="/wiki/Immunotherapy" title="Immunotherapy">Immunotherapy</a></div>
<div class="thumb tleft"><div class="thumbinner" style="width:442px;"><a href="/wiki/File:11_Hegasy_CTLA4_PD1_Immunotherapy.png" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/4/45/11_Hegasy_CTLA4_PD1_Immunotherapy.png/440px-11_Hegasy_CTLA4_PD1_Immunotherapy.png" decoding="async" width="440" height="311" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/4/45/11_Hegasy_CTLA4_PD1_Immunotherapy.png/660px-11_Hegasy_CTLA4_PD1_Immunotherapy.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/4/45/11_Hegasy_CTLA4_PD1_Immunotherapy.png/880px-11_Hegasy_CTLA4_PD1_Immunotherapy.png 2x" data-file-width="3508" data-file-height="2480" /></a>  <div class="thumbcaption"><div class="magnify"><a href="/wiki/File:11_Hegasy_CTLA4_PD1_Immunotherapy.png" class="internal" title="Enlarge"></a></div>Cancer therapy by inhibition of negative immune regulation (CTLA4, PD1)</div></div></div>
<p><a href="/wiki/Immune_checkpoint" title="Immune checkpoint">Immune checkpoints</a> affect immune system function. Immune checkpoints can be stimulatory or inhibitory. Tumors can use these checkpoints to protect themselves from immune system attacks. Currently approved checkpoint therapies block inhibitory checkpoint receptors. Blockade of negative feedback signaling to immune cells thus results in an enhanced immune response against tumors.<sup id="cite_ref-pmid22437870_86-0" class="reference"><a href="#cite_note-pmid22437870-86">&#91;86&#93;</a></sup>
</p><p>One ligand-receptor interaction under investigation is the interaction between the transmembrane <a href="/wiki/Programmed_cell_death_1" class="mw-redirect" title="Programmed cell death 1">programmed cell death 1</a> protein (PDCD1, PD-1; also known as CD279) and its ligand, <a href="/wiki/Programmed_cell_death_1_ligand_1" class="mw-redirect" title="Programmed cell death 1 ligand 1">PD-1 ligand 1</a> (PD-L1, CD274). PD-L1 on the cell surface binds to PD1 on an immune cell surface, which inhibits immune cell activity. Among PD-L1 functions is a key regulatory role on T cell activities. It appears that (cancer-mediated) upregulation of PD-L1 on the cell surface may inhibit T cells that might otherwise attack. PD-L1 on cancer cells also inhibits FAS- and interferon-dependent apoptosis, protecting cells from cytotoxic molecules produced by T cells. Antibodies that bind to either PD-1 or PD-L1 and therefore block the interaction may allow the T-cells to attack the tumor.<sup id="cite_ref-ReferenceA_87-0" class="reference"><a href="#cite_note-ReferenceA-87">&#91;87&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="CTLA-4_blockade">CTLA-4 blockade</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=34" title="Edit section: CTLA-4 blockade">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>The first checkpoint antibody approved by the FDA was ipilimumab, approved in 2011 for treatment of melanoma.<sup id="cite_ref-88" class="reference"><a href="#cite_note-88">&#91;88&#93;</a></sup> It blocks the immune checkpoint molecule <a href="/wiki/CTLA-4" title="CTLA-4">CTLA-4</a>. Clinical trials have also shown some benefits of anti-CTLA-4 therapy on lung cancer or pancreatic cancer, specifically in combination with other drugs.<sup id="cite_ref-89" class="reference"><a href="#cite_note-89">&#91;89&#93;</a></sup><sup id="cite_ref-90" class="reference"><a href="#cite_note-90">&#91;90&#93;</a></sup> In on-going trials the combination of CTLA-4 blockade with PD-1 or <a href="/wiki/PD-L1_inhibitor" class="mw-redirect" title="PD-L1 inhibitor">PD-L1 inhibitors</a> is tested on different types of cancer.<sup id="cite_ref-91" class="reference"><a href="#cite_note-91">&#91;91&#93;</a></sup>
</p><p>However, patients treated with check-point blockade (specifically CTLA-4 blocking antibodies), or a combination of check-point blocking antibodies, are at high risk of suffering from immune-related adverse events such as dermatologic, gastrointestinal, endocrine, or hepatic <a href="/wiki/Autoimmunity" title="Autoimmunity">autoimmune</a> reactions.<sup id="cite_ref-92" class="reference"><a href="#cite_note-92">&#91;92&#93;</a></sup> These are most likely due to the breadth of the induced T-cell activation when anti-CTLA-4 antibodies are administered by injection in the blood stream.
</p><p>Using a mouse model of bladder cancer, researchers have found that a local injection of a low dose anti-CTLA-4 in the tumour area had the same tumour inhibiting capacity as when the antibody was delivered in the blood.<sup id="cite_ref-:3_93-0" class="reference"><a href="#cite_note-:3-93">&#91;93&#93;</a></sup> At the same time the levels of circulating antibodies were lower, suggesting that local administration of the anti-CTLA-4 therapy might result in fewer adverse events.<sup id="cite_ref-:3_93-1" class="reference"><a href="#cite_note-:3-93">&#91;93&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="PD-1_inhibitors">PD-1 inhibitors</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=35" title="Edit section: PD-1 inhibitors">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Initial clinical trial results with IgG4 PD1 antibody <a href="/wiki/Nivolumab" title="Nivolumab">Nivolumab</a> were published in 2010.<sup id="cite_ref-pmid22437870_86-1" class="reference"><a href="#cite_note-pmid22437870-86">&#91;86&#93;</a></sup> It was approved in 2014. Nivolumab is approved to treat melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and <a href="/wiki/Hodgkin%27s_lymphoma" title="Hodgkin&#39;s lymphoma">Hodgkin's lymphoma</a>.<sup id="cite_ref-:2_94-0" class="reference"><a href="#cite_note-:2-94">&#91;94&#93;</a></sup> A 2016 clinical trial for non-small cell lung cancer failed to meet its primary endpoint for treatment in the first line setting, but is FDA approved in subsequent lines of therapy.<sup id="cite_ref-95" class="reference"><a href="#cite_note-95">&#91;95&#93;</a></sup>
</p><p><a href="/wiki/Pembrolizumab" title="Pembrolizumab">Pembrolizumab</a> is another PD1 inhibitor that was approved by the FDA in 2014. 
Keytruda (<a href="/wiki/Pembrolizumab" title="Pembrolizumab">Pembrolizumab</a>) is approved to treat melanoma and lung cancer.<sup id="cite_ref-:2_94-1" class="reference"><a href="#cite_note-:2-94">&#91;94&#93;</a></sup>
</p><p>Antibody <a href="/wiki/BGB-A317" class="mw-redirect" title="BGB-A317">BGB-A317</a> is a PD-1 inhibitor (designed to not bind Fc gamma receptor I) in early clinical trials.<sup id="cite_ref-96" class="reference"><a href="#cite_note-96">&#91;96&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="PD-L1_inhibitors">PD-L1 inhibitors</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=36" title="Edit section: PD-L1 inhibitors">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/PD-L1_inhibitor" class="mw-redirect" title="PD-L1 inhibitor">PD-L1 inhibitor</a></div><p>In May 2016, PD-L1 inhibitor <a href="/wiki/Atezolizumab" title="Atezolizumab">atezolizumab</a><sup id="cite_ref-97" class="reference"><a href="#cite_note-97">&#91;97&#93;</a></sup> was approved for treating bladder cancer.
</p><p>Anti-PD-L1 antibodies currently in development include <a href="/wiki/Avelumab" title="Avelumab">avelumab</a><sup id="cite_ref-98" class="reference"><a href="#cite_note-98">&#91;98&#93;</a></sup> and <a href="/wiki/Durvalumab" title="Durvalumab">durvalumab</a>,<sup id="cite_ref-99" class="reference"><a href="#cite_note-99">&#91;99&#93;</a></sup> in addition to an <a href="/wiki/Affimer" title="Affimer">affimer</a> biotherapeutic.<sup id="cite_ref-100" class="reference"><a href="#cite_note-100">&#91;100&#93;</a></sup>
</p>
<h4><span class="mw-headline" id="Other">Other</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=37" title="Edit section: Other">edit</a><span class="mw-editsection-bracket">]</span></span></h4>
<p>Other modes of enhancing [adoptive] immuno-therapy include targeting so-called <a href="/wiki/Intrinsic_checkpoint_blockade" class="mw-redirect" title="Intrinsic checkpoint blockade">intrinsic checkpoint blockades</a> e.g. <a href="/wiki/CISH" title="CISH">CISH</a>. A number of cancer patients do not respond to immune checkpoint blockade. Response rate may be improved by combining immune checkpoint blockade with additional rationally selected anticancer therapies (out of which some may stimulate T cell infiltration into tumors). For example, targeted therapies such, radiotherapy, vasculature targeting agents, and immunogenic chemotherapy<sup id="cite_ref-101" class="reference"><a href="#cite_note-101">&#91;101&#93;</a></sup> can improve immune checkpoint blockade response in animal models of cancer.
</p>
<h3><span class="mw-headline" id="Oncolytic_virus">Oncolytic virus</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=38" title="Edit section: Oncolytic virus">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>An <a href="/wiki/Oncolytic_virus" title="Oncolytic virus">oncolytic virus</a> is a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by <a href="/wiki/Oncolysis" class="mw-redirect" title="Oncolysis">oncolysis</a>, they release new infectious virus particles or virions to help destroy the remaining tumour. Oncolytic viruses are thought not only to cause direct destruction of the tumour cells, but also to stimulate host anti-tumour immune responses for long-term immunotherapy.<sup id="cite_ref-pmid27486853_102-0" class="reference"><a href="#cite_note-pmid27486853-102">&#91;102&#93;</a></sup><sup id="cite_ref-pmid28589082_103-0" class="reference"><a href="#cite_note-pmid28589082-103">&#91;103&#93;</a></sup><sup id="cite_ref-pmid29329556_104-0" class="reference"><a href="#cite_note-pmid29329556-104">&#91;104&#93;</a></sup>
</p><p>The potential of viruses as anti-cancer agents was first realized in the early twentieth century, although coordinated research efforts did not begin until the 1960s. A number of viruses including adenovirus, reovirus, measles, herpes simplex, Newcastle disease virus and vaccinia have now been clinically tested as oncolytic agents. T-Vec is the first FDA-approved <a href="/wiki/Oncolytic_virus" title="Oncolytic virus">oncolytic virus</a> for the treatment of melanoma.  A number of other oncolytic viruses are in Phase II-III development.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">&#91;<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (February 2018)">citation needed</span></a></i>&#93;</sup>
</p>
<h3><span class="mw-headline" id="Polysaccharides">Polysaccharides</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=39" title="Edit section: Polysaccharides">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Certain compounds found in <a href="/wiki/Medicinal_mushrooms" class="mw-redirect" title="Medicinal mushrooms">mushrooms</a>, primarily <a href="/wiki/Polysaccharide" title="Polysaccharide">polysaccharide</a>s, can up-regulate the immune system and may have anti-cancer properties. For example, <a href="/wiki/Beta-glucans" class="mw-redirect" title="Beta-glucans">beta-glucans</a> such as <a href="/wiki/Lentinan" title="Lentinan">lentinan</a> have been shown in laboratory studies to stimulate <a href="/wiki/Macrophage" title="Macrophage">macrophage</a>, <a href="/wiki/NK_cells" class="mw-redirect" title="NK cells">NK cells</a>, <a href="/wiki/T_cells" class="mw-redirect" title="T cells">T cells</a> and immune system <a href="/wiki/Cytokines" class="mw-redirect" title="Cytokines">cytokines</a> and have been investigated in clinical trials as <a href="/wiki/Immunologic_adjuvant" title="Immunologic adjuvant">immunologic adjuvant</a>s.<sup id="cite_ref-105" class="reference"><a href="#cite_note-105">&#91;105&#93;</a></sup>
</p>
<h3><span class="mw-headline" id="Neoantigens">Neoantigens</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=40" title="Edit section: Neoantigens">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div role="note" class="hatnote navigation-not-searchable">Main article: <a href="/wiki/Neoantigen" class="mw-redirect" title="Neoantigen">Neoantigen</a></div><p>Many tumors express mutations. These mutations potentially create new targetable antigens (neoantigens) for use in T cell immunotherapy. The presence of CD8+ T cells in cancer lesions, as identified using RNA sequencing data, is higher in tumors with a high <a href="/w/index.php?title=Tumor_Mutational_Burden&amp;action=edit&amp;redlink=1" class="new" title="Tumor Mutational Burden (page does not exist)">mutational burden</a>. The level of transcripts associated with cytolytic activity of natural killer cells and T cells positively correlates with mutational load in many human tumors. In non–small cell lung cancer patients treated with lambrolizumab, mutational load shows a strong correlation with clinical response. In melanoma patients treated with ipilimumab, long-term benefit is also associated with a higher mutational load, although less significantly. The predicted MHC binding neoantigens in patients with a long-term clinical benefit were enriched for a series of <a href="/wiki/Tetrapeptide" title="Tetrapeptide">tetrapeptide</a> motifs that were not found in tumors of patients with no or minimal clinical benefit.<sup id="cite_ref-SnyderMakarov2014_106-0" class="reference"><a href="#cite_note-SnyderMakarov2014-106">&#91;106&#93;</a></sup> However, human neoantigens identified in other studies do not show the bias toward tetrapeptide signatures.<sup id="cite_ref-ss15_107-0" class="reference"><a href="#cite_note-ss15-107">&#91;107&#93;</a></sup>
</p><h2><span class="mw-headline" id="See_also">See also</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=41" title="Edit section: See also">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul><li><a href="/wiki/Cancer_vaccine" title="Cancer vaccine">Cancer vaccine</a></li>
<li><a href="/wiki/5T4" class="mw-redirect" title="5T4">Antigen 5T4</a></li>
<li><a href="/wiki/Coley%27s_toxins" title="Coley&#39;s toxins">Coley's toxins</a></li>
<li><a href="/wiki/Combinatorial_ablation_and_immunotherapy" title="Combinatorial ablation and immunotherapy">Combinatorial ablation and immunotherapy</a></li>
<li><a href="/wiki/Cryoimmunotherapy" title="Cryoimmunotherapy">Cryoimmunotherapy</a></li>
<li><a href="/wiki/Photoimmunotherapy" title="Photoimmunotherapy">Photoimmunotherapy</a></li></ul>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=42" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist" style="list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-1"><span class="mw-cite-backlink"><b><a href="#cite_ref-1">^</a></b></span> <span class="reference-text"><cite class="citation journal">Korneev KV, Atretkhany KN, Drutskaya MS, Grivennikov SI, Kuprash DV, Nedospasov SA (January 2017). "TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis". <i>Cytokine</i>. <b>89</b>: 127–35. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2Fj.cyto.2016.01.021">10.1016/j.cyto.2016.01.021</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26854213">26854213</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cytokine&amp;rft.atitle=TLR-signaling+and+proinflammatory+cytokines+as+drivers+of+tumorigenesis&amp;rft.volume=89&amp;rft.pages=127-35&amp;rft.date=2017-01&amp;rft_id=info%3Adoi%2F10.1016%2Fj.cyto.2016.01.021&amp;rft_id=info%3Apmid%2F26854213&amp;rft.aulast=Korneev&amp;rft.aufirst=KV&amp;rft.au=Atretkhany%2C+KN&amp;rft.au=Drutskaya%2C+MS&amp;rft.au=Grivennikov%2C+SI&amp;rft.au=Kuprash%2C+DV&amp;rft.au=Nedospasov%2C+SA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><style data-mw-deduplicate="TemplateStyles:r879151008">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}</style></span>
</li>
<li id="cite_note-pmid11481463-2"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid11481463_2-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Riddell SR (July 2001). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC55350">"Progress in cancer vaccines by enhanced self-presentation"</a>. <i>Proceedings of the National Academy of Sciences of the United States of America</i>. <b>98</b> (16): 8933–35. <a href="/wiki/Bibcode" title="Bibcode">Bibcode</a>:<a rel="nofollow" class="external text" href="http://adsabs.harvard.edu/abs/2001PNAS...98.8933R">2001PNAS...98.8933R</a>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1073%2Fpnas.171326398">10.1073/pnas.171326398</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC55350">55350</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11481463">11481463</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America&amp;rft.atitle=Progress+in+cancer+vaccines+by+enhanced+self-presentation&amp;rft.volume=98&amp;rft.issue=16&amp;rft.pages=8933-35&amp;rft.date=2001-07&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC55350&amp;rft_id=info%3Apmid%2F11481463&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.171326398&amp;rft_id=info%3Abibcode%2F2001PNAS...98.8933R&amp;rft.aulast=Riddell&amp;rft.aufirst=SR&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC55350&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-pmid23890062-3"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid23890062_3-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid23890062_3-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Palucka K, <a href="/wiki/Jacques_Banchereau" title="Jacques Banchereau">Banchereau J</a> (July 2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3788678">"Dendritic-cell-based therapeutic cancer vaccines"</a>. <i>Immunity</i>. <b>39</b> (1): 38–48. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2Fj.immuni.2013.07.004">10.1016/j.immuni.2013.07.004</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3788678">3788678</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23890062">23890062</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Immunity&amp;rft.atitle=Dendritic-cell-based+therapeutic+cancer+vaccines&amp;rft.volume=39&amp;rft.issue=1&amp;rft.pages=38-48&amp;rft.date=2013-07&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3788678&amp;rft_id=info%3Apmid%2F23890062&amp;rft_id=info%3Adoi%2F10.1016%2Fj.immuni.2013.07.004&amp;rft.aulast=Palucka&amp;rft.aufirst=K&amp;rft.au=Banchereau%2C+J&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3788678&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-pmid27235694-4"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid27235694_4-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Hirayama M, Nishimura Y (July 2016). "The present status and future prospects of peptide-based cancer vaccines". <i><a href="/wiki/International_Immunology" title="International Immunology">International Immunology</a></i>. <b>28</b> (7): 319–28. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1093%2Fintimm%2Fdxw027">10.1093/intimm/dxw027</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/27235694">27235694</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=International+Immunology&amp;rft.atitle=The+present+status+and+future+prospects+of+peptide-based+cancer+vaccines&amp;rft.volume=28&amp;rft.issue=7&amp;rft.pages=319-28&amp;rft.date=2016-07&amp;rft_id=info%3Adoi%2F10.1093%2Fintimm%2Fdxw027&amp;rft_id=info%3Apmid%2F27235694&amp;rft.aulast=Hirayama&amp;rft.aufirst=M&amp;rft.au=Nishimura%2C+Y&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-5">^</a></b></span> <span class="reference-text"><cite id="CITEREFDastmalchiKarachiMitchellRahman2018" class="citation">Dastmalchi, Farhad; Karachi, Aida; Mitchell, Duane; Rahman, Maryam (2018), <a rel="nofollow" class="external text" href="https://onlinelibrary.wiley.com/doi/abs/10.1002/9780470015902.a0024243">"Dendritic Cell Therapy"</a>, <i>eLS</i>, American Cancer Society, pp.&#160;1–27, <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1002%2F9780470015902.a0024243">10.1002/9780470015902.a0024243</a>, <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780470015902" title="Special:BookSources/9780470015902">9780470015902</a><span class="reference-accessdate">, retrieved <span class="nowrap">2019-01-08</span></span></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=eLS&amp;rft.atitle=Dendritic+Cell+Therapy&amp;rft.pages=1-27&amp;rft.date=2018&amp;rft_id=info%3Adoi%2F10.1002%2F9780470015902.a0024243&amp;rft.isbn=9780470015902&amp;rft.aulast=Dastmalchi&amp;rft.aufirst=Farhad&amp;rft.au=Karachi%2C+Aida&amp;rft.au=Mitchell%2C+Duane&amp;rft.au=Rahman%2C+Maryam&amp;rft_id=https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2Fabs%2F10.1002%2F9780470015902.a0024243&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-6">^</a></b></span> <span class="reference-text"><cite class="citation journal">Calmeiro J, Carrascal M, Gomes C, Falcão A, Cruz MT, Neves BM (November 2018). "Highlighting the Role of DC-NK Cell Interplay in Immunobiology and Immunotherapy". <i>Dendritic Cells, Intech</i>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.5772%2Fintechopen.78804">10.5772/intechopen.78804</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Dendritic+Cells%2C+Intech&amp;rft.atitle=Highlighting+the+Role+of+DC-NK+Cell+Interplay+in+Immunobiology+and+Immunotherapy&amp;rft.date=2018-11&amp;rft_id=info%3Adoi%2F10.5772%2Fintechopen.78804&amp;rft.aulast=Calmeiro&amp;rft.aufirst=J&amp;rft.au=Carrascal%2C+M&amp;rft.au=Gomes%2C+C&amp;rft.au=Falc%C3%A3o%2C+A&amp;rft.au=Cruz%2C+MT&amp;rft.au=Neves%2C+BM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-7">^</a></b></span> <span class="reference-text"><cite class="citation journal">Gardner TA, Elzey BD, Hahn NM (April 2012). "Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer". <i>Human Vaccines &amp; Immunotherapeutics</i>. <b>8</b> (4): 534–39. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.4161%2Fhv.19795">10.4161/hv.19795</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22832254">22832254</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Human+Vaccines+%26+Immunotherapeutics&amp;rft.atitle=Sipuleucel-T+%28Provenge%29+autologous+vaccine+approved+for+treatment+of+men+with+asymptomatic+or+minimally+symptomatic+castrate-resistant+metastatic+prostate+cancer&amp;rft.volume=8&amp;rft.issue=4&amp;rft.pages=534-39&amp;rft.date=2012-04&amp;rft_id=info%3Adoi%2F10.4161%2Fhv.19795&amp;rft_id=info%3Apmid%2F22832254&amp;rft.aulast=Gardner&amp;rft.aufirst=TA&amp;rft.au=Elzey%2C+BD&amp;rft.au=Hahn%2C+NM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-8"><span class="mw-cite-backlink"><b><a href="#cite_ref-8">^</a></b></span> <span class="reference-text"><cite class="citation journal">Oudard S (May 2013). "Progress in emerging therapies for advanced prostate cancer". <i>Cancer Treatment Reviews</i>. <b>39</b> (3): 275–89. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2Fj.ctrv.2012.09.005">10.1016/j.ctrv.2012.09.005</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23107383">23107383</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer+Treatment+Reviews&amp;rft.atitle=Progress+in+emerging+therapies+for+advanced+prostate+cancer&amp;rft.volume=39&amp;rft.issue=3&amp;rft.pages=275-89&amp;rft.date=2013-05&amp;rft_id=info%3Adoi%2F10.1016%2Fj.ctrv.2012.09.005&amp;rft_id=info%3Apmid%2F23107383&amp;rft.aulast=Oudard&amp;rft.aufirst=S&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-9"><span class="mw-cite-backlink"><b><a href="#cite_ref-9">^</a></b></span> <span class="reference-text"><cite class="citation journal">Sims RB (June 2012). "Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer". <i>Vaccine</i>. <b>30</b> (29): 4394–97. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2Fj.vaccine.2011.11.058">10.1016/j.vaccine.2011.11.058</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22122856">22122856</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Vaccine&amp;rft.atitle=Development+of+sipuleucel-T%3A+autologous+cellular+immunotherapy+for+the+treatment+of+metastatic+castrate+resistant+prostate+cancer&amp;rft.volume=30&amp;rft.issue=29&amp;rft.pages=4394-97&amp;rft.date=2012-06&amp;rft_id=info%3Adoi%2F10.1016%2Fj.vaccine.2011.11.058&amp;rft_id=info%3Apmid%2F22122856&amp;rft.aulast=Sims&amp;rft.aufirst=RB&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-10">^</a></b></span> <span class="reference-text"><cite class="citation journal">Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN (January 2013). "Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer". <i>Cancer Control</i>. <b>20</b> (1): 7–16. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1177%2F107327481302000103">10.1177/107327481302000103</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23302902">23302902</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer+Control&amp;rft.atitle=Building+on+sipuleucel-T+for+immunologic+treatment+of+castration-resistant+prostate+cancer&amp;rft.volume=20&amp;rft.issue=1&amp;rft.pages=7-16&amp;rft.date=2013-01&amp;rft_id=info%3Adoi%2F10.1177%2F107327481302000103&amp;rft_id=info%3Apmid%2F23302902&amp;rft.aulast=Shore&amp;rft.aufirst=ND&amp;rft.au=Mantz%2C+CA&amp;rft.au=Dosoretz%2C+DE&amp;rft.au=Fernandez%2C+E&amp;rft.au=Myslicki%2C+FA&amp;rft.au=McCoy%2C+C&amp;rft.au=Finkelstein%2C+SE&amp;rft.au=Fishman%2C+MN&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-11">^</a></b></span> <span class="reference-text"><cite class="citation web">Commissioner, Office of the. <a rel="nofollow" class="external text" href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm">"Press Announcements – FDA approval brings first gene therapy to the United States"</a>. <i>fda.gov</i><span class="reference-accessdate">. Retrieved <span class="nowrap">13 December</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=fda.gov&amp;rft.atitle=Press+Announcements+%E2%80%93+FDA+approval+brings+first+gene+therapy+to+the+United+States&amp;rft.aulast=Commissioner&amp;rft.aufirst=Office+of+the&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm574058.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-fda.gov-12"><span class="mw-cite-backlink">^ <a href="#cite_ref-fda.gov_12-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-fda.gov_12-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm581216.htm">"FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma"</a>. fda.gov. 18 October 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">8 November</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=FDA+approves+CAR-T+cell+therapy+to+treat+adults+with+certain+types+of+large+B-cell+lymphoma&amp;rft.pub=fda.gov&amp;rft.date=2017-10-18&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm581216.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-pmid22437872-13"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid22437872_13-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid22437872_13-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Scott AM, Wolchok JD, Old LJ (March 2012). "Antibody therapy of cancer". <i>Nature Reviews. Cancer</i>. <b>12</b> (4): 278–87. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fnrc3236">10.1038/nrc3236</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22437872">22437872</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Reviews.+Cancer&amp;rft.atitle=Antibody+therapy+of+cancer&amp;rft.volume=12&amp;rft.issue=4&amp;rft.pages=278-87&amp;rft.date=2012-03&amp;rft_id=info%3Adoi%2F10.1038%2Fnrc3236&amp;rft_id=info%3Apmid%2F22437872&amp;rft.aulast=Scott&amp;rft.aufirst=AM&amp;rft.au=Wolchok%2C+JD&amp;rft.au=Old%2C+LJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-:0-14"><span class="mw-cite-backlink">^ <a href="#cite_ref-:0_14-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:0_14-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Harding FA, Stickler MM, Razo J, DuBridge RB (May–Jun 2010). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2881252">"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions"</a>. <i>MAbs</i>. <b>2</b> (3): 256–65. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.4161%2Fmabs.2.3.11641">10.4161/mabs.2.3.11641</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2881252">2881252</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20400861">20400861</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=MAbs&amp;rft.atitle=The+immunogenicity+of+humanized+and+fully+human+antibodies%3A+residual+immunogenicity+resides+in+the+CDR+regions&amp;rft.volume=2&amp;rft.issue=3&amp;rft.pages=256-65&amp;rft.date=2010-05%2F2010-06&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2881252&amp;rft_id=info%3Apmid%2F20400861&amp;rft_id=info%3Adoi%2F10.4161%2Fmabs.2.3.11641&amp;rft.aulast=Harding&amp;rft.aufirst=FA&amp;rft.au=Stickler%2C+MM&amp;rft.au=Razo%2C+J&amp;rft.au=DuBridge%2C+RB&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2881252&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-15">^</a></b></span> <span class="reference-text"><cite class="citation journal">Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, Fiebiger BM, Ravetch JV (August 2014). "Type I and type II Fc receptors regulate innate and adaptive immunity". <i>Nature Immunology</i>. <b>15</b> (8): 707–16. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fni.2939">10.1038/ni.2939</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25045879">25045879</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Immunology&amp;rft.atitle=Type+I+and+type+II+Fc+receptors+regulate+innate+and+adaptive+immunity&amp;rft.volume=15&amp;rft.issue=8&amp;rft.pages=707-16&amp;rft.date=2014-08&amp;rft_id=info%3Adoi%2F10.1038%2Fni.2939&amp;rft_id=info%3Apmid%2F25045879&amp;rft.aulast=Pincetic&amp;rft.aufirst=A&amp;rft.au=Bournazos%2C+S&amp;rft.au=DiLillo%2C+DJ&amp;rft.au=Maamary%2C+J&amp;rft.au=Wang%2C+TT&amp;rft.au=Dahan%2C+R&amp;rft.au=Fiebiger%2C+BM&amp;rft.au=Ravetch%2C+JV&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-16"><span class="mw-cite-backlink"><b><a href="#cite_ref-16">^</a></b></span> <span class="reference-text"><cite class="citation journal">Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (June 2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3544539">"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer"</a>. <i>The New England Journal of Medicine</i>. <b>366</b> (26): 2443–54. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1056%2FNEJMoa1200690">10.1056/NEJMoa1200690</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3544539">3544539</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22658127">22658127</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+England+Journal+of+Medicine&amp;rft.atitle=Safety%2C+activity%2C+and+immune+correlates+of+anti-PD-1+antibody+in+cancer&amp;rft.volume=366&amp;rft.issue=26&amp;rft.pages=2443-54&amp;rft.date=2012-06&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3544539&amp;rft_id=info%3Apmid%2F22658127&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMoa1200690&amp;rft.aulast=Topalian&amp;rft.aufirst=SL&amp;rft.au=Hodi%2C+FS&amp;rft.au=Brahmer%2C+JR&amp;rft.au=Gettinger%2C+SN&amp;rft.au=Smith%2C+DC&amp;rft.au=McDermott%2C+DF&amp;rft.au=Powderly%2C+JD&amp;rft.au=Carvajal%2C+RD&amp;rft.au=Sosman%2C+JA&amp;rft.au=Atkins%2C+MB&amp;rft.au=Leming%2C+PD&amp;rft.au=Spigel%2C+DR&amp;rft.au=Antonia%2C+SJ&amp;rft.au=Horn%2C+L&amp;rft.au=Drake%2C+CG&amp;rft.au=Pardoll%2C+DM&amp;rft.au=Chen%2C+L&amp;rft.au=Sharfman%2C+WH&amp;rft.au=Anders%2C+RA&amp;rft.au=Taube%2C+JM&amp;rft.au=McMiller%2C+TL&amp;rft.au=Xu%2C+H&amp;rft.au=Korman%2C+AJ&amp;rft.au=Jure-Kunkel%2C+M&amp;rft.au=Agrawal%2C+S&amp;rft.au=McDonald%2C+D&amp;rft.au=Kollia%2C+GD&amp;rft.au=Gupta%2C+A&amp;rft.au=Wigginton%2C+JM&amp;rft.au=Sznol%2C+M&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3544539&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-17">^</a></b></span> <span class="reference-text"><cite class="citation journal">Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV (October 2015). "FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis". <i>Cancer Cell</i>. <b>28</b> (4): 543. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2Fj.ccell.2015.09.011">10.1016/j.ccell.2015.09.011</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/28854351">28854351</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer+Cell&amp;rft.atitle=Fc%CE%B3Rs+Modulate+the+Anti-tumor+Activity+of+Antibodies+Targeting+the+PD-1%2FPD-L1+Axis&amp;rft.volume=28&amp;rft.issue=4&amp;rft.pages=543&amp;rft.date=2015-10&amp;rft_id=info%3Adoi%2F10.1016%2Fj.ccell.2015.09.011&amp;rft_id=info%3Apmid%2F28854351&amp;rft.aulast=Dahan&amp;rft.aufirst=R&amp;rft.au=Sega%2C+E&amp;rft.au=Engelhardt%2C+J&amp;rft.au=Selby%2C+M&amp;rft.au=Korman%2C+AJ&amp;rft.au=Ravetch%2C+JV&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-18"><span class="mw-cite-backlink"><b><a href="#cite_ref-18">^</a></b></span> <span class="reference-text"><cite class="citation journal">Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, Miller MA, Carlson JC, Freeman GJ, Anthony RM, Weissleder R, Pittet MJ (May 2017). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5734617">"In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy"</a>. <i>Science Translational Medicine</i>. <b>9</b> (389): eaal3604. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1126%2Fscitranslmed.aal3604">10.1126/scitranslmed.aal3604</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5734617">5734617</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/28490665">28490665</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Science+Translational+Medicine&amp;rft.atitle=In+vivo+imaging+reveals+a+tumor-associated+macrophage-mediated+resistance+pathway+in+anti-PD-1+therapy&amp;rft.volume=9&amp;rft.issue=389&amp;rft.pages=eaal3604&amp;rft.date=2017-05&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5734617&amp;rft_id=info%3Apmid%2F28490665&amp;rft_id=info%3Adoi%2F10.1126%2Fscitranslmed.aal3604&amp;rft.aulast=Arlauckas&amp;rft.aufirst=SP&amp;rft.au=Garris%2C+CS&amp;rft.au=Kohler%2C+RH&amp;rft.au=Kitaoka%2C+M&amp;rft.au=Cuccarese%2C+MF&amp;rft.au=Yang%2C+KS&amp;rft.au=Miller%2C+MA&amp;rft.au=Carlson%2C+JC&amp;rft.au=Freeman%2C+GJ&amp;rft.au=Anthony%2C+RM&amp;rft.au=Weissleder%2C+R&amp;rft.au=Pittet%2C+MJ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5734617&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-19">^</a></b></span> <span class="reference-text"><cite class="citation journal">Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV (July 2016). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4975533">"Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement"</a>. <i>Cancer Cell</i>. <b>29</b> (6): 820–31. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2Fj.ccell.2016.05.001">10.1016/j.ccell.2016.05.001</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4975533">4975533</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/27265505">27265505</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer+Cell&amp;rft.atitle=Therapeutic+Activity+of+Agonistic%2C+Human+Anti-CD40+Monoclonal+Antibodies+Requires+Selective+Fc%CE%B3R+Engagement&amp;rft.volume=29&amp;rft.issue=6&amp;rft.pages=820-31&amp;rft.date=2016-07&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4975533&amp;rft_id=info%3Apmid%2F27265505&amp;rft_id=info%3Adoi%2F10.1016%2Fj.ccell.2016.05.001&amp;rft.aulast=Dahan&amp;rft.aufirst=R&amp;rft.au=Barnhart%2C+BC&amp;rft.au=Li%2C+F&amp;rft.au=Yamniuk%2C+AP&amp;rft.au=Korman%2C+AJ&amp;rft.au=Ravetch%2C+JV&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4975533&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-20">^</a></b></span> <span class="reference-text"><cite class="citation journal">Weiner LM, Surana R, Wang S (May 2010). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3508064">"Monoclonal antibodies: versatile platforms for cancer immunotherapy"</a>. <i>Nature Reviews. Immunology</i>. <b>10</b> (5): 317–27. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fnri2744">10.1038/nri2744</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3508064">3508064</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20414205">20414205</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Reviews.+Immunology&amp;rft.atitle=Monoclonal+antibodies%3A+versatile+platforms+for+cancer+immunotherapy&amp;rft.volume=10&amp;rft.issue=5&amp;rft.pages=317-27&amp;rft.date=2010-05&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3508064&amp;rft_id=info%3Apmid%2F20414205&amp;rft_id=info%3Adoi%2F10.1038%2Fnri2744&amp;rft.aulast=Weiner&amp;rft.aufirst=LM&amp;rft.au=Surana%2C+R&amp;rft.au=Wang%2C+S&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3508064&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text"><cite class="citation journal">Seidel UJ, Schlegel P, Lang P (2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3608903">"Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies"</a>. <i>Frontiers in Immunology</i>. <b>4</b>: 76. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.3389%2Ffimmu.2013.00076">10.3389/fimmu.2013.00076</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3608903">3608903</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23543707">23543707</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Frontiers+in+Immunology&amp;rft.atitle=Natural+killer+cell+mediated+antibody-dependent+cellular+cytotoxicity+in+tumor+immunotherapy+with+therapeutic+antibodies&amp;rft.volume=4&amp;rft.pages=76&amp;rft.date=2013&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3608903&amp;rft_id=info%3Apmid%2F23543707&amp;rft_id=info%3Adoi%2F10.3389%2Ffimmu.2013.00076&amp;rft.aulast=Seidel&amp;rft.aufirst=UJ&amp;rft.au=Schlegel%2C+P&amp;rft.au=Lang%2C+P&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3608903&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><cite class="citation journal">Gelderman KA, Tomlinson S, Ross GD, Gorter A (March 2004). "Complement function in mAb-mediated cancer immunotherapy". <i>Trends in Immunology</i>. <b>25</b> (3): 158–64. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2Fj.it.2004.01.008">10.1016/j.it.2004.01.008</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15036044">15036044</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Trends+in+Immunology&amp;rft.atitle=Complement+function+in+mAb-mediated+cancer+immunotherapy&amp;rft.volume=25&amp;rft.issue=3&amp;rft.pages=158-64&amp;rft.date=2004-03&amp;rft_id=info%3Adoi%2F10.1016%2Fj.it.2004.01.008&amp;rft_id=info%3Apmid%2F15036044&amp;rft.aulast=Gelderman&amp;rft.aufirst=KA&amp;rft.au=Tomlinson%2C+S&amp;rft.au=Ross%2C+GD&amp;rft.au=Gorter%2C+A&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-Waldmann-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-Waldmann_23-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Waldmann TA (March 2003). "Immunotherapy: past, present and future". <i>Nature Medicine</i>. <b>9</b> (3): 269–77. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fnm0303-269">10.1038/nm0303-269</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12612576">12612576</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Medicine&amp;rft.atitle=Immunotherapy%3A+past%2C+present+and+future&amp;rft.volume=9&amp;rft.issue=3&amp;rft.pages=269-77&amp;rft.date=2003-03&amp;rft_id=info%3Adoi%2F10.1038%2Fnm0303-269&amp;rft_id=info%3Apmid%2F12612576&amp;rft.aulast=Waldmann&amp;rft.aufirst=TA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><cite class="citation journal">Demko S, Summers J, Keegan P, Pazdur R (February 2008). "FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia". <i>The Oncologist</i>. <b>13</b> (2): 167–74. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1634%2Ftheoncologist.2007-0218">10.1634/theoncologist.2007-0218</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18305062">18305062</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Oncologist&amp;rft.atitle=FDA+drug+approval+summary%3A+alemtuzumab+as+single-agent+treatment+for+B-cell+chronic+lymphocytic+leukemia&amp;rft.volume=13&amp;rft.issue=2&amp;rft.pages=167-74&amp;rft.date=2008-02&amp;rft_id=info%3Adoi%2F10.1634%2Ftheoncologist.2007-0218&amp;rft_id=info%3Apmid%2F18305062&amp;rft.aulast=Demko&amp;rft.aufirst=S&amp;rft.au=Summers%2C+J&amp;rft.au=Keegan%2C+P&amp;rft.au=Pazdur%2C+R&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-FDA-BC-2016-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-FDA-BC-2016_25-0">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm501762.htm">"FDA approves new, targeted treatment for bladder cancer"</a>. FDA. 18 May 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">20 May</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=FDA+approves+new%2C+targeted+treatment+for+bladder+cancer&amp;rft.date=2016-05-18&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm501762.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-26">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf">"US Food and Drug Administration – Avelumab Prescribing Label"</a> <span class="cs1-format">(PDF)</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=US+Food+and+Drug+Administration+%E2%80%93+Avelumab+Prescribing+Label&amp;rft_id=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F761049s000lbl.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-27"><span class="mw-cite-backlink"><b><a href="#cite_ref-27">^</a></b></span> <span class="reference-text"><cite class="citation web">Pazdur R. <a rel="nofollow" class="external text" href="http://www.cancer.gov/cancertopics/druginfo/fda-ipilimumab">"FDA approval for Ipilimumab"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">7 November</span> 2013</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=FDA+approval+for+Ipilimumab&amp;rft.aulast=Pazdur&amp;rft.aufirst=Richard&amp;rft_id=http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Fdruginfo%2Ffda-ipilimumab&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-28"><span class="mw-cite-backlink"><b><a href="#cite_ref-28">^</a></b></span> <span class="reference-text"><cite class="citation journal">Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, McDougal A, Pilaro A, Chiang R, Gootenberg JE, Keegan P, Pazdur R (September 2010). "U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab". <i>Clinical Cancer Research</i>. <b>16</b> (17): 4331–38. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1158%2F1078-0432.CCR-10-0570">10.1158/1078-0432.CCR-10-0570</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20601446">20601446</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Cancer+Research&amp;rft.atitle=U.S.+Food+and+Drug+Administration+approval%3A+ofatumumab+for+the+treatment+of+patients+with+chronic+lymphocytic+leukemia+refractory+to+fludarabine+and+alemtuzumab&amp;rft.volume=16&amp;rft.issue=17&amp;rft.pages=4331-38&amp;rft.date=2010-09&amp;rft_id=info%3Adoi%2F10.1158%2F1078-0432.CCR-10-0570&amp;rft_id=info%3Apmid%2F20601446&amp;rft.aulast=Lemery&amp;rft.aufirst=SJ&amp;rft.au=Zhang%2C+J&amp;rft.au=Rothmann%2C+MD&amp;rft.au=Yang%2C+J&amp;rft.au=Earp%2C+J&amp;rft.au=Zhao%2C+H&amp;rft.au=McDougal%2C+A&amp;rft.au=Pilaro%2C+A&amp;rft.au=Chiang%2C+R&amp;rft.au=Gootenberg%2C+JE&amp;rft.au=Keegan%2C+P&amp;rft.au=Pazdur%2C+R&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-sa15-29"><span class="mw-cite-backlink">^ <a href="#cite_ref-sa15_29-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-sa15_29-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Sharma P, Allison JP (April 2015). "The future of immune checkpoint therapy". <i>Science</i>. <b>348</b> (6230): 56–61. <a href="/wiki/Bibcode" title="Bibcode">Bibcode</a>:<a rel="nofollow" class="external text" href="http://adsabs.harvard.edu/abs/2015Sci...348...56S">2015Sci...348...56S</a>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1126%2Fscience.aaa8172">10.1126/science.aaa8172</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25838373">25838373</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Science&amp;rft.atitle=The+future+of+immune+checkpoint+therapy&amp;rft.volume=348&amp;rft.issue=6230&amp;rft.pages=56-61&amp;rft.date=2015-04&amp;rft_id=info%3Apmid%2F25838373&amp;rft_id=info%3Adoi%2F10.1126%2Fscience.aaa8172&amp;rft_id=info%3Abibcode%2F2015Sci...348...56S&amp;rft.aulast=Sharma&amp;rft.aufirst=P&amp;rft.au=Allison%2C+JP&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-30">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.drugs.com/history/opdivo.html">"Opdivo Drug Approval History"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Opdivo+Drug+Approval+History&amp;rft_id=https%3A%2F%2Fwww.drugs.com%2Fhistory%2Fopdivo.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-31">^</a></b></span> <span class="reference-text"><cite class="citation journal">James JS, Dubs G (December 1997). "FDA approves new kind of lymphoma treatment. Food and Drug Administration". <i>AIDS Treatment News</i> (284): 2–3. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11364912">11364912</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=AIDS+Treatment+News&amp;rft.atitle=FDA+approves+new+kind+of+lymphoma+treatment.+Food+and+Drug+Administration&amp;rft.issue=284&amp;rft.pages=2-3&amp;rft.date=1997-12&amp;rft_id=info%3Apmid%2F11364912&amp;rft.aulast=James&amp;rft.aufirst=JS&amp;rft.au=Dubs%2C+G&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-32"><span class="mw-cite-backlink"><b><a href="#cite_ref-32">^</a></b></span> <span class="reference-text"><cite class="citation web">Research, Center for Drug Evaluation and. <a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm555930.htm">"Approved Drugs – Durvalumab (Imfinzi)"</a>. <i>fda.gov</i><span class="reference-accessdate">. Retrieved <span class="nowrap">6 May</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=fda.gov&amp;rft.atitle=Approved+Drugs+%E2%80%93+Durvalumab+%28Imfinzi%29&amp;rft.aulast=Research&amp;rft.aufirst=Center+for+Drug+Evaluation+and&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Finformationondrugs%2Fapproveddrugs%2Fucm555930.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-33">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm597248.htm">"FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=FDA+approves+durvalumab+after+chemoradiation+for+unresectable+stage+III+NSCLC&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm597248.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-34">^</a></b></span> <span class="reference-text">Byrd JC, Stilgenbauer S, Flinn IW. <a rel="nofollow" class="external text" href="http://www.asheducationbook.org/cgi/content/full/2004/1/163">Chronic Lymphocytic Leukemia.</a> Hematology (Am Soc Hematol Educ Program) 2004: 163–83. Date. Retrieved 26 January 2006.</span>
</li>
<li id="cite_note-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-35">^</a></b></span> <span class="reference-text"><cite class="citation journal">Domagała A, Kurpisz M (Mar–Apr 2001). "CD52 antigen – a review". <i>Medical Science Monitor</i>. <b>7</b> (2): 325–31. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11257744">11257744</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Medical+Science+Monitor&amp;rft.atitle=CD52+antigen+%E2%80%93+a+review&amp;rft.volume=7&amp;rft.issue=2&amp;rft.pages=325-31&amp;rft.date=2001-03%2F2001-04&amp;rft_id=info%3Apmid%2F11257744&amp;rft.aulast=Domaga%C5%82a&amp;rft.aufirst=A&amp;rft.au=Kurpisz%2C+M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-36"><span class="mw-cite-backlink"><b><a href="#cite_ref-36">^</a></b></span> <span class="reference-text"><cite class="citation journal">Dearden C (July 2012). "How I treat prolymphocytic leukemia". <i>Blood</i>. <b>120</b> (3): 538–51. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1182%2Fblood-2012-01-380139">10.1182/blood-2012-01-380139</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22649104">22649104</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Blood&amp;rft.atitle=How+I+treat+prolymphocytic+leukemia&amp;rft.volume=120&amp;rft.issue=3&amp;rft.pages=538-51&amp;rft.date=2012-07&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2012-01-380139&amp;rft_id=info%3Apmid%2F22649104&amp;rft.aulast=Dearden&amp;rft.aufirst=C&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-pmid21629286-37"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid21629286_37-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid21629286_37-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P (June 2011). "Ipilimumab". <i>Nature Reviews. Drug Discovery</i>. <b>10</b> (6): 411–12. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fnrd3463">10.1038/nrd3463</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21629286">21629286</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Reviews.+Drug+Discovery&amp;rft.atitle=Ipilimumab&amp;rft.volume=10&amp;rft.issue=6&amp;rft.pages=411-12&amp;rft.date=2011-06&amp;rft_id=info%3Adoi%2F10.1038%2Fnrd3463&amp;rft_id=info%3Apmid%2F21629286&amp;rft.aulast=Sondak&amp;rft.aufirst=VK&amp;rft.au=Smalley%2C+KS&amp;rft.au=Kudchadkar%2C+R&amp;rft.au=Grippon%2C+S&amp;rft.au=Kirkpatrick%2C+P&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-pmid21900389-38"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid21900389_38-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid21900389_38-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Lipson EJ, Drake CG (November 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3575079">"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma"</a>. <i>Clinical Cancer Research</i>. <b>17</b> (22): 6958–62. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1158%2F1078-0432.CCR-11-1595">10.1158/1078-0432.CCR-11-1595</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3575079">3575079</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21900389">21900389</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Cancer+Research&amp;rft.atitle=Ipilimumab%3A+an+anti-CTLA-4+antibody+for+metastatic+melanoma&amp;rft.volume=17&amp;rft.issue=22&amp;rft.pages=6958-62&amp;rft.date=2011-11&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3575079&amp;rft_id=info%3Apmid%2F21900389&amp;rft_id=info%3Adoi%2F10.1158%2F1078-0432.CCR-11-1595&amp;rft.aulast=Lipson&amp;rft.aufirst=EJ&amp;rft.au=Drake%2C+CG&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3575079&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-pmid21294471-39"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid21294471_39-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid21294471_39-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Thumar JR, Kluger HM (December 2010). "Ipilimumab: a promising immunotherapy for melanoma". <i>Oncology</i>. <b>24</b> (14): 1280–88. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21294471">21294471</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Oncology&amp;rft.atitle=Ipilimumab%3A+a+promising+immunotherapy+for+melanoma&amp;rft.volume=24&amp;rft.issue=14&amp;rft.pages=1280-88&amp;rft.date=2010-12&amp;rft_id=info%3Apmid%2F21294471&amp;rft.aulast=Thumar&amp;rft.aufirst=JR&amp;rft.au=Kluger%2C+HM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-pmid11244047-40"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid11244047_40-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid11244047_40-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Chambers CA, Kuhns MS, Egen JG, Allison JP (2001). "CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy". <i>Annual Review of Immunology</i>. <b>19</b>: 565–94. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1146%2Fannurev.immunol.19.1.565">10.1146/annurev.immunol.19.1.565</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11244047">11244047</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annual+Review+of+Immunology&amp;rft.atitle=CTLA-4-mediated+inhibition+in+regulation+of+T+cell+responses%3A+mechanisms+and+manipulation+in+tumor+immunotherapy&amp;rft.volume=19&amp;rft.pages=565-94&amp;rft.date=2001&amp;rft_id=info%3Adoi%2F10.1146%2Fannurev.immunol.19.1.565&amp;rft_id=info%3Apmid%2F11244047&amp;rft.aulast=Chambers&amp;rft.aufirst=CA&amp;rft.au=Kuhns%2C+MS&amp;rft.au=Egen%2C+JG&amp;rft.au=Allison%2C+JP&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-41">^</a></b></span> <span class="reference-text"><cite class="citation journal">Castillo J, Perez K (2010). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3262337">"The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies"</a>. <i>Journal of Blood Medicine</i>. <b>1</b>: 1–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.2147%2Fjbm.s7284">10.2147/jbm.s7284</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3262337">3262337</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22282677">22282677</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Blood+Medicine&amp;rft.atitle=The+role+of+ofatumumab+in+the+treatment+of+chronic+lymphocytic+leukemia+resistant+to+previous+therapies&amp;rft.volume=1&amp;rft.pages=1-8&amp;rft.date=2010&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3262337&amp;rft_id=info%3Apmid%2F22282677&amp;rft_id=info%3Adoi%2F10.2147%2Fjbm.s7284&amp;rft.aulast=Castillo&amp;rft.aufirst=J&amp;rft.au=Perez%2C+K&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3262337&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-42">^</a></b></span> <span class="reference-text"><cite class="citation journal">Zhang B (Jul–Aug 2009). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2726602">"Ofatumumab"</a>. <i>MAbs</i>. <b>1</b> (4): 326–31. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.4161%2Fmabs.1.4.8895">10.4161/mabs.1.4.8895</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2726602">2726602</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20068404">20068404</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=MAbs&amp;rft.atitle=Ofatumumab&amp;rft.volume=1&amp;rft.issue=4&amp;rft.pages=326-31&amp;rft.date=2009-07%2F2009-08&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2726602&amp;rft_id=info%3Apmid%2F20068404&amp;rft_id=info%3Adoi%2F10.4161%2Fmabs.1.4.8895&amp;rft.aulast=Zhang&amp;rft.aufirst=B&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2726602&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-USlabel2016-43"><span class="mw-cite-backlink"><b><a href="#cite_ref-USlabel2016_43-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s014lbl.pdf">"Pembrolizumab label"</a> <span class="cs1-format">(PDF)</span>. FDA. May 2017.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Pembrolizumab+label&amp;rft.pub=FDA&amp;rft.date=2017-05&amp;rft_id=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2017%2F125514s014lbl.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/> linked from <a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=125514">Index page at FDA website</a> November 2016</span>
</li>
<li id="cite_note-UKlabel2016-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-UKlabel2016_44-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.medicines.org.uk/emc/medicine/30602">"Pembrolizumab label at eMC"</a>. UK Electronic Medicines Compendium. 27 January 2017.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Pembrolizumab+label+at+eMC&amp;rft.pub=UK+Electronic+Medicines+Compendium&amp;rft.date=2017-01-27&amp;rft_id=https%3A%2F%2Fwww.medicines.org.uk%2Femc%2Fmedicine%2F30602&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-45"><span class="mw-cite-backlink"><b><a href="#cite_ref-45">^</a></b></span> <span class="reference-text"><cite class="citation journal">Keating GM (July 2010). "Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma". <i>Drugs</i>. <b>70</b> (11): 1445–76. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.2165%2F11201110-000000000-00000">10.2165/11201110-000000000-00000</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20614951">20614951</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drugs&amp;rft.atitle=Rituximab%3A+a+review+of+its+use+in+chronic+lymphocytic+leukaemia%2C+low-grade+or+follicular+lymphoma+and+diffuse+large+B-cell+lymphoma&amp;rft.volume=70&amp;rft.issue=11&amp;rft.pages=1445-76&amp;rft.date=2010-07&amp;rft_id=info%3Adoi%2F10.2165%2F11201110-000000000-00000&amp;rft_id=info%3Apmid%2F20614951&amp;rft.aulast=Keating&amp;rft.aufirst=GM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-Plosker_2003_803–43-46"><span class="mw-cite-backlink">^ <a href="#cite_ref-Plosker_2003_803–43_46-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Plosker_2003_803–43_46-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Plosker GL, Figgitt DP (2003). "Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia". <i>Drugs</i>. <b>63</b> (8): 803–43. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.2165%2F00003495-200363080-00005">10.2165/00003495-200363080-00005</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12662126">12662126</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drugs&amp;rft.atitle=Rituximab%3A+a+review+of+its+use+in+non-Hodgkin%27s+lymphoma+and+chronic+lymphocytic+leukaemia&amp;rft.volume=63&amp;rft.issue=8&amp;rft.pages=803-43&amp;rft.date=2003&amp;rft_id=info%3Adoi%2F10.2165%2F00003495-200363080-00005&amp;rft_id=info%3Apmid%2F12662126&amp;rft.aulast=Plosker&amp;rft.aufirst=GL&amp;rft.au=Figgitt%2C+DP&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-47"><span class="mw-cite-backlink"><b><a href="#cite_ref-47">^</a></b></span> <span class="reference-text"><cite class="citation journal">Cerny T, Borisch B, Introna M, Johnson P, Rose AL (November 2002). "Mechanism of action of rituximab". <i>Anti-Cancer Drugs</i>. 13 Suppl 2: S3–10. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1097%2F00001813-200211002-00002">10.1097/00001813-200211002-00002</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12710585">12710585</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Anti-Cancer+Drugs&amp;rft.atitle=Mechanism+of+action+of+rituximab&amp;rft.volume=13+Suppl+2&amp;rft.pages=S3-10&amp;rft.date=2002-11&amp;rft_id=info%3Adoi%2F10.1097%2F00001813-200211002-00002&amp;rft_id=info%3Apmid%2F12710585&amp;rft.aulast=Cerny&amp;rft.aufirst=T&amp;rft.au=Borisch%2C+B&amp;rft.au=Introna%2C+M&amp;rft.au=Johnson%2C+P&amp;rft.au=Rose%2C+AL&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-Janeway-48"><span class="mw-cite-backlink"><b><a href="#cite_ref-Janeway_48-0">^</a></b></span> <span class="reference-text"><cite class="citation book"><a href="/wiki/Charles_Janeway" title="Charles Janeway">Janeway C</a>, Travers P, Walport M, Shlomchik M (2001). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View..ShowTOC&amp;rid=imm.TOC&amp;depth=10"><i>Immunobiology</i></a> (Fifth ed.). New York and London: Garland Science. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-8153-4101-7" title="Special:BookSources/978-0-8153-4101-7">978-0-8153-4101-7</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Immunobiology&amp;rft.place=New+York+and+London&amp;rft.edition=Fifth&amp;rft.pub=Garland+Science&amp;rft.date=2001&amp;rft.isbn=978-0-8153-4101-7&amp;rft.aulast=Janeway&amp;rft.aufirst=Charles&amp;rft.au=Travers%2C+Paul&amp;rft.au=Walport%2C+Mark&amp;rft.au=Shlomchik%2C+Mark&amp;rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2Fbv.fcgi%3Fcall%3Dbv.View..ShowTOC%26rid%3Dimm.TOC%26depth%3D10&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/><sup class="noprint Inline-Template" style="white-space:nowrap;">&#91;<i><a href="/wiki/Wikipedia:Citing_sources" title="Wikipedia:Citing sources"><span title="This citation requires a reference to the specific page or range of pages in which the material appears. (February 2018)">page&#160;needed</span></a></i>&#93;</sup></span>
</li>
<li id="cite_note-49"><span class="mw-cite-backlink"><b><a href="#cite_ref-49">^</a></b></span> <span class="reference-text"><cite class="citation journal">Weiner GJ (April 2010). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2848172">"Rituximab: mechanism of action"</a>. <i>Seminars in Hematology</i>. <b>47</b> (2): 115–23. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1053%2Fj.seminhematol.2010.01.011">10.1053/j.seminhematol.2010.01.011</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2848172">2848172</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20350658">20350658</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Seminars+in+Hematology&amp;rft.atitle=Rituximab%3A+mechanism+of+action&amp;rft.volume=47&amp;rft.issue=2&amp;rft.pages=115-23&amp;rft.date=2010-04&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2848172&amp;rft_id=info%3Apmid%2F20350658&amp;rft_id=info%3Adoi%2F10.1053%2Fj.seminhematol.2010.01.011&amp;rft.aulast=Weiner&amp;rft.aufirst=GJ&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2848172&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-pmid14708024-50"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid14708024_50-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid14708024_50-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Dranoff G (January 2004). "Cytokines in cancer pathogenesis and cancer therapy". <i>Nature Reviews. Cancer</i>. <b>4</b> (1): 11–22. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fnrc1252">10.1038/nrc1252</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14708024">14708024</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Reviews.+Cancer&amp;rft.atitle=Cytokines+in+cancer+pathogenesis+and+cancer+therapy&amp;rft.volume=4&amp;rft.issue=1&amp;rft.pages=11-22&amp;rft.date=2004-01&amp;rft_id=info%3Adoi%2F10.1038%2Fnrc1252&amp;rft_id=info%3Apmid%2F14708024&amp;rft.aulast=Dranoff&amp;rft.aufirst=G&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-51"><span class="mw-cite-backlink"><b><a href="#cite_ref-51">^</a></b></span> <span class="reference-text"><cite class="citation journal">Dunn GP, Koebel CM, Schreiber RD (November 2006). "Interferons, immunity and cancer immunoediting". <i>Nature Reviews. Immunology</i>. <b>6</b> (11): 836–48. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fnri1961">10.1038/nri1961</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17063185">17063185</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Reviews.+Immunology&amp;rft.atitle=Interferons%2C+immunity+and+cancer+immunoediting&amp;rft.volume=6&amp;rft.issue=11&amp;rft.pages=836-48&amp;rft.date=2006-11&amp;rft_id=info%3Adoi%2F10.1038%2Fnri1961&amp;rft_id=info%3Apmid%2F17063185&amp;rft.aulast=Dunn&amp;rft.aufirst=GP&amp;rft.au=Koebel%2C+CM&amp;rft.au=Schreiber%2C+RD&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-52"><span class="mw-cite-backlink"><b><a href="#cite_ref-52">^</a></b></span> <span class="reference-text"><cite class="citation journal">Lasfar A, Abushahba W, Balan M, Cohen-Solal KA (2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3235441">"Interferon lambda: a new sword in cancer immunotherapy"</a>. <i>Clinical &amp; Developmental Immunology</i>. <b>2011</b>: 349575. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1155%2F2011%2F349575">10.1155/2011/349575</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3235441">3235441</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22190970">22190970</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+%26+Developmental+Immunology&amp;rft.atitle=Interferon+lambda%3A+a+new+sword+in+cancer+immunotherapy&amp;rft.volume=2011&amp;rft.pages=349575&amp;rft.date=2011&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3235441&amp;rft_id=info%3Apmid%2F22190970&amp;rft_id=info%3Adoi%2F10.1155%2F2011%2F349575&amp;rft.aulast=Lasfar&amp;rft.aufirst=A&amp;rft.au=Abushahba%2C+W&amp;rft.au=Balan%2C+M&amp;rft.au=Cohen-Solal%2C+KA&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3235441&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-53"><span class="mw-cite-backlink"><b><a href="#cite_ref-53">^</a></b></span> <span class="reference-text"><cite class="citation journal">Razaghi A, Owens L, Heimann K (December 2016). "Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation". <i>Journal of Biotechnology</i>. <b>240</b>: 48–60. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2Fj.jbiotec.2016.10.022">10.1016/j.jbiotec.2016.10.022</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/27794496">27794496</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Biotechnology&amp;rft.atitle=Review+of+the+recombinant+human+interferon+gamma+as+an+immunotherapeutic%3A+Impacts+of+production+platforms+and+glycosylation&amp;rft.volume=240&amp;rft.pages=48-60&amp;rft.date=2016-12&amp;rft_id=info%3Adoi%2F10.1016%2Fj.jbiotec.2016.10.022&amp;rft_id=info%3Apmid%2F27794496&amp;rft.aulast=Razaghi&amp;rft.aufirst=A&amp;rft.au=Owens%2C+L&amp;rft.au=Heimann%2C+K&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-54">^</a></b></span> <span class="reference-text"><cite class="citation journal">Coventry BJ, Ashdown ML (2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3421468">"The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses"</a>. <i>Cancer Management and Research</i>. <b>4</b>: 215–21. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.2147%2Fcmar.s33979">10.2147/cmar.s33979</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3421468">3421468</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22904643">22904643</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer+Management+and+Research&amp;rft.atitle=The+20th+anniversary+of+interleukin-2+therapy%3A+bimodal+role+explaining+longstanding+random+induction+of+complete+clinical+responses&amp;rft.volume=4&amp;rft.pages=215-21&amp;rft.date=2012&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3421468&amp;rft_id=info%3Apmid%2F22904643&amp;rft_id=info%3Adoi%2F10.2147%2Fcmar.s33979&amp;rft.aulast=Coventry&amp;rft.aufirst=BJ&amp;rft.au=Ashdown%2C+ML&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3421468&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-55"><span class="mw-cite-backlink"><b><a href="#cite_ref-55">^</a></b></span> <span class="reference-text"><cite class="citation journal">Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD (2017). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5319100">"Combination immunotherapy: a road map"</a>. <i>Journal for Immunotherapy of Cancer</i>. <b>5</b>: 16. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1186%2Fs40425-017-0218-5">10.1186/s40425-017-0218-5</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5319100">5319100</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/28239469">28239469</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+for+Immunotherapy+of+Cancer&amp;rft.atitle=Combination+immunotherapy%3A+a+road+map&amp;rft.volume=5&amp;rft.pages=16&amp;rft.date=2017&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5319100&amp;rft_id=info%3Apmid%2F28239469&amp;rft_id=info%3Adoi%2F10.1186%2Fs40425-017-0218-5&amp;rft.aulast=Ott&amp;rft.aufirst=PA&amp;rft.au=Hodi%2C+FS&amp;rft.au=Kaufman%2C+HL&amp;rft.au=Wigginton%2C+JM&amp;rft.au=Wolchok%2C+JD&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5319100&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-56"><span class="mw-cite-backlink"><b><a href="#cite_ref-56">^</a></b></span> <span class="reference-text"><cite class="citation journal">Mahoney KM, Rennert PD, Freeman GJ (August 2015). "Combination cancer immunotherapy and new immunomodulatory targets". <i>Nature Reviews. Drug Discovery</i>. <b>14</b> (8): 561–84. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fnrd4591">10.1038/nrd4591</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26228759">26228759</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Reviews.+Drug+Discovery&amp;rft.atitle=Combination+cancer+immunotherapy+and+new+immunomodulatory+targets&amp;rft.volume=14&amp;rft.issue=8&amp;rft.pages=561-84&amp;rft.date=2015-08&amp;rft_id=info%3Adoi%2F10.1038%2Fnrd4591&amp;rft_id=info%3Apmid%2F26228759&amp;rft.aulast=Mahoney&amp;rft.aufirst=KM&amp;rft.au=Rennert%2C+PD&amp;rft.au=Freeman%2C+GJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-hindawi9251375-57"><span class="mw-cite-backlink"><b><a href="#cite_ref-hindawi9251375_57-0">^</a></b></span> <span class="reference-text"><cite class="citation journal"><a rel="nofollow" class="external text" href="https://www.hindawi.com/journals/grp/2016/9251375/">"Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?"</a>. 2015.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Thermal+Ablative+Therapies+and+Immune+Checkpoint+Modulation%3A+Can+Locoregional+Approaches+Effect+a+Systemic+Response%3F&amp;rft.date=2015&amp;rft_id=https%3A%2F%2Fwww.hindawi.com%2Fjournals%2Fgrp%2F2016%2F9251375%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-58"><span class="mw-cite-backlink"><b><a href="#cite_ref-58">^</a></b></span> <span class="reference-text"><cite class="citation journal">Tang J, Shalabi A, Hubbard-Lucey VM (January 2018). "Comprehensive analysis of the clinical immuno-oncology landscape". <i>Annals of Oncology</i>. <b>29</b> (1): 84–91. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1093%2Fannonc%2Fmdx755">10.1093/annonc/mdx755</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/29228097">29228097</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Annals+of+Oncology&amp;rft.atitle=Comprehensive+analysis+of+the+clinical+immuno-oncology+landscape&amp;rft.volume=29&amp;rft.issue=1&amp;rft.pages=84-91&amp;rft.date=2018-01&amp;rft_id=info%3Adoi%2F10.1093%2Fannonc%2Fmdx755&amp;rft_id=info%3Apmid%2F29228097&amp;rft.aulast=Tang&amp;rft.aufirst=J&amp;rft.au=Shalabi%2C+A&amp;rft.au=Hubbard-Lucey%2C+VM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-59"><span class="mw-cite-backlink"><b><a href="#cite_ref-59">^</a></b></span> <span class="reference-text"><cite class="citation journal">Perry CJ, Muñoz-Rojas AR, Meeth KM, Kellman LN, Amezquita RA, Thakral D, Du VY, Wang JX, Damsky W, Kuhlmann AL, Sher JW, Bosenberg M, Miller-Jensen K, Kaech SM (March 2018). "Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity". <i>The Journal of Experimental Medicine</i>. <b>215</b> (3): 877–93. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1084%2Fjem.20171435">10.1084/jem.20171435</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/29436395">29436395</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Journal+of+Experimental+Medicine&amp;rft.atitle=Myeloid-targeted+immunotherapies+act+in+synergy+to+induce+inflammation+and+antitumor+immunity&amp;rft.volume=215&amp;rft.issue=3&amp;rft.pages=877-93&amp;rft.date=2018-03&amp;rft_id=info%3Adoi%2F10.1084%2Fjem.20171435&amp;rft_id=info%3Apmid%2F29436395&amp;rft.aulast=Perry&amp;rft.aufirst=CJ&amp;rft.au=Mu%C3%B1oz-Rojas%2C+AR&amp;rft.au=Meeth%2C+KM&amp;rft.au=Kellman%2C+LN&amp;rft.au=Amezquita%2C+RA&amp;rft.au=Thakral%2C+D&amp;rft.au=Du%2C+VY&amp;rft.au=Wang%2C+JX&amp;rft.au=Damsky%2C+W&amp;rft.au=Kuhlmann%2C+AL&amp;rft.au=Sher%2C+JW&amp;rft.au=Bosenberg%2C+M&amp;rft.au=Miller-Jensen%2C+K&amp;rft.au=Kaech%2C+SM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-60"><span class="mw-cite-backlink"><b><a href="#cite_ref-60">^</a></b></span> <span class="reference-text"><cite class="citation journal">Rodell CB, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, Kohler RH, Pittet MJ, Weissleder R (21 May 2018). "TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy". <i>Nature Biomedical Engineering</i>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fs41551-018-0236-8">10.1038/s41551-018-0236-8</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Biomedical+Engineering&amp;rft.atitle=TLR7%2F8-agonist-loaded+nanoparticles+promote+the+polarization+of+tumour-associated+macrophages+to+enhance+cancer+immunotherapy&amp;rft.date=2018-05-21&amp;rft_id=info%3Adoi%2F10.1038%2Fs41551-018-0236-8&amp;rft.aulast=Rodell&amp;rft.aufirst=CB&amp;rft.au=Arlauckas%2C+SP&amp;rft.au=Cuccarese%2C+MF&amp;rft.au=Garris%2C+CS&amp;rft.au=Li%2C+R&amp;rft.au=Ahmed%2C+MS&amp;rft.au=Kohler%2C+RH&amp;rft.au=Pittet%2C+MJ&amp;rft.au=Weissleder%2C+R&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-CoriolusVersicolor-61"><span class="mw-cite-backlink"><b><a href="#cite_ref-CoriolusVersicolor_61-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20060215064239/http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Coriolous_Versicolor.asp">"Coriolus Versicolor"</a>. American Cancer Society. Archived from <a rel="nofollow" class="external text" href="http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Coriolous_Versicolor.asp">the original</a> on 15 February 2006.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Coriolus+Versicolor&amp;rft.pub=American+Cancer+Society&amp;rft_id=http%3A%2F%2Fwww.cancer.org%2Fdocroot%2FETO%2Fcontent%2FETO_5_3X_Coriolous_Versicolor.asp&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-62"><span class="mw-cite-backlink"><b><a href="#cite_ref-62">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.cancergenetics.com/cancer-genetics-offers-the-fda-approved-dako-pd-l1-ihc-22c3-pharmdx-companion-diagnostic-test-for-keytruda/">"Cancer Genetics offers the FDA-approved DAKO PD-L1 IHC 22C3 pharmDx companion diagnostic test for KEYTRUDA®"</a>. 3 February 2016.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Cancer+Genetics+offers+the+FDA-approved+DAKO+PD-L1+IHC+22C3+pharmDx+companion+diagnostic+test+for+KEYTRUDA%C2%AE&amp;rft.date=2016-02-03&amp;rft_id=http%3A%2F%2Fwww.cancergenetics.com%2Fcancer-genetics-offers-the-fda-approved-dako-pd-l1-ihc-22c3-pharmdx-companion-diagnostic-test-for-keytruda%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-63"><span class="mw-cite-backlink"><b><a href="#cite_ref-63">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pubmed/29426340">PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics</a> Margarita Utal et al. February 2018, online. Public Medical Library (NCBI website)</span>
</li>
<li id="cite_note-64"><span class="mw-cite-backlink"><b><a href="#cite_ref-64">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://academic.oup.com/annonc/article-abstract/29/4/791/4904099?redirectedFrom=fulltext">Time is up for PD-L1 testing in lung cancer</a>, S. Dacic, 23 February 2018, from Annals of Oncology, Volume 29 Issue 4, April 2018 (Oxfard Academic website)</span>
</li>
<li id="cite_note-65"><span class="mw-cite-backlink"><b><a href="#cite_ref-65">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://mct.aacrjournals.org/content/16/11/2598">Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers</a> A. Goodman et al. Molecular Cancer Therapeutics magazine, August 2017</span>
</li>
<li id="cite_note-66"><span class="mw-cite-backlink"><b><a href="#cite_ref-66">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://www.medpagetoday.com/pathology/generalpathology/72704">Optimism tempered by lack of standardization</a>, Charles Bankhead, 4 May 2018 (Medpage Today website)</span>
</li>
<li id="cite_note-67"><span class="mw-cite-backlink"><b><a href="#cite_ref-67">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.ascopost.com/News/59015">FDA Accepts sBLA for First-Line Nivolumab Plus Low-Dose Ipilimumab in NSCLC With Tumor Mutational Burden ≥ 10 mut/mb</a>, 7 February 2018, <a href="/wiki/American_Society_of_Clinical_Oncology" title="American Society of Clinical Oncology">American Society of Clinical Oncology</a> (ASCO Post website, mostly repeating a <a href="/wiki/Bristol-Myers_Squibb" title="Bristol-Myers Squibb">Bristol-Myers Squibb</a> publication)</span>
</li>
<li id="cite_note-68"><span class="mw-cite-backlink"><b><a href="#cite_ref-68">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm611981.htm">FDA approves Encorafenib and Binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations</a> 27 June 2018 (FDA website)</span>
</li>
<li id="cite_note-69"><span class="mw-cite-backlink"><b><a href="#cite_ref-69">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://www.forbes.com/sites/fayeflam/2015/01/22/investigator-offers-lessons-from-precision-medicines-cancer-scandal/">Duke U Cancer Fraud Scandal: A Cautionary Tale For Obama's Precision Medicine Push</a>, Faye Flam, 17 February 2015 (Forbes website)</span>
</li>
<li id="cite_note-70"><span class="mw-cite-backlink"><b><a href="#cite_ref-70">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://sciencebasedmedicine.org/liquid-biopsies-for-cancer-life-saving-tests-or-overdiagnosis-and-overtreatment-taken-to-a-new-level/">“Liquid biopsies” for cancer screening: Life-saving tests, or overdiagnosis and overtreatment taken to a new level?</a> David Gorski, September 2015, <a href="/wiki/Science-Based_Medicine" title="Science-Based Medicine">Science-Based Medicine</a> website</span>
</li>
<li id="cite_note-71"><span class="mw-cite-backlink"><b><a href="#cite_ref-71">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="https://www.melanoma.org/find-support/patient-community/mpip-melanoma-patients-information-page/insurance-wont-pay-braf-test">A public discussion by cancer patients</a> from 2011 on the melanoma.org website shows costs and claims.</span>
</li>
<li id="cite_note-NatureRev2012-72"><span class="mw-cite-backlink"><b><a href="#cite_ref-NatureRev2012_72-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Restifo NP, Dudley ME, Rosenberg SA (March 2012). "Adoptive immunotherapy for cancer: harnessing the T cell response". <i>Nature Reviews. Immunology</i>. <b>12</b> (4): 269–81. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fnri3191">10.1038/nri3191</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22437939">22437939</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Reviews.+Immunology&amp;rft.atitle=Adoptive+immunotherapy+for+cancer%3A+harnessing+the+T+cell+response&amp;rft.volume=12&amp;rft.issue=4&amp;rft.pages=269-81&amp;rft.date=2012-03&amp;rft_id=info%3Adoi%2F10.1038%2Fnri3191&amp;rft_id=info%3Apmid%2F22437939&amp;rft.aulast=Restifo&amp;rft.aufirst=NP&amp;rft.au=Dudley%2C+ME&amp;rft.au=Rosenberg%2C+SA&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-73"><span class="mw-cite-backlink"><b><a href="#cite_ref-73">^</a></b></span> <span class="reference-text"><cite class="citation web">Carroll J (December 2013). <a rel="nofollow" class="external text" href="http://www.fiercebiotech.com/story/novartispenns-customized-t-cell-wows-ash-stellar-leukemia-data/2013-12-09">"Novartis/Penn's customized T cell wows ASH with stellar leukemia data"</a>. <i>Fierce Biotech</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Fierce+Biotech&amp;rft.atitle=Novartis%2FPenn%27s+customized+T+cell+wows+ASH+with+stellar+leukemia+data&amp;rft.date=2013-12&amp;rft.aulast=Carroll&amp;rft.aufirst=John&amp;rft_id=http%3A%2F%2Fwww.fiercebiotech.com%2Fstory%2Fnovartispenns-customized-t-cell-wows-ash-stellar-leukemia-data%2F2013-12-09&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-74"><span class="mw-cite-backlink"><b><a href="#cite_ref-74">^</a></b></span> <span class="reference-text"><cite class="citation web">Carroll, John (February 2014). <a rel="nofollow" class="external text" href="http://www.fiercebiotech.com/story/servier-stages-entry-high-stakes-car-t-showdown-novartis/2014-02-18">"Servier stages an entry into high-stakes CAR-T showdown with Novartis"</a>. <i>FierceBiotech</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=FierceBiotech&amp;rft.atitle=Servier+stages+an+entry+into+high-stakes+CAR-T+showdown+with+Novartis&amp;rft.date=2014-02&amp;rft.aulast=Carroll&amp;rft.aufirst=John&amp;rft_id=http%3A%2F%2Fwww.fiercebiotech.com%2Fstory%2Fservier-stages-entry-high-stakes-car-t-showdown-novartis%2F2014-02-18&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-75"><span class="mw-cite-backlink"><b><a href="#cite_ref-75">^</a></b></span> <span class="reference-text"><cite class="citation web">Regalado A (June 2015). <a rel="nofollow" class="external text" href="http://www.technologyreview.com/featuredstory/538441/biotechs-coming-cancer-cure/">"Biotech's Coming Cancer Cure: Supercharge your immune cells to defeat cancer? Juno Therapeutics believes its treatments can do exactly that"</a>. <i><a href="/wiki/MIT_Technology_Review" title="MIT Technology Review">MIT Technology Review</a></i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=MIT+Technology+Review&amp;rft.atitle=Biotech%27s+Coming+Cancer+Cure%3A+Supercharge+your+immune+cells+to+defeat+cancer%3F+Juno+Therapeutics+believes+its+treatments+can+do+exactly+that&amp;rft.date=2015-06&amp;rft.aulast=Regalado&amp;rft.aufirst=Antonio&amp;rft_id=http%3A%2F%2Fwww.technologyreview.com%2Ffeaturedstory%2F538441%2Fbiotechs-coming-cancer-cure%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-76"><span class="mw-cite-backlink"><b><a href="#cite_ref-76">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.cancer.gov/cancertopics/research-updates/2013/CAR-T-Cells">"CAR T-Cell Therapy: Engineering Patients' Immune Cells to Treat Their Cancers"</a>. cancer.gov. 6 December 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">9 May</span> 2014</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=CAR+T-Cell+Therapy%3A+Engineering+Patients%E2%80%99+Immune+Cells+to+Treat+Their+Cancers&amp;rft.pub=cancer.gov&amp;rft.date=2013-12-06&amp;rft_id=http%3A%2F%2Fwww.cancer.gov%2Fcancertopics%2Fresearch-updates%2F2013%2FCAR-T-Cells&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-77"><span class="mw-cite-backlink"><b><a href="#cite_ref-77">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.nih.gov/news/health/may2014/nci-08.htm">"NIH study demonstrates that a new cancer immunotherapy method could be effective against a wide range of cancers"</a>. nih.gov. 8 May 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">9 May</span> 2014</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=NIH+study+demonstrates+that+a+new+cancer+immunotherapy+method+could+be+effective+against+a+wide+range+of+cancers&amp;rft.pub=nih.gov&amp;rft.date=2014-05-08&amp;rft_id=http%3A%2F%2Fwww.nih.gov%2Fnews%2Fhealth%2Fmay2014%2Fnci-08.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-pmid29688262-78"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid29688262_78-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Andersen R, Borch TH, Draghi A, Gokuldass A, Rana MA, Pedersen M, Nielsen M, Kongsted P, Kjeldsen JW, Westergaard MC, Radic HD, Chamberlain CA, Holmich LR, Hendel HW, Larsen MS, Met O, Svane IM, Donia M (April 2018). "T cells isolated from patients with checkpoint inhibitor resistant-melanoma are functional and can mediate tumor regression". <i>Ann. Oncol</i>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1093%2Fannonc%2Fmdy139">10.1093/annonc/mdy139</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/29688262">29688262</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Ann.+Oncol.&amp;rft.atitle=T+cells+isolated+from+patients+with+checkpoint+inhibitor+resistant-melanoma+are+functional+and+can+mediate+tumor+regression.&amp;rft.date=2018-04&amp;rft_id=info%3Adoi%2F10.1093%2Fannonc%2Fmdy139&amp;rft_id=info%3Apmid%2F29688262&amp;rft.aulast=Andersen&amp;rft.aufirst=R&amp;rft.au=Borch%2C+TH&amp;rft.au=Draghi%2C+A&amp;rft.au=Gokuldass%2C+A&amp;rft.au=Rana%2C+MA&amp;rft.au=Pedersen%2C+M&amp;rft.au=Nielsen%2C+M&amp;rft.au=Kongsted%2C+P&amp;rft.au=Kjeldsen%2C+JW&amp;rft.au=Westergaard%2C+MC&amp;rft.au=Radic%2C+HD&amp;rft.au=Chamberlain%2C+CA&amp;rft.au=Holmich%2C+LR&amp;rft.au=Hendel%2C+HW&amp;rft.au=Larsen%2C+MS&amp;rft.au=Met%2C+O&amp;rft.au=Svane%2C+IM&amp;rft.au=Donia%2C+M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-79"><span class="mw-cite-backlink"><b><a href="#cite_ref-79">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm">"FDA approval brings first gene therapy to the United States"</a>. fda.gov. 30 August 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">8 November</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=FDA+approval+brings+first+gene+therapy+to+the+United+States&amp;rft.pub=fda.gov&amp;rft.date=2017-08-30&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm574058.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-pmid_=_24528541-80"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid_=_24528541_80-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H, Kunzmann V (February 2014). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3926263">"Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells"</a>. <i>Journal of Translational Medicine</i>. <b>12</b>: 45. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1186%2F1479-5876-12-45">10.1186/1479-5876-12-45</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3926263">3926263</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24528541">24528541</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Translational+Medicine&amp;rft.atitle=Successful+adoptive+transfer+and+in+vivo+expansion+of+haploidentical+%CE%B3%CE%B4+T+cells&amp;rft.volume=12&amp;rft.pages=45&amp;rft.date=2014-02&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3926263&amp;rft_id=info%3Apmid%2F24528541&amp;rft_id=info%3Adoi%2F10.1186%2F1479-5876-12-45&amp;rft.aulast=Wilhelm&amp;rft.aufirst=M&amp;rft.au=Smetak%2C+M&amp;rft.au=Schaefer-Eckart%2C+K&amp;rft.au=Kimmel%2C+B&amp;rft.au=Birkmann%2C+J&amp;rft.au=Einsele%2C+H&amp;rft.au=Kunzmann%2C+V&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3926263&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-81"><span class="mw-cite-backlink"><b><a href="#cite_ref-81">^</a></b></span> <span class="reference-text"><cite class="citation journal">Jaiswal S, Chao MP, Majeti R, Weissman IL (June 2010). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3646798">"Macrophages as mediators of tumor immunosurveillance"</a>. <i>Trends in Immunology</i>. <b>31</b> (6): 212–19. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2Fj.it.2010.04.001">10.1016/j.it.2010.04.001</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3646798">3646798</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20452821">20452821</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Trends+in+Immunology&amp;rft.atitle=Macrophages+as+mediators+of+tumor+immunosurveillance&amp;rft.volume=31&amp;rft.issue=6&amp;rft.pages=212-19&amp;rft.date=2010-06&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3646798&amp;rft_id=info%3Apmid%2F20452821&amp;rft_id=info%3Adoi%2F10.1016%2Fj.it.2010.04.001&amp;rft.aulast=Jaiswal&amp;rft.aufirst=S&amp;rft.au=Chao%2C+MP&amp;rft.au=Majeti%2C+R&amp;rft.au=Weissman%2C+IL&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3646798&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-:1-82"><span class="mw-cite-backlink">^ <a href="#cite_ref-:1_82-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:1_82-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-:1_82-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Weiskopf K (May 2017). "Cancer immunotherapy targeting the CD47/SIRPα axis". <i>European Journal of Cancer</i>. <b>76</b>: 100–09. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2Fj.ejca.2017.02.013">10.1016/j.ejca.2017.02.013</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/28286286">28286286</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=European+Journal+of+Cancer&amp;rft.atitle=Cancer+immunotherapy+targeting+the+CD47%2FSIRP%CE%B1+axis&amp;rft.volume=76&amp;rft.pages=100-09&amp;rft.date=2017-05&amp;rft_id=info%3Adoi%2F10.1016%2Fj.ejca.2017.02.013&amp;rft_id=info%3Apmid%2F28286286&amp;rft.aulast=Weiskopf&amp;rft.aufirst=K&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-83"><span class="mw-cite-backlink"><b><a href="#cite_ref-83">^</a></b></span> <span class="reference-text"><cite class="citation journal">Matlung HL, Szilagyi K, Barclay NA, van den Berg TK (March 2017). "The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer". <i>Immunological Reviews</i>. <b>276</b> (1): 145–64. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1111%2Fimr.12527">10.1111/imr.12527</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/28258703">28258703</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Immunological+Reviews&amp;rft.atitle=The+CD47-SIRP%CE%B1+signaling+axis+as+an+innate+immune+checkpoint+in+cancer&amp;rft.volume=276&amp;rft.issue=1&amp;rft.pages=145-64&amp;rft.date=2017-03&amp;rft_id=info%3Adoi%2F10.1111%2Fimr.12527&amp;rft_id=info%3Apmid%2F28258703&amp;rft.aulast=Matlung&amp;rft.aufirst=HL&amp;rft.au=Szilagyi%2C+K&amp;rft.au=Barclay%2C+NA&amp;rft.au=van+den+Berg%2C+TK&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-84"><span class="mw-cite-backlink"><b><a href="#cite_ref-84">^</a></b></span> <span class="reference-text"><cite class="citation journal">Veillette A, Chen J (March 2018). "SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy". <i>Trends in Immunology</i>. <b>39</b> (3): 173–84. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2Fj.it.2017.12.005">10.1016/j.it.2017.12.005</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/29336991">29336991</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Trends+in+Immunology&amp;rft.atitle=SIRP%CE%B1-CD47+Immune+Checkpoint+Blockade+in+Anticancer+Therapy&amp;rft.volume=39&amp;rft.issue=3&amp;rft.pages=173-84&amp;rft.date=2018-03&amp;rft_id=info%3Adoi%2F10.1016%2Fj.it.2017.12.005&amp;rft_id=info%3Apmid%2F29336991&amp;rft.aulast=Veillette&amp;rft.aufirst=A&amp;rft.au=Chen%2C+J&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-85"><span class="mw-cite-backlink"><b><a href="#cite_ref-85">^</a></b></span> <span class="reference-text"><cite class="citation journal">Ahmed M, Cheung NK (January 2014). "Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy". <i>FEBS Letters</i>. <b>588</b> (2): 288–97. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2Fj.febslet.2013.11.030">10.1016/j.febslet.2013.11.030</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24295643">24295643</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=FEBS+Letters&amp;rft.atitle=Engineering+anti-GD2+monoclonal+antibodies+for+cancer+immunotherapy&amp;rft.volume=588&amp;rft.issue=2&amp;rft.pages=288-97&amp;rft.date=2014-01&amp;rft_id=info%3Adoi%2F10.1016%2Fj.febslet.2013.11.030&amp;rft_id=info%3Apmid%2F24295643&amp;rft.aulast=Ahmed&amp;rft.aufirst=M&amp;rft.au=Cheung%2C+NK&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-pmid22437870-86"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid22437870_86-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid22437870_86-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Pardoll DM (March 2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023">"The blockade of immune checkpoints in cancer immunotherapy"</a>. <i>Nature Reviews. Cancer</i>. <b>12</b> (4): 252–64. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1038%2Fnrc3239">10.1038/nrc3239</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023">4856023</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22437870">22437870</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature+Reviews.+Cancer&amp;rft.atitle=The+blockade+of+immune+checkpoints+in+cancer+immunotherapy&amp;rft.volume=12&amp;rft.issue=4&amp;rft.pages=252-64&amp;rft.date=2012-03&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4856023&amp;rft_id=info%3Apmid%2F22437870&amp;rft_id=info%3Adoi%2F10.1038%2Fnrc3239&amp;rft.aulast=Pardoll&amp;rft.aufirst=DM&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4856023&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-ReferenceA-87"><span class="mw-cite-backlink"><b><a href="#cite_ref-ReferenceA_87-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, Saldmann A, Gey A, Oudard S, Tartour E (2017). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5518304">"Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer"</a>. <i>ESMO Open</i>. <b>2</b> (2): e000213. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1136%2Fesmoopen-2017-000213">10.1136/esmoopen-2017-000213</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5518304">5518304</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/28761757">28761757</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=ESMO+Open&amp;rft.atitle=Mechanisms+of+action+and+rationale+for+the+use+of+checkpoint+inhibitors+in+cancer&amp;rft.volume=2&amp;rft.issue=2&amp;rft.pages=e000213&amp;rft.date=2017&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5518304&amp;rft_id=info%3Apmid%2F28761757&amp;rft_id=info%3Adoi%2F10.1136%2Fesmoopen-2017-000213&amp;rft.aulast=Granier&amp;rft.aufirst=C&amp;rft.au=De+Guillebon%2C+E&amp;rft.au=Blanc%2C+C&amp;rft.au=Roussel%2C+H&amp;rft.au=Badoual%2C+C&amp;rft.au=Colin%2C+E&amp;rft.au=Saldmann%2C+A&amp;rft.au=Gey%2C+A&amp;rft.au=Oudard%2C+S&amp;rft.au=Tartour%2C+E&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5518304&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-88"><span class="mw-cite-backlink"><b><a href="#cite_ref-88">^</a></b></span> <span class="reference-text"><cite class="citation journal">Cameron F, Whiteside G, Perry C (May 2011). "Ipilimumab: first global approval". <i>Drugs</i>. <b>71</b> (8): 1093–104. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.2165%2F11594010-000000000-00000">10.2165/11594010-000000000-00000</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21668044">21668044</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drugs&amp;rft.atitle=Ipilimumab%3A+first+global+approval&amp;rft.volume=71&amp;rft.issue=8&amp;rft.pages=1093-104&amp;rft.date=2011-05&amp;rft_id=info%3Adoi%2F10.2165%2F11594010-000000000-00000&amp;rft_id=info%3Apmid%2F21668044&amp;rft.aulast=Cameron&amp;rft.aufirst=F&amp;rft.au=Whiteside%2C+G&amp;rft.au=Perry%2C+C&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-89"><span class="mw-cite-backlink"><b><a href="#cite_ref-89">^</a></b></span> <span class="reference-text"><cite class="citation journal">Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M (June 2012). "Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study". <i>Journal of Clinical Oncology</i>. <b>30</b> (17): 2046–54. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1200%2FJCO.2011.38.4032">10.1200/JCO.2011.38.4032</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22547592">22547592</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Clinical+Oncology&amp;rft.atitle=Ipilimumab+in+combination+with+paclitaxel+and+carboplatin+as+first-line+treatment+in+stage+IIIB%2FIV+non-small-cell+lung+cancer%3A+results+from+a+randomized%2C+double-blind%2C+multicenter+phase+II+study&amp;rft.volume=30&amp;rft.issue=17&amp;rft.pages=2046-54&amp;rft.date=2012-06&amp;rft_id=info%3Adoi%2F10.1200%2FJCO.2011.38.4032&amp;rft_id=info%3Apmid%2F22547592&amp;rft.aulast=Lynch&amp;rft.aufirst=TJ&amp;rft.au=Bondarenko%2C+I&amp;rft.au=Luft%2C+A&amp;rft.au=Serwatowski%2C+P&amp;rft.au=Barlesi%2C+F&amp;rft.au=Chacko%2C+R&amp;rft.au=Sebastian%2C+M&amp;rft.au=Neal%2C+J&amp;rft.au=Lu%2C+H&amp;rft.au=Cuillerot%2C+JM&amp;rft.au=Reck%2C+M&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-90"><span class="mw-cite-backlink"><b><a href="#cite_ref-90">^</a></b></span> <span class="reference-text"><cite class="citation journal">Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA, Donehower RC, Jaffee EM, Laheru DA (September 2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3779664">"Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer"</a>. <i>Journal of Immunotherapy</i>. <b>36</b> (7): 382–89. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1097%2FCJI.0b013e31829fb7a2">10.1097/CJI.0b013e31829fb7a2</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3779664">3779664</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23924790">23924790</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Immunotherapy&amp;rft.atitle=Evaluation+of+ipilimumab+in+combination+with+allogeneic+pancreatic+tumor+cells+transfected+with+a+GM-CSF+gene+in+previously+treated+pancreatic+cancer&amp;rft.volume=36&amp;rft.issue=7&amp;rft.pages=382-89&amp;rft.date=2013-09&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3779664&amp;rft_id=info%3Apmid%2F23924790&amp;rft_id=info%3Adoi%2F10.1097%2FCJI.0b013e31829fb7a2&amp;rft.aulast=Le&amp;rft.aufirst=DT&amp;rft.au=Lutz%2C+E&amp;rft.au=Uram%2C+JN&amp;rft.au=Sugar%2C+EA&amp;rft.au=Onners%2C+B&amp;rft.au=Solt%2C+S&amp;rft.au=Zheng%2C+L&amp;rft.au=Diaz%2C+LA&amp;rft.au=Donehower%2C+RC&amp;rft.au=Jaffee%2C+EM&amp;rft.au=Laheru%2C+DA&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3779664&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-91"><span class="mw-cite-backlink"><b><a href="#cite_ref-91">^</a></b></span> <span class="reference-text">Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT01928394">NCT01928394</a></i> for "A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></span>
</li>
<li id="cite_note-92"><span class="mw-cite-backlink"><b><a href="#cite_ref-92">^</a></b></span> <span class="reference-text"><cite class="citation journal">Postow MA, Callahan MK, Wolchok JD (June 2015). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4980573">"Immune Checkpoint Blockade in Cancer Therapy"</a>. <i>Journal of Clinical Oncology</i>. <b>33</b> (17): 1974–82. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1200%2FJCO.2014.59.4358">10.1200/JCO.2014.59.4358</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4980573">4980573</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25605845">25605845</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Clinical+Oncology&amp;rft.atitle=Immune+Checkpoint+Blockade+in+Cancer+Therapy&amp;rft.volume=33&amp;rft.issue=17&amp;rft.pages=1974-82&amp;rft.date=2015-06&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4980573&amp;rft_id=info%3Apmid%2F25605845&amp;rft_id=info%3Adoi%2F10.1200%2FJCO.2014.59.4358&amp;rft.aulast=Postow&amp;rft.aufirst=MA&amp;rft.au=Callahan%2C+MK&amp;rft.au=Wolchok%2C+JD&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4980573&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-:3-93"><span class="mw-cite-backlink">^ <a href="#cite_ref-:3_93-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:3_93-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">van Hooren L, Sandin LC, Moskalev I, Ellmark P, Dimberg A, Black P, Tötterman TH, Mangsbo SM (February 2017). "Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer". <i>European Journal of Immunology</i>. <b>47</b> (2): 385–93. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1002%2Feji.201646583">10.1002/eji.201646583</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/27873300">27873300</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=European+Journal+of+Immunology&amp;rft.atitle=Local+checkpoint+inhibition+of+CTLA-4+as+a+monotherapy+or+in+combination+with+anti-PD1+prevents+the+growth+of+murine+bladder+cancer&amp;rft.volume=47&amp;rft.issue=2&amp;rft.pages=385-93&amp;rft.date=2017-02&amp;rft_id=info%3Adoi%2F10.1002%2Feji.201646583&amp;rft_id=info%3Apmid%2F27873300&amp;rft.aulast=van+Hooren&amp;rft.aufirst=L&amp;rft.au=Sandin%2C+LC&amp;rft.au=Moskalev%2C+I&amp;rft.au=Ellmark%2C+P&amp;rft.au=Dimberg%2C+A&amp;rft.au=Black%2C+P&amp;rft.au=T%C3%B6tterman%2C+TH&amp;rft.au=Mangsbo%2C+SM&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-:2-94"><span class="mw-cite-backlink">^ <a href="#cite_ref-:2_94-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:2_94-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Pollack A (18 May 2016). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2016/05/19/business/food-and-drug-administration-immunotherapy-bladder-cancer.html">"F.D.A. Approves an Immunotherapy Drug for Bladder Cancer"</a>. <i>The New York Times</i>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0362-4331">0362-4331</a><span class="reference-accessdate">. Retrieved <span class="nowrap">21 May</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=F.D.A.+Approves+an+Immunotherapy+Drug+for+Bladder+Cancer&amp;rft.date=2016-05-18&amp;rft.issn=0362-4331&amp;rft.aulast=Pollack&amp;rft.aufirst=Andrew&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2016%2F05%2F19%2Fbusiness%2Ffood-and-drug-administration-immunotherapy-bladder-cancer.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-95"><span class="mw-cite-backlink"><b><a href="#cite_ref-95">^</a></b></span> <span class="reference-text"><cite class="citation news">Steele A (5 August 2016). <a rel="nofollow" class="external text" href="https://www.wsj.com/articles/bristol-myers-opdivo-failed-to-meet-endpoint-in-key-lung-cancer-study-1470400926">"Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung-Cancer Study"</a>. <i>The Wall Street Journal</i>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/issn/0099-9660">0099-9660</a><span class="reference-accessdate">. Retrieved <span class="nowrap">5 August</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Wall+Street+Journal&amp;rft.atitle=Bristol+Myers%3A+Opdivo+Failed+to+Meet+Endpoint+in+Key+Lung-Cancer+Study&amp;rft.date=2016-08-05&amp;rft.issn=0099-9660&amp;rft.aulast=Steele&amp;rft.aufirst=Anne&amp;rft_id=https%3A%2F%2Fwww.wsj.com%2Farticles%2Fbristol-myers-opdivo-failed-to-meet-endpoint-in-key-lung-cancer-study-1470400926&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-96"><span class="mw-cite-backlink"><b><a href="#cite_ref-96">^</a></b></span> <span class="reference-text"><cite class="citation web">BeiGene, Ltd. <a rel="nofollow" class="external text" href="https://globenewswire.com/news-release/2016/06/05/846118/0/en/BeiGene-Presents-Initial-Clinical-Data-on-PD-1-Antibody-BGB-A317-at-the-2016-American-Society-of-Clinical-Oncology-Annual-Meeting.html">"BeiGene Presents Initial Clinical Data on PD-1 Antibody BGB-A317 at the 2016 American Society of Clinical Oncology Annual Meeting"</a>. Globe Newswire.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=BeiGene+Presents+Initial+Clinical+Data+on+PD-1+Antibody+BGB-A317+at+the+2016+American+Society+of+Clinical+Oncology+Annual+Meeting&amp;rft.pub=Globe+Newswire&amp;rft.au=BeiGene%2C+Ltd.&amp;rft_id=https%3A%2F%2Fglobenewswire.com%2Fnews-release%2F2016%2F06%2F05%2F846118%2F0%2Fen%2FBeiGene-Presents-Initial-Clinical-Data-on-PD-1-Antibody-BGB-A317-at-the-2016-American-Society-of-Clinical-Oncology-Annual-Meeting.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-97"><span class="mw-cite-backlink"><b><a href="#cite_ref-97">^</a></b></span> <span class="reference-text"><cite class="citation web">Roche. <a rel="nofollow" class="external text" href="http://www.roche.com/investors/updates/inv-update-2016-04-11.htm">"FDA grants priority review for Roche's cancer immunotherapy atezolizumab in specific type of lung cancer"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=FDA+grants+priority+review+for+Roche%27s+cancer+immunotherapy+atezolizumab+in+specific+type+of+lung+cancer&amp;rft.au=Roche&amp;rft_id=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fupdates%2Finv-update-2016-04-11.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-98"><span class="mw-cite-backlink"><b><a href="#cite_ref-98">^</a></b></span> <span class="reference-text"><cite class="citation web">Merck Group. <a rel="nofollow" class="external text" href="http://www.merckgroup.com/en/innovation/research_activities/immuno_oncology/immuno_oncology.html">"Immuno-oncology Avelumab"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Immuno-oncology+Avelumab&amp;rft.au=Merck+Group&amp;rft_id=http%3A%2F%2Fwww.merckgroup.com%2Fen%2Finnovation%2Fresearch_activities%2Fimmuno_oncology%2Fimmuno_oncology.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-99"><span class="mw-cite-backlink"><b><a href="#cite_ref-99">^</a></b></span> <span class="reference-text"><cite class="citation web">Cure today. <a rel="nofollow" class="external text" href="http://www.curetoday.com/articles/durvalumab-continues-to-progress-in-treatment-of-advanced-bladder-cancer">"Durvalumab continues to progress in treatment of advanced bladder cancer"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Durvalumab+continues+to+progress+in+treatment+of+advanced+bladder+cancer.&amp;rft.au=Cure+today&amp;rft_id=http%3A%2F%2Fwww.curetoday.com%2Farticles%2Fdurvalumab-continues-to-progress-in-treatment-of-advanced-bladder-cancer&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-100"><span class="mw-cite-backlink"><b><a href="#cite_ref-100">^</a></b></span> <span class="reference-text"><cite class="citation web">Avacta Life Sciences. <a rel="nofollow" class="external text" href="https://www.avactalifesciences.com/blogs/affimer-biotherapeutics-target-cancer-s-switch-pd-l1-inhibitor">"Affimer biotherapeutics target cancer's off-switch with PD-L1 inhibitor"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Affimer+biotherapeutics+target+cancer%27s+off-switch+with+PD-L1+inhibitor&amp;rft.au=Avacta+Life+Sciences&amp;rft_id=https%3A%2F%2Fwww.avactalifesciences.com%2Fblogs%2Faffimer-biotherapeutics-target-cancer-s-switch-pd-l1-inhibitor&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-101"><span class="mw-cite-backlink"><b><a href="#cite_ref-101">^</a></b></span> <span class="reference-text"><cite class="citation journal">Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F,  et al. (February 2016). "Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy". <i>Immunity</i>. <b>44</b> (2): 343–54. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1016%2Fj.immuni.2015.11.024">10.1016/j.immuni.2015.11.024</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26872698">26872698</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Immunity&amp;rft.atitle=Immunogenic+Chemotherapy+Sensitizes+Tumors+to+Checkpoint+Blockade+Therapy&amp;rft.volume=44&amp;rft.issue=2&amp;rft.pages=343-54&amp;rft.date=2016-02&amp;rft_id=info%3Adoi%2F10.1016%2Fj.immuni.2015.11.024&amp;rft_id=info%3Apmid%2F26872698&amp;rft.aulast=Pfirschke&amp;rft.aufirst=C&amp;rft.au=Engblom%2C+C&amp;rft.au=Rickelt%2C+S&amp;rft.au=Cortez-Retamozo%2C+V&amp;rft.au=Garris%2C+C&amp;rft.au=Pucci%2C+F&amp;rft.au=Yamazaki%2C+T&amp;rft.au=Poirier-Colame%2C+V&amp;rft.au=Newton%2C+A&amp;rft.au=Redouane%2C+Y&amp;rft.au=Lin%2C+YJ&amp;rft.au=Wojtkiewicz%2C+G&amp;rft.au=Iwamoto%2C+Y&amp;rft.au=Mino-Kenudson%2C+M&amp;rft.au=Huynh%2C+TG&amp;rft.au=Hynes%2C+RO&amp;rft.au=Freeman%2C+GJ&amp;rft.au=Kroemer%2C+G&amp;rft.au=Zitvogel%2C+L&amp;rft.au=Weissleder%2C+R&amp;rft.au=Pittet%2C+MJ&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-pmid27486853-102"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid27486853_102-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Fukuhara H, Ino Y, Todo T (October 2016). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5084676">"Oncolytic virus therapy: A new era of cancer treatment at dawn"</a>. <i>Cancer Science</i>. <b>107</b> (10): 1373–79. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1111%2Fcas.13027">10.1111/cas.13027</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5084676">5084676</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/27486853">27486853</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Cancer+Science&amp;rft.atitle=Oncolytic+virus+therapy%3A+A+new+era+of+cancer+treatment+at+dawn&amp;rft.volume=107&amp;rft.issue=10&amp;rft.pages=1373-79&amp;rft.date=2016-10&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5084676&amp;rft_id=info%3Apmid%2F27486853&amp;rft_id=info%3Adoi%2F10.1111%2Fcas.13027&amp;rft.aulast=Fukuhara&amp;rft.aufirst=H&amp;rft.au=Ino%2C+Y&amp;rft.au=Todo%2C+T&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5084676&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-pmid28589082-103"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid28589082_103-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Haddad D (2017). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5440573">"Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery"</a>. <i>Frontiers in Oncology</i>. <b>7</b>: 96. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.3389%2Ffonc.2017.00096">10.3389/fonc.2017.00096</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5440573">5440573</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/28589082">28589082</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Frontiers+in+Oncology&amp;rft.atitle=Genetically+Engineered+Vaccinia+Viruses+As+Agents+for+Cancer+Treatment%2C+Imaging%2C+and+Transgene+Delivery&amp;rft.volume=7&amp;rft.pages=96&amp;rft.date=2017&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5440573&amp;rft_id=info%3Apmid%2F28589082&amp;rft_id=info%3Adoi%2F10.3389%2Ffonc.2017.00096&amp;rft.aulast=Haddad&amp;rft.aufirst=D&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5440573&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-pmid29329556-104"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid29329556_104-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y (January 2018). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5767051">"Cancer immunotherapy beyond immune checkpoint inhibitors"</a>. <i>Journal of Hematology &amp; Oncology</i>. <b>11</b> (1): 8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1186%2Fs13045-017-0552-6">10.1186/s13045-017-0552-6</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC5767051">5767051</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/29329556">29329556</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Hematology+%26+Oncology&amp;rft.atitle=Cancer+immunotherapy+beyond+immune+checkpoint+inhibitors&amp;rft.volume=11&amp;rft.issue=1&amp;rft.pages=8&amp;rft.date=2018-01&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5767051&amp;rft_id=info%3Apmid%2F29329556&amp;rft_id=info%3Adoi%2F10.1186%2Fs13045-017-0552-6&amp;rft.aulast=Marin-Acevedo&amp;rft.aufirst=JA&amp;rft.au=Soyano%2C+AE&amp;rft.au=Dholaria%2C+B&amp;rft.au=Knutson%2C+KL&amp;rft.au=Lou%2C+Y&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC5767051&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-105"><span class="mw-cite-backlink"><b><a href="#cite_ref-105">^</a></b></span> <span class="reference-text"><cite class="citation journal">Aleem E (June 2013). "β-Glucans and their applications in cancer therapy: focus on human studies". <i>Anti-Cancer Agents in Medicinal Chemistry</i>. <b>13</b> (5): 709–19. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.2174%2F1871520611313050007">10.2174/1871520611313050007</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23140353">23140353</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Anti-Cancer+Agents+in+Medicinal+Chemistry&amp;rft.atitle=%CE%B2-Glucans+and+their+applications+in+cancer+therapy%3A+focus+on+human+studies&amp;rft.volume=13&amp;rft.issue=5&amp;rft.pages=709-19&amp;rft.date=2013-06&amp;rft_id=info%3Adoi%2F10.2174%2F1871520611313050007&amp;rft_id=info%3Apmid%2F23140353&amp;rft.aulast=Aleem&amp;rft.aufirst=E&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-SnyderMakarov2014-106"><span class="mw-cite-backlink"><b><a href="#cite_ref-SnyderMakarov2014_106-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA (December 2014). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4315319">"Genetic basis for clinical response to CTLA-4 blockade in melanoma"</a>. <i>The New England Journal of Medicine</i>. <b>371</b> (23): 2189–99. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1056%2FNEJMoa1406498">10.1056/NEJMoa1406498</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4315319">4315319</a></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25409260">25409260</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+England+Journal+of+Medicine&amp;rft.atitle=Genetic+basis+for+clinical+response+to+CTLA-4+blockade+in+melanoma&amp;rft.volume=371&amp;rft.issue=23&amp;rft.pages=2189-99&amp;rft.date=2014-12&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4315319&amp;rft_id=info%3Apmid%2F25409260&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMoa1406498&amp;rft.aulast=Snyder&amp;rft.aufirst=A&amp;rft.au=Makarov%2C+V&amp;rft.au=Merghoub%2C+T&amp;rft.au=Yuan%2C+J&amp;rft.au=Zaretsky%2C+JM&amp;rft.au=Desrichard%2C+A&amp;rft.au=Walsh%2C+LA&amp;rft.au=Postow%2C+MA&amp;rft.au=Wong%2C+P&amp;rft.au=Ho%2C+TS&amp;rft.au=Hollmann%2C+TJ&amp;rft.au=Bruggeman%2C+C&amp;rft.au=Kannan%2C+K&amp;rft.au=Li%2C+Y&amp;rft.au=Elipenahli%2C+C&amp;rft.au=Liu%2C+C&amp;rft.au=Harbison%2C+CT&amp;rft.au=Wang%2C+L&amp;rft.au=Ribas%2C+A&amp;rft.au=Wolchok%2C+JD&amp;rft.au=Chan%2C+TA&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4315319&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
<li id="cite_note-ss15-107"><span class="mw-cite-backlink"><b><a href="#cite_ref-ss15_107-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Schumacher TN, Schreiber RD (April 2015). "Neoantigens in cancer immunotherapy". <i>Science</i>. <b>348</b> (6230): 69–74. <a href="/wiki/Bibcode" title="Bibcode">Bibcode</a>:<a rel="nofollow" class="external text" href="http://adsabs.harvard.edu/abs/2015Sci...348...69S">2015Sci...348...69S</a>. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//doi.org/10.1126%2Fscience.aaa4971">10.1126/science.aaa4971</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25838375">25838375</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Science&amp;rft.atitle=Neoantigens+in+cancer+immunotherapy&amp;rft.volume=348&amp;rft.issue=6230&amp;rft.pages=69-74&amp;rft.date=2015-04&amp;rft_id=info%3Apmid%2F25838375&amp;rft_id=info%3Adoi%2F10.1126%2Fscience.aaa4971&amp;rft_id=info%3Abibcode%2F2015Sci...348...69S&amp;rft.aulast=Schumacher&amp;rft.aufirst=TN&amp;rft.au=Schreiber%2C+RD&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></span>
</li>
</ol></div></div>
<h2><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit&amp;section=43" title="Edit section: External links">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul><li><a rel="nofollow" class="external text" href="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy">An easy to understand primer on "Immunotherapy to Treat Cancer"</a></li>
<li><a rel="nofollow" class="external text" href="https://www.cancer.gov/research/areas/treatment/immunotherapy-using-immune-system">Immunotherapy – Using the Immune System to Treat Cancer</a></li>
<li><a rel="nofollow" class="external text" href="http://www.cancerresearch.org/cancer-immunotherapy">Cancer Research Institute – What is Cancer Immunotherapy</a></li></ul>
<li> <a rel="nofollow" class="external text" href="http://www.c-imt.org">Association for Immunotherapy of Cancer</a></li>
<ul><li><a rel="nofollow" class="external text" href="http://www.sitcancer.org">Society for Immunotherapy of Cancer</a></li>
<li><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.economist.com/news/science-and-technology/21653602-doctors-are-tryingwith-some-successto-recruit-immune-system-help">"And Then There Were Five"</a>. <i>Economist</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Economist&amp;rft.atitle=And+Then+There+Were+Five&amp;rft_id=https%3A%2F%2Fwww.economist.com%2Fnews%2Fscience-and-technology%2F21653602-doctors-are-tryingwith-some-successto-recruit-immune-system-help&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></li>
<li><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.immunooncology.com/home.aspx">"Discover the Science of Immuno-Oncology"</a>. <a href="/wiki/Bristol-Myers_Squibb" title="Bristol-Myers Squibb">Bristol-Myers Squibb</a><span class="reference-accessdate">. Retrieved <span class="nowrap">13 March</span> 2014</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Discover+the+Science+of+Immuno-Oncology&amp;rft.pub=Bristol-Myers+Squibb&amp;rft_id=http%3A%2F%2Fwww.immunooncology.com%2Fhome.aspx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></li>
<li><cite class="citation journal">Eggermont A, Finn O. <a rel="nofollow" class="external text" href="http://annonc.oxfordjournals.org/content/23/suppl_8/viii5.full">"Advances in immuno-oncology"</a>. Oxford University Press<span class="reference-accessdate">. Retrieved <span class="nowrap">13 March</span> 2014</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Advances+in+immuno-oncology&amp;rft.aulast=Eggermont&amp;rft.aufirst=A&amp;rft.au=Finn%2C+O&amp;rft_id=http%3A%2F%2Fannonc.oxfordjournals.org%2Fcontent%2F23%2Fsuppl_8%2Fviii5.full&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></li>
<li><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.merckserono.com/en/research_development/therapeutic_focus/immuno_oncology/immuno_oncology.html;jsessionid=B776F4E8CCC023654F278E890F95B80D">"Immuno-Oncology: Investigating Cancer Therapies Powered by the Immune System"</a>. <a href="/wiki/Merck_Serono" title="Merck Serono">Merck Serono</a><span class="reference-accessdate">. Retrieved <span class="nowrap">13 March</span> 2014</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Immuno-Oncology%3A+Investigating+Cancer+Therapies+Powered+by+the+Immune+System&amp;rft.pub=Merck+Serono&amp;rft_id=http%3A%2F%2Fwww.merckserono.com%2Fen%2Fresearch_development%2Ftherapeutic_focus%2Fimmuno_oncology%2Fimmuno_oncology.html%3Bjsessionid%3DB776F4E8CCC023654F278E890F95B80D&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></li>
<li><cite class="citation journal">Calmeiro J, Carrascal M, Gomes C, Falcão A, Cruz MT, Neves BM. <a rel="nofollow" class="external text" href="https://www.intechopen.com/books/dendritic-cells/highlighting-the-role-of-dc-nk-cell-interplay-in-immunobiology-and-immunotherapy">"Highlighting the Role of DC-NK Cell Interplay in Immunobiology and Immunotherapy=November 5, 2018"</a>. IntechOpen.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Highlighting+the+Role+of+DC-NK+Cell+Interplay+in+Immunobiology+and+Immunotherapy%3DNovember+5%2C+2018&amp;rft.aulast=Calmeiro&amp;rft.aufirst=J&amp;rft.au=Carrascal%2C+M&amp;rft.au=Gomes%2C+C&amp;rft.au=Falc%C3%A3o%2C+A&amp;rft.au=Cruz%2C+MT&amp;rft.au=Neves%2C+BM&amp;rft_id=https%3A%2F%2Fwww.intechopen.com%2Fbooks%2Fdendritic-cells%2Fhighlighting-the-role-of-dc-nk-cell-interplay-in-immunobiology-and-immunotherapy&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3ACancer+immunotherapy" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r879151008"/></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Overview_of_tumors,_cancer_and_oncology_(C00–D48,_140–239)" style="padding:3px"><table class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div class="plainlinks hlist navbar mini"><ul><li class="nv-view"><a href="/wiki/Template:Tumors" title="Template:Tumors"><abbr title="View this template" style=";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:Tumors" title="Template talk:Tumors"><abbr title="Discuss this template" style=";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">t</abbr></a></li><li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Tumors&amp;action=edit"><abbr title="Edit this template" style=";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">e</abbr></a></li></ul></div><div id="Overview_of_tumors,_cancer_and_oncology_(C00–D48,_140–239)" style="font-size:114%;margin:0 4em">Overview of <a href="/wiki/Neoplasm" title="Neoplasm">tumors</a>, <a href="/wiki/Cancer" title="Cancer">cancer</a> and <a href="/wiki/Oncology" title="Oncology">oncology</a> (<a href="/wiki/ICD-10_Chapter_II:_Neoplasms" title="ICD-10 Chapter II: Neoplasms">C00–D48</a>, <a href="/wiki/List_of_ICD-9_codes_140%E2%80%93239:_neoplasms" title="List of ICD-9 codes 140–239: neoplasms">140–239</a>)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Conditions</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Benign_tumor" title="Benign tumor">Benign tumors</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Hyperplasia" title="Hyperplasia">Hyperplasia</a></li>
<li><a href="/wiki/Cyst" title="Cyst">Cyst</a></li>
<li><a href="/wiki/Pseudocyst" title="Pseudocyst">Pseudocyst</a></li>
<li><a href="/wiki/Hamartoma" title="Hamartoma">Hamartoma</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Malignant progression</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Dysplasia" title="Dysplasia">Dysplasia</a></li>
<li><a href="/wiki/Carcinoma_in_situ" title="Carcinoma in situ">Carcinoma in situ</a></li>
<li><a href="/wiki/Cancer" title="Cancer">Cancer</a></li>
<li><a href="/wiki/Metastasis" title="Metastasis">Metastasis</a></li>
<li><a href="/wiki/Primary_tumor" title="Primary tumor">Primary tumor</a></li>
<li><a href="/wiki/Sentinel_lymph_node" title="Sentinel lymph node">Sentinel lymph node</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Topography</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Head_and_neck_cancer" title="Head and neck cancer">Head/Neck</a> (<a href="/wiki/Oral_cancer" title="Oral cancer">Oral</a>, <a href="/wiki/Nasopharynx_cancer" title="Nasopharynx cancer">Nasopharyngeal</a>)</li>
<li><a href="/wiki/Digestive_system_neoplasm" title="Digestive system neoplasm">Digestive system</a></li>
<li><a href="/wiki/Neoplasm" title="Neoplasm">Respiratory system</a></li>
<li><a href="/wiki/Bone_tumor" title="Bone tumor">Bone</a></li>
<li><a href="/wiki/Skin_cancer" title="Skin cancer">Skin</a></li>
<li><a href="/wiki/Leukemia" title="Leukemia">Blood</a></li>
<li><a href="/wiki/Urogenital_neoplasm" title="Urogenital neoplasm">Urogenital</a></li>
<li><a href="/wiki/Nervous_system_neoplasm" title="Nervous system neoplasm">Nervous system</a></li>
<li><a href="/wiki/Endocrine_gland_neoplasm" title="Endocrine gland neoplasm">Endocrine system</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Histology</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Carcinoma" title="Carcinoma">Carcinoma</a></li>
<li><a href="/wiki/Sarcoma" title="Sarcoma">Sarcoma</a></li>
<li><a href="/wiki/Blastoma" title="Blastoma">Blastoma</a></li>
<li><a href="/wiki/Papilloma" title="Papilloma">Papilloma</a></li>
<li><a href="/wiki/Adenoma" title="Adenoma">Adenoma</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Precancerous_condition" title="Precancerous condition">Precancerous condition</a></li>
<li><a href="/wiki/Paraneoplastic_syndrome" title="Paraneoplastic syndrome">Paraneoplastic syndrome</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Cancer_staging" title="Cancer staging">Staging</a>/<a href="/wiki/Grading_(tumors)" title="Grading (tumors)">grading</a></th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/TNM_staging_system" title="TNM staging system">TNM</a></li>
<li><a href="/wiki/Ann_Arbor_staging" title="Ann Arbor staging">Ann Arbor</a></li>
<li><a href="/wiki/Prostate_cancer_staging" title="Prostate cancer staging">Prostate cancer staging</a></li>
<li><a href="/wiki/Gleason_grading_system" title="Gleason grading system">Gleason grading system</a></li>
<li><a href="/wiki/Dukes_classification" class="mw-redirect" title="Dukes classification">Dukes classification</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Carcinogenesis" title="Carcinogenesis">Carcinogenesis</a></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Cancer_cell" title="Cancer cell">Cancer cell</a></li>
<li><a href="/wiki/Carcinogen" title="Carcinogen">Carcinogen</a></li>
<li><a href="/wiki/Tumor_suppressor_gene" class="mw-redirect" title="Tumor suppressor gene">Tumor suppressor genes</a>/<a href="/wiki/Oncogene" title="Oncogene">oncogenes</a></li>
<li><a href="/wiki/Clonally_transmissible_cancer" title="Clonally transmissible cancer">Clonally transmissible cancer</a></li>
<li><a href="/wiki/Oncovirus" title="Oncovirus">Oncovirus</a></li>
<li><a href="/wiki/Carcinogenic_bacteria" title="Carcinogenic bacteria">Carcinogenic bacteria</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Misc.</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Cancer_research" title="Cancer research">Research</a></li>
<li><a href="/wiki/Index_of_oncology_articles" title="Index of oncology articles">Index of oncology articles</a></li>
<li><a href="/wiki/History_of_cancer" title="History of cancer">History</a></li>
<li><a href="/wiki/Cancer_pain" title="Cancer pain">Cancer pain</a></li>
<li><a href="/wiki/Cancer_and_nausea" title="Cancer and nausea">Cancer and nausea</a></li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Intracellular_chemotherapeutic_agents_/_antineoplastic_agents_(L01)" style="padding:3px"><table class="nowraplinks collapsible collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div class="plainlinks hlist navbar mini"><ul><li class="nv-view"><a href="/wiki/Template:Chemotherapeutic_agents" title="Template:Chemotherapeutic agents"><abbr title="View this template" style=";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:Chemotherapeutic_agents" class="mw-redirect" title="Template talk:Chemotherapeutic agents"><abbr title="Discuss this template" style=";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">t</abbr></a></li><li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Chemotherapeutic_agents&amp;action=edit"><abbr title="Edit this template" style=";;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">e</abbr></a></li></ul></div><div id="Intracellular_chemotherapeutic_agents_/_antineoplastic_agents_(L01)" style="font-size:114%;margin:0 4em">Intracellular <a href="/wiki/Chemotherapy" title="Chemotherapy">chemotherapeutic agents</a>&#160;/ <a href="/wiki/Antineoplastic" class="mw-redirect" title="Antineoplastic">antineoplastic agents</a> (<a href="/wiki/ATC_code_L01" title="ATC code L01">L01</a>)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Spindle_poison" title="Spindle poison">SPs</a>/<a href="/wiki/Mitotic_inhibitor" title="Mitotic inhibitor">MIs</a><br />(<a href="/wiki/M_phase" class="mw-redirect" title="M phase">M phase</a>)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Block <a href="/wiki/Microtubule" title="Microtubule">microtubule</a> assembly</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i><a href="/wiki/Catharanthus#Vinca_alkaloids" title="Catharanthus">Vinca alkaloids</a></i> (<a href="/wiki/Vinblastine" title="Vinblastine">Vinblastine</a><sup>#</sup></li>
<li><a href="/wiki/Vincristine" title="Vincristine">Vincristine</a><sup>#</sup></li>
<li><a href="/wiki/Vinflunine" title="Vinflunine">Vinflunine</a><sup>§</sup></li>
<li><a href="/wiki/Vindesine" title="Vindesine">Vindesine</a></li>
<li><a href="/wiki/Vinorelbine" title="Vinorelbine">Vinorelbine</a><sup>#</sup>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Block microtubule disassembly</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i><a href="/wiki/Taxane" title="Taxane">Taxanes</a></i> (<a href="/wiki/Cabazitaxel" title="Cabazitaxel">Cabazitaxel</a></li>
<li><a href="/wiki/Docetaxel" title="Docetaxel">Docetaxel</a><sup>#</sup></li>
<li><a href="/wiki/Larotaxel" title="Larotaxel">Larotaxel</a></li>
<li><a href="/wiki/Ortataxel" title="Ortataxel">Ortataxel</a><sup>†</sup></li>
<li><a href="/wiki/Paclitaxel" title="Paclitaxel">Paclitaxel</a><sup>#</sup></li>
<li><a href="/wiki/Tesetaxel" title="Tesetaxel">Tesetaxel</a>)</li>
<li><i><a href="/wiki/Epothilone" title="Epothilone">Epothilones</a></i> (<a href="/wiki/Ixabepilone" title="Ixabepilone">Ixabepilone</a>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/DNA_replication" title="DNA replication">DNA replication</a><br />inhibitor</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">DNA precursors/<br /><a href="/wiki/Antimetabolite" title="Antimetabolite">antimetabolites</a><br />(<a href="/wiki/S_phase" title="S phase">S phase</a>)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Antifolate" title="Antifolate">Folic acid</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i><a href="/wiki/Dihydrofolate_reductase_inhibitor" title="Dihydrofolate reductase inhibitor">Dihydrofolate reductase inhibitor</a></i> (<a href="/wiki/Aminopterin" title="Aminopterin">Aminopterin</a></li>
<li><a href="/wiki/Methotrexate" title="Methotrexate">Methotrexate</a><sup>#</sup></li>
<li><a href="/wiki/Pemetrexed" title="Pemetrexed">Pemetrexed</a></li>
<li><a href="/wiki/Pralatrexate" title="Pralatrexate">Pralatrexate</a>)</li>
<li><i><a href="/wiki/Thymidylate_synthase_inhibitor" title="Thymidylate synthase inhibitor">Thymidylate synthase inhibitor</a></i> (<a href="/wiki/Raltitrexed" title="Raltitrexed">Raltitrexed</a></li>
<li><a href="/wiki/Pemetrexed" title="Pemetrexed">Pemetrexed</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Purine_analogue" title="Purine analogue">Purine</a></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i><a href="/wiki/Adenosine_deaminase_inhibitor" class="mw-redirect" title="Adenosine deaminase inhibitor">Adenosine deaminase inhibitor</a></i> (<a href="/wiki/Pentostatin" title="Pentostatin">Pentostatin</a>)</li></ul>
<ul><li><i><a href="/wiki/Halogenation" title="Halogenation">Halogenated</a>/<a href="/wiki/Ribonucleotide_reductase_inhibitor" title="Ribonucleotide reductase inhibitor">ribonucleotide reductase inhibitors</a></i> (<a href="/wiki/Cladribine" title="Cladribine">Cladribine</a></li>
<li><a href="/wiki/Clofarabine" title="Clofarabine">Clofarabine</a></li>
<li><a href="/wiki/Fludarabine" title="Fludarabine">Fludarabine</a>)</li>
<li><a href="/wiki/Nelarabine" title="Nelarabine">Nelarabine</a></li></ul>
<ul><li><i><a href="/wiki/Thiopurine" title="Thiopurine">Thiopurine</a></i> (<a href="/wiki/Tioguanine" title="Tioguanine">Tioguanine</a><sup>#</sup></li>
<li><a href="/wiki/Mercaptopurine" title="Mercaptopurine">Mercaptopurine</a><sup>#</sup>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Pyrimidine_analogue" title="Pyrimidine analogue">Pyrimidine</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i><a href="/wiki/Thymidylate_synthase_inhibitor" title="Thymidylate synthase inhibitor">Thymidylate synthase inhibitor</a></i> (<a href="/wiki/Fluorouracil" title="Fluorouracil">Fluorouracil</a><sup>#</sup></li>
<li><a href="/wiki/Capecitabine" title="Capecitabine">Capecitabine</a><sup>#</sup></li>
<li><a href="/wiki/Doxifluridine" title="Doxifluridine">Doxifluridine</a></li>
<li><a href="/wiki/Tegafur" title="Tegafur">Tegafur</a> (<a href="/wiki/Tegafur/gimeracil/oteracil" title="Tegafur/gimeracil/oteracil">+gimeracil/oteracil</a>)</li>
<li><a href="/wiki/Carmofur" title="Carmofur">Carmofur</a></li>
<li><a href="/wiki/Floxuridine" title="Floxuridine">Floxuridine</a>)</li></ul>
<ul><li><i><a href="/wiki/DNA_polymerase_inhibitor" class="mw-redirect" title="DNA polymerase inhibitor">DNA polymerase inhibitor</a></i> (<a href="/wiki/Cytarabine" title="Cytarabine">Cytarabine</a><sup>#</sup>)</li></ul>
<ul><li><i><a href="/wiki/Ribonucleotide_reductase_inhibitor" title="Ribonucleotide reductase inhibitor">Ribonucleotide reductase inhibitor</a></i> (<a href="/wiki/Gemcitabine" title="Gemcitabine">Gemcitabine</a><sup>#</sup>)</li></ul>
<ul><li><i><a href="/wiki/Hypomethylating_agent" title="Hypomethylating agent">Hypomethylating agent</a></i> (<a href="/wiki/Azacitidine" title="Azacitidine">Azacitidine</a></li>
<li><a href="/wiki/Decitabine" title="Decitabine">Decitabine</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Deoxyribonucleotide" title="Deoxyribonucleotide">Deoxyribonucleotide</a></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i><a href="/wiki/Ribonucleotide_reductase_inhibitor" title="Ribonucleotide reductase inhibitor">Ribonucleotide reductase inhibitor</a></i> (<a href="/wiki/Hydroxycarbamide" title="Hydroxycarbamide">Hydroxycarbamide</a><sup>#</sup>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Topoisomerase_inhibitor" title="Topoisomerase inhibitor">Topoisomerase inhibitors</a><br />(<a href="/wiki/S_phase" title="S phase">S phase</a>)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Type_I_topoisomerase#Inhibition" title="Type I topoisomerase">I</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i><a href="/wiki/Camptotheca" title="Camptotheca">Camptotheca</a></i> (<a href="/wiki/Camptothecin" title="Camptothecin">Camptothecin</a></li>
<li><a href="/w/index.php?title=Cositecan&amp;action=edit&amp;redlink=1" class="new" title="Cositecan (page does not exist)">Cositecan</a><sup>†</sup></li>
<li><a href="/wiki/Belotecan" title="Belotecan">Belotecan</a></li>
<li><a href="/w/index.php?title=Gimatecan&amp;action=edit&amp;redlink=1" class="new" title="Gimatecan (page does not exist)">Gimatecan</a></li>
<li><a href="/wiki/Exatecan" title="Exatecan">Exatecan</a></li>
<li><a href="/wiki/Irinotecan" title="Irinotecan">Irinotecan</a></li>
<li><a href="/wiki/Lurtotecan" title="Lurtotecan">Lurtotecan</a><sup>‡</sup></li>
<li><a href="/w/index.php?title=Silatecan&amp;action=edit&amp;redlink=1" class="new" title="Silatecan (page does not exist)">Silatecan</a><sup>§</sup></li>
<li><a href="/wiki/Topotecan" title="Topotecan">Topotecan</a></li>
<li><a href="/wiki/Rubitecan" title="Rubitecan">Rubitecan</a><sup>‡</sup>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Type_II_topoisomerase#Inhibition" title="Type II topoisomerase">II</a></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i><a href="/wiki/Podophyllum_peltatum" class="mw-redirect" title="Podophyllum peltatum">Podophyllum</a></i> (<a href="/wiki/Etoposide" title="Etoposide">Etoposide</a><sup>#</sup></li>
<li><a href="/wiki/Teniposide" title="Teniposide">Teniposide</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Type_II_topoisomerase#Inhibition" title="Type II topoisomerase">II</a>+<a href="/wiki/Intercalation_(biochemistry)" title="Intercalation (biochemistry)">Intercalation</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i><a href="/wiki/Anthracycline" title="Anthracycline">Anthracyclines</a></i> (<a href="/wiki/Aclarubicin" title="Aclarubicin">Aclarubicin</a></li>
<li><a href="/wiki/Daunorubicin" title="Daunorubicin">Daunorubicin</a><sup>#</sup></li>
<li><a href="/wiki/Doxorubicin" title="Doxorubicin">Doxorubicin</a><sup>#</sup></li>
<li><a href="/wiki/Epirubicin" title="Epirubicin">Epirubicin</a></li>
<li><a href="/wiki/Idarubicin" title="Idarubicin">Idarubicin</a></li>
<li><a href="/wiki/Amrubicin" title="Amrubicin">Amrubicin</a><sup>†</sup></li>
<li><a href="/wiki/Pirarubicin" title="Pirarubicin">Pirarubicin</a></li>
<li><a href="/wiki/Valrubicin" title="Valrubicin">Valrubicin</a></li>
<li><a href="/wiki/Zorubicin" title="Zorubicin">Zorubicin</a>)</li>
<li><i><a href="/wiki/Anthraquinone" title="Anthraquinone">Anthracenediones</a></i> (<a href="/wiki/Mitoxantrone" title="Mitoxantrone">Mitoxantrone</a></li>
<li><a href="/wiki/Pixantrone" title="Pixantrone">Pixantrone</a>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Crosslinking_of_DNA" title="Crosslinking of DNA">Crosslinking of DNA</a><br />(<a href="/wiki/Cell-cycle_nonspecific_antineoplastic_agents" title="Cell-cycle nonspecific antineoplastic agents">CCNS</a>)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Alkylating_antineoplastic_agent" title="Alkylating antineoplastic agent">Alkylating</a></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i><a href="/wiki/Nitrogen_mustard" title="Nitrogen mustard">Nitrogen mustards</a>:</i> <a href="/wiki/Chlormethine" title="Chlormethine">Chlormethine</a></li>
<li><a href="/wiki/Cyclophosphamide" title="Cyclophosphamide">Cyclophosphamide</a><sup>#</sup> (<a href="/wiki/Ifosfamide" title="Ifosfamide">Ifosfamide</a><sup>#</sup></li>
<li><a href="/wiki/Trofosfamide" title="Trofosfamide">Trofosfamide</a>)</li>
<li><a href="/wiki/Chlorambucil" title="Chlorambucil">Chlorambucil</a><sup>#</sup> (<a href="/wiki/Melphalan" title="Melphalan">Melphalan</a></li>
<li><a href="/wiki/Prednimustine" title="Prednimustine">Prednimustine</a>)</li>
<li><a href="/wiki/Bendamustine" title="Bendamustine">Bendamustine</a><sup>#</sup></li>
<li><a href="/wiki/Uramustine" title="Uramustine">Uramustine</a></li></ul>
<ul><li><i><a href="/wiki/Nitrosourea" title="Nitrosourea">Nitrosoureas</a>:</i> <a href="/wiki/Carmustine" title="Carmustine">Carmustine</a></li>
<li><a href="/wiki/Lomustine" title="Lomustine">Lomustine</a> (<a href="/wiki/Semustine" title="Semustine">Semustine</a>)</li>
<li><a href="/wiki/Fotemustine" title="Fotemustine">Fotemustine</a></li>
<li><a href="/wiki/Nimustine" title="Nimustine">Nimustine</a></li>
<li><a href="/wiki/Ranimustine" title="Ranimustine">Ranimustine</a></li>
<li><a href="/wiki/Streptozotocin" title="Streptozotocin">Streptozocin</a></li></ul>
<ul><li><i><a href="/wiki/Alkyl_sulfonate" title="Alkyl sulfonate">Alkyl sulfonates</a>:</i> <a href="/wiki/Busulfan" title="Busulfan">Busulfan</a> (<a href="/wiki/Mannosulfan" title="Mannosulfan">Mannosulfan</a></li>
<li><a href="/wiki/Treosulfan" title="Treosulfan">Treosulfan</a>)</li></ul>
<ul><li><i><a href="/wiki/Aziridine" title="Aziridine">Aziridines</a>:</i> <a href="/wiki/Carboquone" title="Carboquone">Carboquone</a></li>
<li><a href="/wiki/Thiotepa" title="Thiotepa">Thiotepa</a></li>
<li><a href="/wiki/Triaziquone" title="Triaziquone">Triaziquone</a></li>
<li><a href="/wiki/Triethylenemelamine" title="Triethylenemelamine">Triethylenemelamine</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Platinum-based_antineoplastic" title="Platinum-based antineoplastic">Platinum-based</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Carboplatin" title="Carboplatin">Carboplatin</a><sup>#</sup></li>
<li><a href="/wiki/Cisplatin" title="Cisplatin">Cisplatin</a><sup>#</sup></li>
<li><a href="/wiki/Dicycloplatin" title="Dicycloplatin">Dicycloplatin</a></li>
<li><a href="/wiki/Nedaplatin" title="Nedaplatin">Nedaplatin</a></li>
<li><a href="/wiki/Oxaliplatin" title="Oxaliplatin">Oxaliplatin</a><sup>#</sup></li>
<li><a href="/wiki/Satraplatin" title="Satraplatin">Satraplatin</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Alkylating_antineoplastic_agent#Nonclassical" title="Alkylating antineoplastic agent">Nonclassical</a></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i><a href="/wiki/Hydrazine" title="Hydrazine">Hydrazines</a></i> (<a href="/wiki/Procarbazine" title="Procarbazine">Procarbazine</a><sup>#</sup>)</li>
<li><i><a href="/wiki/Triazene" title="Triazene">Triazenes</a></i> (<a href="/wiki/Dacarbazine" title="Dacarbazine">Dacarbazine</a><sup>#</sup></li>
<li><a href="/wiki/Temozolomide" title="Temozolomide">Temozolomide</a>)</li>
<li><a href="/wiki/Altretamine" title="Altretamine">Altretamine</a></li>
<li><a href="/wiki/Mitobronitol" title="Mitobronitol">Mitobronitol</a></li>
<li><a href="/wiki/Pipobroman" title="Pipobroman">Pipobroman</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Intercalation_(biochemistry)" title="Intercalation (biochemistry)">Intercalation</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Streptomyces" title="Streptomyces">Streptomyces</a> (<a href="/wiki/Actinomycin" class="mw-redirect" title="Actinomycin">Actinomycin</a><sup>#</sup></li>
<li><a href="/wiki/Bleomycin" title="Bleomycin">Bleomycin</a><sup>#</sup></li>
<li><a href="/wiki/Mitomycins" title="Mitomycins">Mitomycins</a></li>
<li><a href="/wiki/Plicamycin" title="Plicamycin">Plicamycin</a>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Photosensitizer" title="Photosensitizer">Photosensitizers</a>/<a href="/wiki/Photodynamic_therapy" title="Photodynamic therapy">PDT</a></th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Aminolevulinic_acid" title="Aminolevulinic acid">Aminolevulinic acid</a>&#160;/ <a href="/wiki/Methyl_aminolevulinate" title="Methyl aminolevulinate">Methyl aminolevulinate</a></li>
<li><a href="/wiki/Efaproxiral" title="Efaproxiral">Efaproxiral</a></li>
<li><i><a href="/wiki/Porphyrin" title="Porphyrin">Porphyrin derivatives</a></i> (<a href="/wiki/Porfimer_sodium" title="Porfimer sodium">Porfimer sodium</a></li>
<li><a href="/wiki/Talaporfin" title="Talaporfin">Talaporfin</a></li>
<li><a href="/wiki/Temoporfin" title="Temoporfin">Temoporfin</a></li>
<li><a href="/wiki/Verteporfin" title="Verteporfin">Verteporfin</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Enzyme_inhibitor" title="Enzyme inhibitor">Enzyme inhibitors</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i><a href="/wiki/Farnesyltransferase_inhibitor" title="Farnesyltransferase inhibitor">FI</a></i> (<a href="/wiki/Tipifarnib" title="Tipifarnib">Tipifarnib</a><sup>§</sup>)</li>
<li><i><a href="/wiki/Cyclin-dependent_kinase" title="Cyclin-dependent kinase">CDK</a> <a href="/wiki/Protein_kinase_inhibitor" title="Protein kinase inhibitor">inhibitors</a></i> (<a href="/wiki/Abemaciclib" title="Abemaciclib">Abemaciclib</a></li>
<li><a href="/wiki/Alvocidib" title="Alvocidib">Alvocidib</a><sup>†</sup></li>
<li><a href="/wiki/Palbociclib" title="Palbociclib">Palbociclib</a></li>
<li><a href="/wiki/Ribociclib" title="Ribociclib">Ribociclib</a></li>
<li><a href="/wiki/Seliciclib" title="Seliciclib">Seliciclib</a><sup>†</sup>)</li>
<li><i><a href="/wiki/Proteasome_inhibitor" title="Proteasome inhibitor">PrI</a></i>
<ul><li><a href="/wiki/Bortezomib" title="Bortezomib">Bortezomib</a></li>
<li><a href="/wiki/Carfilzomib" title="Carfilzomib">Carfilzomib</a></li>
<li><a href="/wiki/Ixazomib" title="Ixazomib">Ixazomib</a></li></ul></li>
<li><i><a href="/wiki/Phosphodiesterase_inhibitor" title="Phosphodiesterase inhibitor">PhI</a></i> (<a href="/wiki/Anagrelide" title="Anagrelide">Anagrelide</a>)</li>
<li><i><a href="/wiki/IMP_dehydrogenase" title="IMP dehydrogenase">IMPDI</a></i> (<a href="/wiki/Tiazofurin" title="Tiazofurin">Tiazofurin</a><sup>§</sup>)</li>
<li><i><a href="/wiki/Lipoxygenase_inhibitor" class="mw-redirect" title="Lipoxygenase inhibitor">LI</a></i> (<a href="/wiki/Masoprocol" title="Masoprocol">Masoprocol</a>)</li>
<li><i><a href="/wiki/PARP_inhibitor" title="PARP inhibitor">PARP inhibitor</a></i> (<a href="/wiki/Niraparib" title="Niraparib">Niraparib</a></li>
<li><a href="/wiki/Olaparib" title="Olaparib">Olaparib</a></li>
<li><a href="/wiki/Rucaparib" title="Rucaparib">Rucaparib</a>)</li>
<li><i><a href="/wiki/Histone_deacetylase_inhibitor" title="Histone deacetylase inhibitor">HDAC</a></i> (<a href="/wiki/Belinostat" title="Belinostat">Belinostat</a></li>
<li><a href="/wiki/Panobinostat" title="Panobinostat">Panobinostat</a></li>
<li><a href="/wiki/Romidepsin" title="Romidepsin">Romidepsin</a></li>
<li><a href="/wiki/Vorinostat" title="Vorinostat">Vorinostat</a>)</li>
<li><i><a href="/wiki/Phosphoinositide_3-kinase_inhibitor" title="Phosphoinositide 3-kinase inhibitor">PIKI</a></i> (<a href="/wiki/Idelalisib" title="Idelalisib">Idelalisib</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Receptor_antagonist" title="Receptor antagonist">Receptor antagonists</a></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i><a href="/wiki/Endothelin_receptor_antagonist" title="Endothelin receptor antagonist">ERA</a></i> (<a href="/wiki/Atrasentan" title="Atrasentan">Atrasentan</a>)</li>
<li><i><a href="/wiki/Retinoid_X_receptor" title="Retinoid X receptor">Retinoid X receptor</a></i> (<a href="/wiki/Bexarotene" title="Bexarotene">Bexarotene</a>)</li>
<li><i><a href="/wiki/Sex_steroid" title="Sex steroid">Sex steroid</a></i> (<a href="/wiki/Testolactone" title="Testolactone">Testolactone</a>)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other/ungrouped</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="/wiki/Amsacrine" title="Amsacrine">Amsacrine</a></li>
<li><a href="/wiki/Trabectedin" title="Trabectedin">Trabectedin</a></li>
<li><i><a href="/wiki/Retinoid" title="Retinoid">Retinoids</a></i> (<a href="/wiki/Alitretinoin" title="Alitretinoin">Alitretinoin</a></li>
<li><a href="/wiki/Tretinoin" title="Tretinoin">Tretinoin</a><sup>#</sup>)</li>
<li><a href="/wiki/Arsenic_trioxide" title="Arsenic trioxide">Arsenic trioxide</a></li>
<li><i><a href="/wiki/Asparagine" title="Asparagine">Asparagine depleters</a></i> (<a href="/wiki/Asparaginase" title="Asparaginase">Asparaginase</a><sup>#</sup>/<a href="/wiki/Pegaspargase" title="Pegaspargase">Pegaspargase</a>)</li>
<li><a href="/wiki/Celecoxib" title="Celecoxib">Celecoxib</a></li>
<li><a href="/wiki/Demecolcine" title="Demecolcine">Demecolcine</a></li>
<li><a href="/wiki/Elesclomol" title="Elesclomol">Elesclomol</a><sup>§</sup></li>
<li><a href="/wiki/Elsamitrucin" title="Elsamitrucin">Elsamitrucin</a></li>
<li><a href="/wiki/Estramustine_phosphate" title="Estramustine phosphate">Estramustine phosphate</a></li>
<li><a href="/wiki/Etoglucid" title="Etoglucid">Etoglucid</a></li>
<li><a href="/wiki/Lonidamine" title="Lonidamine">Lonidamine</a></li>
<li><a href="/wiki/Lucanthone" title="Lucanthone">Lucanthone</a></li>
<li><a href="/wiki/Mitoguazone" title="Mitoguazone">Mitoguazone</a></li>
<li><a href="/wiki/Mitotane" title="Mitotane">Mitotane</a></li>
<li><a href="/wiki/Oblimersen" title="Oblimersen">Oblimersen</a><sup>†</sup></li>
<li><a href="/wiki/Omacetaxine_mepesuccinate" title="Omacetaxine mepesuccinate">Omacetaxine mepesuccinate</a></li>
<li><a href="/wiki/Eribulin" title="Eribulin">Eribulin</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup><a href="/wiki/WHO_Model_List_of_Essential_Medicines" title="WHO Model List of Essential Medicines">WHO-EM</a></li>
<li><sup>‡</sup><a href="/wiki/List_of_withdrawn_drugs" title="List of withdrawn drugs">Withdrawn</a> from market</li>
<li><a href="/wiki/Clinical_trial" title="Clinical trial">Clinical trials</a>:
<ul><li><sup>†</sup><a href="/wiki/Phases_of_clinical_research#Phase_III" title="Phases of clinical research">Phase III</a></li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Breakthrough_of_the_Year" style="padding:3px"><table class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2" style="text-align:center;"><div class="plainlinks hlist navbar mini"><ul><li class="nv-view"><a href="/wiki/Template:Breakthrough_of_the_Year" title="Template:Breakthrough of the Year"><abbr title="View this template" style="text-align:center;;;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:Breakthrough_of_the_Year" title="Template talk:Breakthrough of the Year"><abbr title="Discuss this template" style="text-align:center;;;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">t</abbr></a></li><li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Breakthrough_of_the_Year&amp;action=edit"><abbr title="Edit this template" style="text-align:center;;;background:none transparent;border:none;-moz-box-shadow:none;-webkit-box-shadow:none;box-shadow:none; padding:0;">e</abbr></a></li></ul></div><div id="Breakthrough_of_the_Year" style="font-size:114%;margin:0 4em"><a href="/wiki/Breakthrough_of_the_Year" title="Breakthrough of the Year">Breakthrough of the Year</a></div></th></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%"><i><a href="/wiki/Science_(journal)" title="Science (journal)">Science</a></i><br />journal</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="nowrap">1996: <a href="/wiki/HIV" title="HIV">HIV</a> understanding</span></li>
<li><span class="nowrap">1997: <a href="/wiki/Dolly_(sheep)" title="Dolly (sheep)">Dolly the sheep</a></span></li>
<li><span class="nowrap">1998: <a href="/wiki/Accelerating_expansion_of_the_universe" title="Accelerating expansion of the universe">Accelerating universe</a></span></li>
<li><span class="nowrap">1999: <a href="/wiki/Stem_cell" title="Stem cell">Stem cell</a></span></li>
<li><span class="nowrap">2000: <a href="/wiki/Whole_genome_sequencing" title="Whole genome sequencing">Whole genome sequencing</a></span></li>
<li><span class="nowrap">2001: <a href="/wiki/Nanocircuitry" title="Nanocircuitry">Nanocircuits</a> or <a href="/wiki/Molecular_scale_electronics" title="Molecular scale electronics">Molecular circuit</a></span></li>
<li><span class="nowrap">2002: <a href="/wiki/RNA_interference" title="RNA interference">RNA interference</a></span></li>
<li><span class="nowrap">2003: <a href="/wiki/Dark_energy" title="Dark energy">Dark energy</a></span></li>
<li><span class="nowrap">2004: <a href="/wiki/Spirit_(rover)" title="Spirit (rover)"><i>Spirit</i> rover</a></span></li>
<li><span class="nowrap">2005: <a href="/wiki/Evolution" title="Evolution">Evolution</a> in action</span></li>
<li><span class="nowrap">2006: <a href="/wiki/Poincar%C3%A9_conjecture" title="Poincaré conjecture">Poincaré conjecture</a> proof</span></li>
<li><span class="nowrap">2007: <a href="/wiki/Human_genetic_variation" title="Human genetic variation">Human genetic variation</a></span></li>
<li><span class="nowrap">2008: <a href="/wiki/Cellular_reprogramming" class="mw-redirect" title="Cellular reprogramming">Cellular reprogramming</a></span></li>
<li><span class="nowrap">2009: <i><a href="/wiki/Ardipithecus" title="Ardipithecus">Ardipithecus</a> ramidus</i></span></li>
<li><span class="nowrap">2010: First <a href="/wiki/Quantum_machine" title="Quantum machine">quantum machine</a></span></li>
<li><span class="nowrap">2011: <a href="/wiki/HPTN_052" title="HPTN 052">HPTN 052</a> clinical trial</span></li>
<li><span class="nowrap">2012: <a href="/wiki/Higgs_boson" title="Higgs boson">Higgs boson</a> discovery</span></li>
<li><span class="nowrap">2013: <a class="mw-selflink selflink">Cancer immunotherapy</a></span></li>
<li><span class="nowrap">2014: <a href="/wiki/Rosetta_(spacecraft)" title="Rosetta (spacecraft)"><i>Rosetta</i> comet mission</a></span></li>
<li><span class="nowrap">2015: <a href="/wiki/CRISPR" title="CRISPR">CRISPR</a> genome-editing method</span></li>
<li><span class="nowrap">2016: <a href="/wiki/First_observation_of_gravitational_waves" title="First observation of gravitational waves">First observation</a> of <a href="/wiki/Gravitational_wave" title="Gravitational wave">gravitational waves</a></span></li>
<li><span class="nowrap">2017: <a href="/wiki/GW170817" title="GW170817">GW170817</a> (<a href="/wiki/Neutron_star_merger" title="Neutron star merger">neutron star merger</a>)</span></li></ul>
</div></td></tr></tbody></table></div>

<!-- 
NewPP limit report
Parsed by mw1261
Cached time: 20190127202137
Cache expiry: 2073600
Dynamic content: false
CPU time usage: 1.468 seconds
Real time usage: 1.635 seconds
Preprocessor visited node count: 5542/1000000
Preprocessor generated node count: 0/1500000
Post‐expand include size: 318450/2097152 bytes
Template argument size: 2289/2097152 bytes
Highest expansion depth: 12/40
Expensive parser function count: 8/500
Unstrip recursion depth: 1/20
Unstrip post‐expand size: 334566/5000000 bytes
Number of Wikibase entities loaded: 5/400
Lua time usage: 0.840/10.000 seconds
Lua memory usage: 6.5 MB/50 MB
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00% 1294.250      1 -total
 70.76%  915.875      1 Template:Reflist
 49.48%  640.383     71 Template:Cite_journal
  8.13%  105.282     24 Template:Cite_web
  5.54%   71.638      1 Template:Infobox_medical_intervention
  5.10%   65.968      1 Template:Infobox
  4.09%   52.882     10 Template:Navbox
  3.34%   43.194      1 Template:Clarify
  3.09%   39.968      1 Template:Fix-span
  2.66%   34.408      4 Template:Cite_news
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:1661124-0!canonical and timestamp 20190127202136 and revision id 878193815
 -->
</div><noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div>					<div class="printfooter">
						Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Cancer_immunotherapy&amp;oldid=878193815">https://en.wikipedia.org/w/index.php?title=Cancer_immunotherapy&amp;oldid=878193815</a>"					</div>
				<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Monoclonal_antibodies_for_tumors" title="Category:Monoclonal antibodies for tumors">Monoclonal antibodies for tumors</a></li><li><a href="/wiki/Category:Branches_of_immunology" title="Category:Branches of immunology">Branches of immunology</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:CS1:_long_volume_value" title="Category:CS1: long volume value">CS1: long volume value</a></li><li><a href="/wiki/Category:Wikipedia_articles_needing_page_number_citations_from_February_2018" title="Category:Wikipedia articles needing page number citations from February 2018">Wikipedia articles needing page number citations from February 2018</a></li><li><a href="/wiki/Category:Use_dmy_dates_from_December_2018" title="Category:Use dmy dates from December 2018">Use dmy dates from December 2018</a></li><li><a href="/wiki/Category:Articles_with_short_description" title="Category:Articles with short description">Articles with short description</a></li><li><a href="/wiki/Category:Wikipedia_articles_needing_clarification_from_April_2016" title="Category:Wikipedia articles needing clarification from April 2016">Wikipedia articles needing clarification from April 2016</a></li><li><a href="/wiki/Category:All_articles_with_unsourced_statements" title="Category:All articles with unsourced statements">All articles with unsourced statements</a></li><li><a href="/wiki/Category:Articles_with_unsourced_statements_from_February_2018" title="Category:Articles with unsourced statements from February 2018">Articles with unsourced statements from February 2018</a></li></ul></div></div>				<div class="visualClear"></div>
							</div>
		</div>
		<div id="mw-navigation">
			<h2>Navigation menu</h2>
			<div id="mw-head">
									<div id="p-personal" role="navigation" aria-labelledby="p-personal-label">
						<h3 id="p-personal-label">Personal tools</h3>
						<ul>
							<li id="pt-anonuserpage">Not logged in</li><li id="pt-anontalk"><a href="/wiki/Special:MyTalk" title="Discussion about edits from this IP address [n]" accesskey="n">Talk</a></li><li id="pt-anoncontribs"><a href="/wiki/Special:MyContributions" title="A list of edits made from this IP address [y]" accesskey="y">Contributions</a></li><li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Cancer+immunotherapy" title="You are encouraged to create an account and log in; however, it is not mandatory">Create account</a></li><li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Cancer+immunotherapy" title="You&#039;re encouraged to log in; however, it&#039;s not mandatory. [o]" accesskey="o">Log in</a></li>						</ul>
					</div>
									<div id="left-navigation">
										<div id="p-namespaces" role="navigation" class="vectorTabs" aria-labelledby="p-namespaces-label">
						<h3 id="p-namespaces-label">Namespaces</h3>
						<ul>
							<li id="ca-nstab-main" class="selected"><span><a href="/wiki/Cancer_immunotherapy" title="View the content page [c]" accesskey="c">Article</a></span></li><li id="ca-talk"><span><a href="/wiki/Talk:Cancer_immunotherapy" rel="discussion" title="Discussion about the content page [t]" accesskey="t">Talk</a></span></li>						</ul>
					</div>
										<div id="p-variants" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-variants-label">
												<input type="checkbox" class="vectorMenuCheckbox" aria-labelledby="p-variants-label" />
						<h3 id="p-variants-label">
							<span>Variants</span>
						</h3>
						<ul class="menu">
													</ul>
					</div>
									</div>
				<div id="right-navigation">
										<div id="p-views" role="navigation" class="vectorTabs" aria-labelledby="p-views-label">
						<h3 id="p-views-label">Views</h3>
						<ul>
							<li id="ca-view" class="collapsible selected"><span><a href="/wiki/Cancer_immunotherapy">Read</a></span></li><li id="ca-edit" class="collapsible"><span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=edit" title="Edit this page [e]" accesskey="e">Edit</a></span></li><li id="ca-history" class="collapsible"><span><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=history" title="Past revisions of this page [h]" accesskey="h">View history</a></span></li>						</ul>
					</div>
										<div id="p-cactions" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-cactions-label">
						<input type="checkbox" class="vectorMenuCheckbox" aria-labelledby="p-cactions-label" />
						<h3 id="p-cactions-label"><span>More</span></h3>
						<ul class="menu">
													</ul>
					</div>
										<div id="p-search" role="search">
						<h3>
							<label for="searchInput">Search</label>
						</h3>
						<form action="/w/index.php" id="searchform">
							<div id="simpleSearch">
								<input type="search" name="search" placeholder="Search Wikipedia" title="Search Wikipedia [f]" accesskey="f" id="searchInput"/><input type="hidden" value="Special:Search" name="title"/><input type="submit" name="fulltext" value="Search" title="Search Wikipedia for this text" id="mw-searchButton" class="searchButton mw-fallbackSearchButton"/><input type="submit" name="go" value="Go" title="Go to a page with this exact name if it exists" id="searchButton" class="searchButton"/>							</div>
						</form>
					</div>
									</div>
			</div>
			<div id="mw-panel">
				<div id="p-logo" role="banner"><a class="mw-wiki-logo" href="/wiki/Main_Page" title="Visit the main page"></a></div>
						<div class="portal" role="navigation" id="p-navigation" aria-labelledby="p-navigation-label">
			<h3 id="p-navigation-label">Navigation</h3>
			<div class="body">
								<ul>
					<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li><li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li><li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content – the best of Wikipedia">Featured content</a></li><li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li><li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li><li id="n-sitesupport"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us">Donate to Wikipedia</a></li><li id="n-shoplink"><a href="//shop.wikimedia.org" title="Visit the Wikipedia store">Wikipedia store</a></li>				</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id="p-interaction" aria-labelledby="p-interaction-label">
			<h3 id="p-interaction-label">Interaction</h3>
			<div class="body">
								<ul>
					<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li><li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li><li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li><li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="A list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li><li id="n-contactpage"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia">Contact page</a></li>				</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id="p-tb" aria-labelledby="p-tb-label">
			<h3 id="p-tb-label">Tools</h3>
			<div class="body">
								<ul>
					<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Cancer_immunotherapy" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li><li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Cancer_immunotherapy" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li><li id="t-upload"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li><li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li><li id="t-permalink"><a href="/w/index.php?title=Cancer_immunotherapy&amp;oldid=878193815" title="Permanent link to this revision of the page">Permanent link</a></li><li id="t-info"><a href="/w/index.php?title=Cancer_immunotherapy&amp;action=info" title="More information about this page">Page information</a></li><li id="t-wikibase"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q2012719" title="Link to connected data repository item [g]" accesskey="g">Wikidata item</a></li><li id="t-cite"><a href="/w/index.php?title=Special:CiteThisPage&amp;page=Cancer_immunotherapy&amp;id=878193815" title="Information on how to cite this page">Cite this page</a></li>				</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id="p-coll-print_export" aria-labelledby="p-coll-print_export-label">
			<h3 id="p-coll-print_export-label">Print/export</h3>
			<div class="body">
								<ul>
					<li id="coll-create_a_book"><a href="/w/index.php?title=Special:Book&amp;bookcmd=book_creator&amp;referer=Cancer+immunotherapy">Create a book</a></li><li id="coll-download-as-rdf2latex"><a href="/w/index.php?title=Special:ElectronPdf&amp;page=Cancer+immunotherapy&amp;action=show-download-screen">Download as PDF</a></li><li id="t-print"><a href="/w/index.php?title=Cancer_immunotherapy&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>				</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id="p-lang" aria-labelledby="p-lang-label">
			<h3 id="p-lang-label">Languages</h3>
			<div class="body">
								<ul>
					<li class="interlanguage-link interwiki-ar"><a href="https://ar.wikipedia.org/wiki/%D9%85%D8%B9%D8%A7%D9%84%D8%AC%D8%A9_%D9%85%D9%86%D8%A7%D8%B9%D9%8A%D8%A9_%D9%84%D9%84%D8%B3%D8%B1%D8%B7%D8%A7%D9%86" title="معالجة مناعية للسرطان – Arabic" lang="ar" hreflang="ar" class="interlanguage-link-target">العربية</a></li><li class="interlanguage-link interwiki-cs"><a href="https://cs.wikipedia.org/wiki/Biologick%C3%A1_l%C3%A9%C4%8Dba_n%C3%A1dorov%C3%BDch_onemocn%C4%9Bn%C3%AD" title="Biologická léčba nádorových onemocnění – Czech" lang="cs" hreflang="cs" class="interlanguage-link-target">Čeština</a></li><li class="interlanguage-link interwiki-da"><a href="https://da.wikipedia.org/wiki/Cancer_immunterapi" title="Cancer immunterapi – Danish" lang="da" hreflang="da" class="interlanguage-link-target">Dansk</a></li><li class="interlanguage-link interwiki-de"><a href="https://de.wikipedia.org/wiki/Krebsimmuntherapie" title="Krebsimmuntherapie – German" lang="de" hreflang="de" class="interlanguage-link-target">Deutsch</a></li><li class="interlanguage-link interwiki-et"><a href="https://et.wikipedia.org/wiki/V%C3%A4hi_immunoteraapia" title="Vähi immunoteraapia – Estonian" lang="et" hreflang="et" class="interlanguage-link-target">Eesti</a></li><li class="interlanguage-link interwiki-es"><a href="https://es.wikipedia.org/wiki/Inmunoterapia_contra_el_c%C3%A1ncer" title="Inmunoterapia contra el cáncer – Spanish" lang="es" hreflang="es" class="interlanguage-link-target">Español</a></li><li class="interlanguage-link interwiki-fr"><a href="https://fr.wikipedia.org/wiki/Immunologie_des_tumeurs" title="Immunologie des tumeurs – French" lang="fr" hreflang="fr" class="interlanguage-link-target">Français</a></li><li class="interlanguage-link interwiki-ko"><a href="https://ko.wikipedia.org/wiki/%EB%A9%B4%EC%97%AD%ED%95%AD%EC%95%94%EC%9A%94%EB%B2%95" title="면역항암요법 – Korean" lang="ko" hreflang="ko" class="interlanguage-link-target">한국어</a></li><li class="interlanguage-link interwiki-it"><a href="https://it.wikipedia.org/wiki/Terapia_con_anticorpi_monoclonali" title="Terapia con anticorpi monoclonali – Italian" lang="it" hreflang="it" class="interlanguage-link-target">Italiano</a></li><li class="interlanguage-link interwiki-lt"><a href="https://lt.wikipedia.org/wiki/Imunoterapija" title="Imunoterapija – Lithuanian" lang="lt" hreflang="lt" class="interlanguage-link-target">Lietuvių</a></li><li class="interlanguage-link interwiki-hu"><a href="https://hu.wikipedia.org/wiki/Immunonkol%C3%B3gia" title="Immunonkológia – Hungarian" lang="hu" hreflang="hu" class="interlanguage-link-target">Magyar</a></li><li class="interlanguage-link interwiki-ja"><a href="https://ja.wikipedia.org/wiki/%E3%81%8C%E3%82%93%E5%85%8D%E7%96%AB%E7%99%82%E6%B3%95" title="がん免疫療法 – Japanese" lang="ja" hreflang="ja" class="interlanguage-link-target">日本語</a></li><li class="interlanguage-link interwiki-pl"><a href="https://pl.wikipedia.org/wiki/Immunoterapia_nowotwor%C3%B3w" title="Immunoterapia nowotworów – Polish" lang="pl" hreflang="pl" class="interlanguage-link-target">Polski</a></li><li class="interlanguage-link interwiki-ru"><a href="https://ru.wikipedia.org/wiki/%D0%98%D0%BC%D0%BC%D1%83%D0%BD%D0%BE%D0%BE%D0%BD%D0%BA%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F" title="Иммуноонкология – Russian" lang="ru" hreflang="ru" class="interlanguage-link-target">Русский</a></li><li class="interlanguage-link interwiki-sl"><a href="https://sl.wikipedia.org/wiki/Biolo%C5%A1ka_zdravila" title="Biološka zdravila – Slovenian" lang="sl" hreflang="sl" class="interlanguage-link-target">Slovenščina</a></li><li class="interlanguage-link interwiki-fi"><a href="https://fi.wikipedia.org/wiki/Sy%C3%B6v%C3%A4n_immuunihoito" title="Syövän immuunihoito – Finnish" lang="fi" hreflang="fi" class="interlanguage-link-target">Suomi</a></li><li class="interlanguage-link interwiki-te"><a href="https://te.wikipedia.org/wiki/%E0%B0%AE%E0%B1%8B%E0%B0%A8%E0%B1%8B%E0%B0%95%E0%B1%8D%E0%B0%B2%E0%B1%8B%E0%B0%A8%E0%B0%B2%E0%B1%8D_%E0%B0%AF%E0%B0%BE%E0%B0%82%E0%B0%9F%E0%B1%80%E0%B0%AC%E0%B0%BE%E0%B0%A1%E0%B1%80_%E0%B0%A5%E0%B1%86%E0%B0%B0%E0%B0%AA%E0%B1%80" title="మోనోక్లోనల్ యాంటీబాడీ థెరపీ – Telugu" lang="te" hreflang="te" class="interlanguage-link-target">తెలుగు</a></li><li class="interlanguage-link interwiki-tr"><a href="https://tr.wikipedia.org/wiki/Kanser_imm%C3%BCnoterapisi" title="Kanser immünoterapisi – Turkish" lang="tr" hreflang="tr" class="interlanguage-link-target">Türkçe</a></li><li class="interlanguage-link interwiki-uk"><a href="https://uk.wikipedia.org/wiki/%D0%86%D0%BC%D1%83%D0%BD%D0%BE%D0%BE%D0%BD%D0%BA%D0%BE%D0%BB%D0%BE%D0%B3%D1%96%D1%8F" title="Імуноонкологія – Ukrainian" lang="uk" hreflang="uk" class="interlanguage-link-target">Українська</a></li><li class="interlanguage-link interwiki-vi"><a href="https://vi.wikipedia.org/wiki/%C4%90i%E1%BB%81u_tr%E1%BB%8B_mi%E1%BB%85n_d%E1%BB%8Bch_ung_th%C6%B0" title="Điều trị miễn dịch ung thư – Vietnamese" lang="vi" hreflang="vi" class="interlanguage-link-target">Tiếng Việt</a></li><li class="interlanguage-link interwiki-zh"><a href="https://zh.wikipedia.org/wiki/%E7%99%8C%E7%97%87%E5%85%8D%E7%96%AB%E7%96%97%E6%B3%95" title="癌症免疫疗法 – Chinese" lang="zh" hreflang="zh" class="interlanguage-link-target">中文</a></li>				</ul>
				<div class="after-portlet after-portlet-lang"><span class="wb-langlinks-edit wb-langlinks-link"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q2012719#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></span></div>			</div>
		</div>
				</div>
		</div>
				<div id="footer" role="contentinfo">
						<ul id="footer-info">
								<li id="footer-info-lastmod"> This page was last edited on 13 January 2019, at 16:26<span class="anonymous-show">&#160;(UTC)</span>.</li>
								<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License</a><a rel="license" href="//creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="//foundation.wikimedia.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="//foundation.wikimedia.org/wiki/Privacy_policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
							</ul>
						<ul id="footer-places">
								<li id="footer-places-privacy"><a href="https://foundation.wikimedia.org/wiki/Privacy_policy" class="extiw" title="wmf:Privacy policy">Privacy policy</a></li>
								<li id="footer-places-about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
								<li id="footer-places-disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
								<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
								<li id="footer-places-developers"><a href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
								<li id="footer-places-cookiestatement"><a href="https://foundation.wikimedia.org/wiki/Cookie_statement">Cookie statement</a></li>
								<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Cancer_immunotherapy&amp;mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
							</ul>
										<ul id="footer-icons" class="noprint">
										<li id="footer-copyrightico">
						<a href="https://wikimediafoundation.org/"><img src="/static/images/wikimedia-button.png" srcset="/static/images/wikimedia-button-1.5x.png 1.5x, /static/images/wikimedia-button-2x.png 2x" width="88" height="31" alt="Wikimedia Foundation"/></a>					</li>
										<li id="footer-poweredbyico">
						<a href="//www.mediawiki.org/"><img src="/static/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/static/images/poweredby_mediawiki_132x47.png 1.5x, /static/images/poweredby_mediawiki_176x62.png 2x" width="88" height="31"/></a>					</li>
									</ul>
						<div style="clear: both;"></div>
		</div>
		
<script>(window.RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"1.468","walltime":"1.635","ppvisitednodes":{"value":5542,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":318450,"limit":2097152},"templateargumentsize":{"value":2289,"limit":2097152},"expansiondepth":{"value":12,"limit":40},"expensivefunctioncount":{"value":8,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":334566,"limit":5000000},"entityaccesscount":{"value":5,"limit":400},"timingprofile":["100.00% 1294.250      1 -total"," 70.76%  915.875      1 Template:Reflist"," 49.48%  640.383     71 Template:Cite_journal","  8.13%  105.282     24 Template:Cite_web","  5.54%   71.638      1 Template:Infobox_medical_intervention","  5.10%   65.968      1 Template:Infobox","  4.09%   52.882     10 Template:Navbox","  3.34%   43.194      1 Template:Clarify","  3.09%   39.968      1 Template:Fix-span","  2.66%   34.408      4 Template:Cite_news"]},"scribunto":{"limitreport-timeusage":{"value":"0.840","limit":"10.000"},"limitreport-memusage":{"value":6814121,"limit":52428800}},"cachereport":{"origin":"mw1261","timestamp":"20190127202137","ttl":2073600,"transientcontent":false}}});});</script>
<script type="application/ld+json">{"@context":"https:\/\/schema.org","@type":"Article","name":"Cancer immunotherapy","url":"https:\/\/en.wikipedia.org\/wiki\/Cancer_immunotherapy","sameAs":"http:\/\/www.wikidata.org\/entity\/Q2012719","mainEntity":"http:\/\/www.wikidata.org\/entity\/Q2012719","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https:\/\/www.wikimedia.org\/static\/images\/wmf-hor-googpub.png"}},"datePublished":"2005-03-28T20:51:16Z","dateModified":"2019-01-13T16:26:14Z","image":"https:\/\/upload.wikimedia.org\/wikipedia\/commons\/f\/f5\/Peptide_bound_to_Rituximab_FAB.png","headline":"use of the immune system to treat cancer"}</script>
<script>(window.RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgBackendResponseTime":1808,"wgHostname":"mw1261"});});</script>
	</body>
</html>
